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South Africa has a high burden of multidrug-resistant (MDR) and extensively drug-resistant (XDR) 
tuberculosis (TB), with the Eastern Cape (EC) being one of the worst affected provinces in the 
country.  This study provides the first in-depth analysis of the molecular epidemiology of drug-
resistant TB in the EC.  
A convenience sample of drug-sensitive and drug-resistant isolates was collected over one year by 
the National Health Laboratory Services in Port Elizabeth.  These isolates were characterized by 
various molecular techniques.  Our results were compared to data from three additional provinces, 
to contextualise the population structure of MDR-TB strains.  Each province had a distinct population 
structure.  The population structure of XDR-TB cases in the Western Cape was significantly 
influenced by strains originating from the EC.  A high degree of clustering of drug resistance 
mutation patterns was detected in each setting, suggestive of transmission.  Clustering was 
particularly pronounced in the EC, with 93% of pre-XDR and XDR-TB isolates belonging to the 
Atypical Beijing genotype.  We showed that this genotype was programmatically selected through a 
weakened MDR-TB regimen that failed to recognise inhA defined ethionamide resistance.  This 
weakened regimen has facilitated transmission and is the underlying cause of mortality.  We 
propose that existing molecular assays which detect inhA mutations should be used to identify 
patients at risk of XDR-TB and to adjust treatment.  
Through spoligotyping, restriction fragment length polymorphism typing and mutation analysis we 
demonstrated that the EC Atypical Beijing isolates evolved from a common progenitor, giving rise to 
two sub-groups, each with unique features, including mutations that confer resistance to up to 11 
anti-TB drugs.  This finding was supported by whole genome sequencing (WGS) and RNA sequencing 
demonstrating close relatedness and suggests the emergence and spread of totally drug-resistant TB 
in the EC. 
We showed that isolates harbouring the rrs A1401G mutation displayed a decreased susceptibility to 
capreomycin, thereby questioning the utility of this drug in the treatment of XDR-TB when amikacin 
resistance was already noted.  Importantly, strains harbouring the rpoB516 mutation were shown to 
be susceptible to rifabutin, despite low-level resistance to rifampicin (RIF).  Therefore the use of 
rifabutin in the EC may improve therapeutic success and limit transmission of XDR-TB. 
WGS was used to investigate molecular features that may confer a selective advantage to the EC 
Atypical Beijing genotype strains.  These analyses revealed that all represented Atypical Beijing 
genotype strains – including those diagnosed as pan-susceptible – harboured a mutation in ethA, 




conferring phenotypic ethionamide resistance.  This surprising finding may explain the apparent 
increased ability of the Atypical Beijing genotype strains to develop higher drug-resistance in the 
context of an ethionamide-containing MDR-TB treatment regimen.  It is unclear why some strains 
additionally acquire inhA promoter mutations.  This requires further investigation. 
A large number of genes were shown by RNAseq to be differentially regulated, however, their 
influence on the physiological properties of the bacillus remain to be determined.  
Together these findings have challenged the use of standardised MDR-TB treatment without 
comprehensive DST.  This view is now widely recognised but has not influenced the South African TB 
guidelines (2014) which promote treatment of RIF resistance without relevant knowledge of drug 
resistance.  We propose that the effective treatment of highly resistant TB can only be achieved with 
the development of new drugs, new drug combinations and comprehensive rapid DST.   
  





Suid-Afrika het ‘n hoë voorkoms van multi-middelweerstandige (MDR) en uiters middelweerstandige 
(XDR) tuberkulose (TB), veral in die Oos-Kaap.  Hierdie studie bied die eerste in-diepte analise van 
die molekulêre epidemiologie van middelweerstandige TB in die Oos-Kaap. 
‘n Gerieflikheidsteekproef wat oor een jaar geneem is en bestaan het uit middelsensitiewe sowel as 
middelweerstandige isolate is van die National Health Laboratory Services in Port Elizabeth ontvang.  
Hierdie isolate is deur verskeie molekulêre metodes gekarakteriseer.  Ons resultate is vergelyk met 
data van drie addisionele provinsies om die populasiesamestelling van MDR-TB stamme in konteks 
te plaas.  Elke provinsie het ‘n unieke populasiesamestelling getoon.  Die populasiesamestelling van 
XDR-TB gevalle in die Wes-Kaap is beduidend deur stamme van die Oos-Kaap beïnvloed.  ‘n Hoë 
mate van groepering van weerstandigheidspatrone is in elke provinsie gevind, wat dui op 
transmissie.  Groepering was besonder duidelik in die Oos-Kaap, waar 93% van pre-XDR en XDR-TB 
isolate van die Atipiese Beijing genotipe was.  Ons het getoon dat hierdie genotipe programmaties 
geselekteer is deur ‘n suboptimale MDR-TB behandelingsregime wat nie inhA-gedefiniëerde 
ethionamied weerstandigheid in ag neem nie.  Hierdie ondoeltreffende behandelingsregime het 
transmissie gefasiliteer en is die onderliggende oorsaak van mortaliteit.  Ons stel voor dat bestaande 
molekulêre toetse gebruik word wat inhA mutasies opspoor om XDR-TB risiko-pasiënte te 
identifiseer en hul behandeling dienooreenkomstig aan te pas. 
Ons het gedemonstreer dat twee sub-groepe van Oos-Kaap Atipiese Beijing isolate ontwikkel het uit 
‘n gemene voorsaat, elk met unieke eienskappe, insluitend mutasies wat weerstandigheid teen tot 
11 middels veroorsaak.  Hierdie bevinding word gerugsteun deur heelgenoom volgordebepaling en 
ribonukleïensuur volgordebepaling en dui op die ontluiking en verspreiding van algeheel 
middelweerstandige TB in die Oos-Kaap. 
Ons het getoon dat isolate wat die rrs A1401G mutasie het, verminderde vatbaarheid vir 
capreomisien het, en dit bevraagteken die bruikbaarheid van hierdie middel in die behandeling van 
XDR-TB waar amikasienweerstandigheid teenwoordig is.  Van belang is dat stamme wat die rpoB516 
mutasie het, vatbaar is vir rifabutien, ten spyte van weerstandigheid teen rifampisien.  Die gebruik 
van rifabutien kan dus die uitkomste van XDR-TB pasiënte in die Oos-Kaap verbeter, en ook 
transmissie beperk. 
Heelgenoom volgordebepaling is gebruik om molekulêre eienskappe te ondersoek wat moontlik ‘n 
selektiewe voordeel kan bied aan die Oos-Kaapse Atipiese Beijing genotipe stamme.  Ons het getoon 
dat alle verteenwoordigde Atipiese Beijing genotipe stamme – insluitend dié wat as algeheel 




middelsensitief gediagnoseer is – ‘n ethA mutasie het wat ethionamied weerstandigheid veroorsaak.  
Dit mag die oënskynlike verhoogde vermoë van die Atipiese Beijing genotipe stamme om hoër 
weerstandigheid te ontwikkel verklaar.   
Verder het ribonukleïensuur volgordebepaling getoon dat ‘n groot aantal gene verskillend 
gereguleer is.  Hierdie verskille moet verder ondersoek word om die invloed daarvan op die 
fisiologiese eienskappe van die bacillus te verklaar. 
Hierdie bevindinge betwis die gebruik van gestandardiseerde MDR-TB behandeling in die 
afwesigheid van omvattende middelsensitiwiteitstoetse.  Hierdie siening word tans algemeen 
aanvaar, en tog het dit nie die Suid-Afrikaanse TB-riglyne (2014), wat behandeling van 
rifampisienweerstandigheid sonder die relevante kennis van middelweerstandigheid voorstaan, 
beïnvloed nie.  Ons stel voor dat die effektiewe behandeling van hoogs weerstandige TB net bereik 
kan word deur die ontwikkeling van nuwe middels, nuwe kombinasies van middels en vinnige, 
omvattende middelsensitiwiteitstoetse. 
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1.1  Background 
1.1.1  TB in South Africa, in relation to the world 
South Africa has one of the highest recorded incidences of tuberculosis (TB) world-wide; estimated at 
>1000 new TB cases per 100 000 population per year according to the World Health Organization 
(WHO) 2013 report (1).  South Africa reports the highest number of confirmed MDR-TB (resistant to 
at least isoniazid and rifapicin) cases in the Afro-region of the WHO and ranks fourth among the 
world’s high burden MDR-TB countries (1).  In South Africa, 10% of all TB cases are believed to be 
MDR-TB of which one-tenth are XDR-TB (MDR with additional resistance to a fluoroquinolone and a 
second-line injectable drug) (1).  The highest rates of MDR and XDR-TB were notified for the Western 
Cape, Eastern Cape and KwaZulu-Natal provinces (2).  In a nationwide survey conducted by the 
National Institute for Communicable Diseases in 2008, 20.2% of all notified TB cases showed resistance 
to isoniazid and nearly half of these (9.6% of all cases) were MDR-TB (2).  This represents a 3-fold 
increase since 2002, when it was shown that 3.1% of all TB cases (new and retreatment) had MDR-TB 
(2).  These findings are supported by a report from the National Health Laboratory Service (NHLS) 
which showed a steady increase in the number of MDR-TB cases since 2004 (2), and a study in 
Khayelitsha which showed that MDR-TB was diagnosed in 4.4% of all TB cases in 2008 (3).  These 
statistics appear significantly worse if we consider that only 8,200 of the projected 13,000 patients 
were diagnosed with MDR-TB or XDR-TB by the NHLS in 2008, suggesting a case detection rate of 63%.  
More worrying is the fact that no more than 50% of diagnosed cases were placed on MDR treatment 
in 2009 (Dr. Norbert Ndjeka, Director Drug‐Resistant TB, TB and HIV, National Department of Health).  
Treatment success rates are below 50% for MDR-TB (4,5) with considerably poorer outcomes for XDR-
TB (6,7).  In South Africa today, the standard first-line regimen consists of a two-month initiation phase 
of isoniazid, rifampicin, pyrazinamide and ethambutol and four months continuation of isoniazid and 
rifampicin.  MDR-TB is treated with six months of kanamycin, moxifloxacin, ethionamide, 
pyrazinamide and terizidone, followed by 18 months omitting kanamycin. 
Research in the 1950’s led to the dogma that drug-resistant strains were less fit than drug-susceptible 
strains, suggesting decreased ability to spread and cause disease (8).  From this the notion was 
developed that if drug-susceptible TB was treated adequately, drug-resistant TB would disappear.  
However, there are many examples of the transmission of drug-resistant strains, including MDR-TB 




and XDR-TB.  This indicates that drug-resistant strains are sufficiently virulent to enable them to spread 
and cause disease (9–13).  Molecular epidemiological studies have demonstrated that the drug-
resistant TB epidemic in SA is endemic and driven by outbreaks (11,14–19).  Today there is evidence 
that the success of drug-resistant strains may be attributable to compensatory mutations which allow 
it to overcome the loss of fitness associated with certain drug resistance-associated mutations (20,21).  
In addition, these strains are able to spread even more efficiently in a population co-infected with HIV 
(19). 
 
1.1.2  The tuberculosis burden in the Eastern Cape 
The Eastern Cape Province of South Africa is an area of special concern in terms of TB incidence, the 
high burden of drug-resistant TB (1) and HIV incidence (22).  In 2006, two Eastern Cape districts 
(Amatole and Nelson Mandela Metropole) were identified as areas of particularly high TB incidence 
in the country, and as such were included in the TB Crisis Management Plan launched by the National 
Department of Health.  This plan focused on social mobilization to ensure that TB is de-stigmatised, 
encouraging early treatment seeking and completion of treatment (23).  However, at the time, 
diagnostic procedures relied on culture-based drug susceptibility testing (DST), and this was only done 
on request when a patient failed to respond to treatment.  This lengthy process often leaves the 
infectious patient on standard and possibly ineffective treatment for several weeks before an accurate 
diagnosis has been made and appropriate treatment is initiated.  During such diagnostic delay periods 
drug resistant TB (MDR-TB up to XDR-TB) will continue to spread in the community.  Furthermore, 
inappropriate treatment may lead to the acquisition of additional resistance by chromosomal 
mutations in target genes.   
Before commencement of this research project, only one small-scale study on the molecular features 
of the tuberculosis epidemic in the Eastern Cape has been done, showing an overrepresentation of 
the Atypical Beijing genotype among rifampicin resistant isolates (19).   
 
 




1.1.3  Beijing Genotype 
The Mycobacterium tuberculosis Beijing genotype was first described in 1995 and the name was 
coined based on the region from where the majority of these strains originated (24).  This family of 
strains was initially identified by having similar IS6110 banding patterns (24).  IS6110 is a transposon 
of which multiple copies may exist in a genome at various insertion sites, and is unique to members 
of the M. tuberculosis complex (25).  Strains with this same IS6110 banding pattern were shown to 
have identical spoligotype signatures, showing 9 specific spacer sequences (24).  Beijing genotype 
strains have also been shown to have specific Regions of Difference (RDs, large deletions), compared 
to H37Rv (26). 
The Beijing genotype is widespread in the world, including in South Africa (27,28) and is known to be 
highly transmissible and frequently associated with drug-resistance (27,29).  The Beijing genotype 
can be divided into two distinct groups, namely Typical and Atypical (30).  The Atypical Beijing 
genotype is defined by the absence of an IS6110 insertion in the NTF region (Rv0001 – Rv0002), as 
opposed to Typical Beijing genotype that harbours an IS6110 insertion on the right side of the NTF 
region, which can be detected by a PCR-based assay (31).  Atypical and Typical Beijing genotype can 
also be distinguished by their IS6110 restriction fragment length polymorphism (RFLP) pattern.  RFLP 
additionally allows further sub-classification of Typical or Atypical Beijing genotypes, denoted by a 
strain family number.  For example, strain family 29 (F29) is the predominant Typical Beijing 
genotype, whereas F31 is the most commonly seen Atypical Beijing genotype in the Eastern Cape.  In 
addition, numerous other genetic changes have been shown to be characteristic of the Atypical and 
Typical Beijing genotypes, respectively (29).  Phylogenetic analysis has positioned the Atypical Beijing 
genotype at the root of the tree which has led to the designation of “ancient” while the Typical 
Beijing genotype is positioned towards the termini leading to the designation “modern”. 
 
1.1.4  World-wide distribution of Atypical Beijing strains 
The Atypical Beijing is considered to be relatively rare in most settings worldwide, not frequently 
associated with drug-resistance (31), and less virulent than its typical counterpart (32).  In a multi-
site study, the Beijing genotype represented 6%, 53% and 71% of strains from the Netherlands, 




Vietnam and Hong Kong, respectively.  Among the Beijing genotype strains, the Atypical sub-lineage 
represented 21.2%, 25.4% and 13.6%, respectively, indicating that the distribution of both the 
Beijing genotype and its sub-lineages differ markedly in different settings across the world.  In 
contrast to these relatively low prevalence settings, the Atypical sub-lineage represents 
approximately 79% of Beijing genotype strains in Japan (31); 50% among Aborigines in Taiwan (33); 
and 65% of drug-resistant Beijing genotype strains in the Eastern Cape, South Africa (17).  However, 
in general, existing studies often do not specify which sub-lineage the observed Beijing strains 
belong to.  Therefore, it is possible that the notion that Atypical Beijing strains are rare in most parts 
of the world, may be inaccurate.  
1.1.5  Drug resistance associated with the Beijing genotype 
In a small study from Brazil, Atypical Beijing genotype strains showed varying patterns of drug-
resistance, ranging from fully drug-susceptible to polyresistant and MDR with additional 
streptomycin resistance (34).  Similarly, in Japan, certain subdivisions of the Atypical Beijing 
genotype were significantly associated with drug resistance, whereas other subdivisions were 
underrepresented in the drug resistance groups (31).  However, small sample sizes may have 
introduced bias in some of the subdivisions.   
A study across the Netherlands, Vietnam and China (35) also showed that drug-resistance in Beijing 
subgroups varied by country. However, the published data only clearly indicate that drug-resistance 
in Beijing  genotype strains was more prevalent in Vietnam than in the Netherlands, and that 
Atypical Beijing strains in these settings are more likely to be MDR or INH resistant and less likely to 
be streptomycin (STR) resistant than Typical Beijing strains (35).  In the Eastern Cape, South Africa, 
Atypical Beijing genotype strains were significantly associated with pre-XDR and XDR, including STR 
resistance (18,19).  The dominance of one particular strain type (Atypical Beijing) strengthens the 
view that drug-resistant strains may be equally fit to drug-susceptible strains or at a selective 
advantage in this setting (17,36). 
Conversely, a study conducted in Beijing, China concluded that among isolates belonging to the 
Beijing strain family (92% of the total number of strains investigated) there was no statistical 
difference in resistance-causing mutations in rpoB or katG between strains of the Typical or Atypical 
sub-lineage (37).  




These observations indicate that even within a sub-lineage of the Beijing genotype, considerable 
variation exists.  It also shows that the features which define a strain as Atypical Beijing, is not 
responsible for the acquisition of resistance or fitness.   
 
1.2  Hypotheses 
We hypothesise that Atypical Beijing genotype strains historically acquired genomic mutations and 
initial drug-resistance, giving them a selective advantage to spread and acquire additional resistance 
in the absence of comprehensive drug susceptibility testing and adequate treatment.  
 
1.3  Aims and thesis structure  
The purpose of this study was to investigate the molecular characteristics which describe the 
phenotypic properties of the drug-resistant TB epidemic in the Eastern Cape Province and to 
contextualise the epidemic in relation to the TB strain population structure in South Africa.  Chapter 2 
is presented as three separate publications.  The first publication (section 2.1 - 2.5) aimed to describe 
the molecular epidemiology of drug-resistant TB in four South African provinces.  This study shows 
that the population structures of MDR-TB is distinct in these provinces and that the dominant strain 
type in the Eastern Cape Province has influenced the population structure of M(X)DR-TB in the 
Western Cape (17).  The second publication (section 2.6 - 2.10) aimed to determine whether inhA 
promoter mutations are associated with XDR-TB in South Africa, and to assess the usefulness of the 
GenoType® MTBDRplus assay for the detection of mutations conferring INH resistance in order to 
guide treatment regimens for MDR-TB.  It was shown that in three of these provinces the inhA 
promoter mutations predispose the strains to acquire mutations leading to the evolution of XDR-TB 
and that the GenoType® MTBDRplus assay can be used as a screening tool to identify patients at risk 
of XDR-TB (38).  The third publication (section 2.11 - 2.15) aimed to elucidate whether and how 
standardized treatment impacted the strain population structure of drug-sensitive and drug-resistant 
M. tuberculosis in South Africa.  This study demonstrated programmatic errors where the 
implementation of a standardised treatment regimen failed to recognise cross-resistance thereby 




compromising treatment efficacy, culminating in the development and selection of highly resistant 
strains (36).   
Chapter 3 aimed to describe the Mycobacterium tuberculosis strain population structure among MDR-
TB and XDR-TB cases in the Eastern Cape Province of South Africa in order to determine whether the 
epidemic is driven by acquisition or transmission of resistance and to describe the extent of resistance 
within these strains (18).  It showed that the population structure of different classes of drug-
resistance (pan-susceptible, MDR-, pre-XDR- and XDR-TB) are distinct, and importantly, that Atypical 
Beijing genotype strains are vastly overrepresented among pre-XDR- and XDR-TB isolates.  It was 
further shown that within the population of pre- and XDR-TB strains, two dominant clones exist, that 
are both resistant beyond the definition of XDR-TB, are endemic and are spreading.  This was the first 
study to highlight TDR-TB in Africa and reported the highest number of these cases. 
A concurrent study of the Eastern Cape isolates confirmed the association between the rrs A1401G 
mutation and capreomycin resistance.  Chapter 4 (section 4.1-4.5) aimed to correlate the 
susceptibility levels of M. tuberculosis isolates against AMK and CAP with the molecular mechanisms 
that cause drug resistance and to determine whether the rrs and tlyA genes of isolates displaying 
resistance to both AMK and CAP contain specific mutations that mediate cross-resistance between 
the two drugs.  The potential value of capreomycin in patients infected with strains with the 
mutation was explored by quantitative drug-susceptibility testing (39).  This study led to a change in 
methods used to do routine capreomycin DST in the NHLS laboratory in Port Elizabeth.  In addition, 
our study (Chapter 4, section 4.6-4.10) investigated the extent of cross-resistance between 
rifampicin and rifabutin in the largest clone of the drug resistant Atypical Beijing genotype (40).  Our 
objectives were to correlate the MICs of RIF and RFB in a subset of M(X)DR M. tuberculosis isolates, 
to analyse the MIC data to establish whether cross-resistance occurs between RIF and its analogue 
RFB and to translate the gained knowledge into clinical practice for further assessment concerning 
RFBs potential to improve clinical outcome.  This study confirmed that the rpoB516 mutation confers 
low level rifampicin resistance and retains susceptibility towards rifabutin.  This finding has 
stimulated research towards determining whether rifabutin can be included in the regimen to treat 
patients with drug resistant strains harbouring the rpoB 516 mutation.  Furthermore, this study has 
highlighted the importance of mycobacterial pharmacogenetics which will be an essential 
component of future molecular-based diagnostics.  




In Chapter 5, we aimed to interrogate the genomes of highly resistant Atypical Beijing strains 
(resistant to up to 11 drugs) from the EC through high resolution next-generation sequencing.  
Through this analysis we aimed to infer evolutionary relationships, as well as to investigate genetic 
variation among individual isolates in order to find genetic traits that may be responsible for their 
increased transmissibility. We also sought to discover a novel mechanism of para-aminosalicylic acid 
(PAS) resistance, as six isolates were phenotypically resistant to PAS, but did not have mutations 
known to be associated with this phenotype.  We demonstrated the phylogenetic relatedness of 
Atypical Beijing genotype strains, as well as the existence of two distinct clones, each with unique 
molecular characteristics.  No genetic mechanism could be identified that may be related to PAS 
resistance in these isolates.  However, preliminary evidence suggest underlying ethionamide 
resistance in all investigated Atypical Beijing genotype strains.  This resistance would go undetected 
in most strains that are not also resistant to at least isoniazid and rifampicin.  Furthermore, the 
ethionamide resistance undermines standard second-line therapy, leading to increased acquisition 
of drug-resistance. 
The concept of totally drug-resistant TB, its definition and its management is discussed in Chapter 6. 
This review contextualises our findings with the current literature and thereby highlights the 
importance of comprehensive, rapid drug-susceptibility testing in order to prevent the acquisition of 
drug-resistance, as well as the spread of resistant TB. 
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Chapter 2   Epidemiology of drug-resistant tuberculosis in the Eastern 
Cape in the South African context 
 
This chapter consists of three peer-reviewed publications.   
1. Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains 
in South Africa. 
Chihota VN, Müller B, Mlambo CK, Pillay M, Tait M, Streicher EM, Marais E, van der Spuy GD, Hanekom 
M, Coetzee G, Trollip A, Hayes C, Bosman ME, Gey van Pittius NC, Victor TC, van Helden PD, Warren RM. 
Published in Journal of Clinical Microbiology 2012 Mar;50(3):995-1002.  
 
2. inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? 
Müller B, Streicher EM, Hoek KG, Tait M, Trollip A, Bosman ME, Coetzee GJ, Chabula-Nxiweni EM, 
Hoosain E, Gey van Pittius NC, Victor TC, van Helden PD, Warren RM. 
Published in International Journal of Tuberculosis and Lung Disease 2011 Mar;15(3):344-51. 
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My contribution to this work includes design and planning of the projects; database construction, 
management and analyses for the Eastern Cape isolates; all molecular laboratory analyses for the 
Eastern Cape isolates; and writing of the manuscripts.  
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Abstract 
Genotyping of multidrug-resistant (MDR) Mycobacterium tuberculosis strains isolated from tuberculosis 
(TB) patients in four South African provinces (Western Cape, Eastern Cape, KwaZulu-Natal and Gauteng) 
revealed a distinct population structure of the MDR strains in all four regions despite the evidence of 
substantial human migration between these settings.  In all analyzed provinces, a negative correlation 
between strain diversity and an increasing level of drug resistance (from MDR-TB to extensively drug-
resistant TB, XDR-TB) was observed.  Strains predominating in XDR-TB in the Western and Eastern Cape 
and KwaZulu-Natal provinces were strongly associated with harboring an inhA promoter mutation, 
potentially suggesting a role of these mutations in XDR-TB development in South Africa.  Approximately 
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50% of XDR-TB cases detected in the Western Cape were due to strains probably originating from the 
Eastern Cape.  This situation may illustrate how failure of efficient health care delivery in one setting can 
burden health clinics in other areas. 
 
2.1  Introduction 
Drug-resistant tuberculosis (TB) threatens TB control efforts throughout the world (1).  In particular, 
multidrug-resistant (MDR) TB, defined by resistance to at least isoniazid (INH) and rifampicin (RMP), has 
profound effects on patient treatment outcomes, since these two most effective anti-TB drugs with the 
fewest side effects, must be replaced by less effective, more expensive and more toxic drugs (2).  South 
Africa is among the countries with the worldwide highest numbers of MDR-TB cases (an estimated 
amount of 13,000 cases in 2008) (3).  In a nationwide survey in 2008, 20.2% of all notified TB cases 
showed resistance to INH and nearly half of these (9.6% of all cases) were MDR (4).  Six years earlier, in 
2002, MDR-TB had been reported in a considerably lower proportion (3.1%) of TB cases, indicating a 
dramatic increase of MDR-TB, in recent years (4;5).  Furthermore, a high rate of extensively drug-
resistant (XDR) TB (defined by MDR-TB plus additional resistance to a fluoroquinolone and at least one 
second-line injectable drug) of 10.5% was estimated among MDR-TB cases tested for second-line drug 
resistance (4).  MDR-TB is responsible for the majority of the financial burden of TB in South Africa with 
approximately 70% of the budget of the national TB control program allocated to the management of 
MDR-TB (6). 
Various reports suggest that the drug-resistant TB epidemic in South Africa is primarily caused by the 
transmission of MDR strains and the amplification of resistance as a result of the use of inappropriate 
empiric drug regimens in the context of delayed drug-susceptibility testing (DST) (7-14).  As suggested by 
mathematical models, future levels of M/XDR-TB will be largely determined by the efficiency of the 
transmission of MDR strains (15;16).  Hence, the elaboration of strategies to contain the M/XDR-TB 
epidemic requires an understanding of the disease transmission dynamics.  Our knowledge in this 
respect has increased considerably through the application of genotyping techniques such as 
spoligotyping (17) and IS6110 restriction fragment length polymorphism (RFLP) analysis (18), enabling 
the detection of TB transmission chains and the study of the evolution of M. tuberculosis population 
structures (19).  Worldwide, molecular genotyping of M. tuberculosis strains has led to the identification 
of strain families or lineages; some of which are associated with drug resistant-TB, including the Beijing 
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family of strains (10;11;20;21) the LAM genotype (22) and strains belonging to the IS6110 low copy 
number clade (13).  However, information on the genetic diversity of M. tuberculosis is primarily based 
on studies of drug-sensitive M. tuberculosis and specific data on the population structure of drug 
resistant strains is lacking (23). 
This study aimed to decipher the population structure of M/XDR M. tuberculosis strains isolated from TB 
patients in four South African provinces.  Our results help understanding the evolution and spread of 
M/XDR-TB in a high-incidence setting of drug-resistant TB and provide important baseline data for the 
assessment of future treatment changes and interventions. 
 
2.2  Materials and Methods 
2.2.1  Study Population 
This study was approved by the Ethics Committees of the participating universities.  Suspect drug-
resistant isolates of TB patients attending public health facilities in South Africa are routinely subjected 
to DST.  A random sample of diagnosed MDR isolates from the Western Cape, Eastern Cape, KwaZulu-
Natal and Gauteng provinces was characterized by spoligotyping.  Only one isolate per patient was 
included in the study.  Isolates from patients visiting primary health care clinics in the Western Cape 
were collected from August 2000-December 2010.  Isolates collected until end of 2007 only covered two 
of the four health districts of the Western Cape; however, from 2008 isolates were collected from all 
four health districts.  Isolates from patients attending primary health care clinics in the Eastern Cape, 
referral hospitals in KwaZulu-Natal or referral hospitals in Gauteng, respectively, were collected from 
July 2008-November 2009, May 2005-April 2006 or March 2004-December 2007.  Altogether, 2145, 503, 
233 and 765 (a total of 3646) isolates from the Western Cape, Eastern Cape, KwaZulu-Natal and 
Gauteng, respectively, were included in the study, corresponding to approximately 15%, 21%, 17% and 
27% of the MDR patients notified for the respective study period and province (Table 1) (24). 
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Table 1. Number of isolates analyzed by province and year.                 
Year 
  Province 
  Western Cape   Eastern Cape   KwaZulu-Natal   Gauteng 
  Isolates Notified %   Isolates Notified %   Isolates Notified %   Isolates Notified % 
2000   8 N/A N/A   0 N/A N/A   0 N/A N/A   0 N/A N/A 
2001   67 N/A N/A   0 N/A N/A   0 N/A N/A   0 N/A N/A 
2002   47 N/A N/A   0 N/A N/A   0 N/A N/A   0 N/A N/A 
2003   32 N/A N/A   0 N/A N/A   0 N/A N/A   0 N/A N/A 
2004   40 1085 3.7   0 N/A N/A   0 N/A N/A   152 537 34.0* 
2005   87 1192 7.3   0 N/A N/A   156 1024 22.9*   238 676 35.2 
2006   106 1179 9.0   0 N/A N/A   77 2200 10.5*   223 732 30.5 
2007   158 1771 8.9   0 N/A N/A   0 N/A N/A   152 986 15.4 
2008   426 2220 19.2   220 1501 29.3*   0 N/A N/A   0 N/A N/A 
2009   566 2078 27.2   282 1858 16.6*   0 N/A N/A   0 N/A N/A 
2010   592 N/A N/A   0 N/A N/A   0 N/A N/A   0 N/A N/A 
Unknown   16 N/A N/A   1 N/A N/A   0 N/A N/A   0 N/A N/A 
Total   2145 9525 14.5**   503 3359 20.5*   233 3346 16.5*   765 2931 26.9* 
Isolates: Number of MDR isolates collected in the indicated year             
Notified: Number of MDR-TB cases notified by the National Health Laboratory Service (NHLS), in the indicated year 
%: Estimated proportion of isolates analyzed among MDR-TB cases detected during sampling months   
N/A: No data available or not applicable                     
*Sampling only occurred during part of the indicated year. To estimate the proportion of notified MDR isolates analyzed, 
the number of notified cases during the sampling period was calculated pro rata temporis.     
**The overall proportion of isolates analyzed only considered years for which NHLS data was available   
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2.2.2  Routine culture and drug susceptibility testing 
Samples were decontaminated and subjected to bacterial culture using the BACTEC™ MGIT™ 960 
Culture System for mycobacteria (27).  Isolates from the Western Cape, Eastern Cape and Gauteng were 
subjected to routine DST by the National Health Laboratory Services (NHLS) using the indirect proportion 
method on Middlebrook 7H11 medium (25).  In Gauteng, DST was done for INH, RMP, ethambutol 
(EMB) and streptomycin (SM) only; in the Western and Eastern Cape, DST was extended to ethionamide 
(ETH), kanamycin (KM), amikacin (AMK) and ofloxacin (OFX).  However, in the Western Cape, testing for 
second line drugs only covered isolates collected in late 2006 onwards.  In KwaZulu-Natal, during the 
study period, culture and DST was routinely done by the Regional Laboratory Service at Inkosi Albert 
Luthuli Central Hospital, using the agar proportion method on Middlebrook 7H10 agar plates containing 
INH, RMP, EMB, SM, KM and OFX (25). 
 
2.2.3  Genotypic characterization 
M. tuberculosis isolates from patients were subcultured on LJ medium and genotyped using 
spoligotyping (17).  The spoligotype patterns were compared to the data deposited in the fourth 
international spoligotyping database (SpolDB4) (26), and grouped according to the different strain 
families as defined in SpolDB4.  Sub-classification of Beijing genotypes into typical and atypical Beijing 
strains was performed on a random sample of Beijing genotypes from the Western Cape, Eastern Cape 
and Gauteng using a previously described PCR protocol or IS6110 RFLP analysis (13;18).  Beijing isolates 
from KwaZulu-Natal were not available for further sub-classification.  A random sample of 13 typical and 
19 atypical XDR Beijing isolates from the Western Cape and 65 atypical XDR Beijing isolates from the 
Eastern Cape were tested for mutations in the inhA promoter using previously described methods (27). 
 
2.2.4  Definitions 
MDR and XDR strains were classified according to WHO definitions (4).  Pre-XDR-TB isolates were 
defined as MDR-TB isolates with additional resistance to either a fluoroquinolone (e.g. OFX) or a second-
line injectable drug (capreomycin, KM or AMK) but not both (28).  The MDR sensu stricto (s.s.) group 
excluded identified pre-XDR and XDR isolates. 
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2.2.5  Statistical analysis  
Statistical analyses were done using STATA 10.0 (StataCorp LP, College Station, Texas, USA).  The 
Pearson’s chi-squared test was performed to test for a significant difference in the proportion of M. 
tuberculosis genotypes between two provinces or drug resistance groups.  A p-value <0.05 was 
considered statistically significant. 
 
2.3  Results 
A sample of 3646 MDR isolates of M. tuberculosis collected between 2000 and 2010 from patients in 
four South African provinces, namely the Western Cape, Eastern Cape, KwaZulu-Natal and Gauteng, was 
genotyped by spoligotyping (17).  A total of 220 spoligotype patterns were identified of which 122 could 
be grouped into 41 strain families according to the international spoligotyping database (SpolDB4) (26).  
The remaining isolates showed spoligotype patterns that did not match with any of the patterns in 
SpolDB4 (i.e., 206 isolates representing 98 different spoligotype patterns; 5.7% of all isolates; Table 2).  
The frequency distribution of isolates from all identified strain families stratified by origin and drug 
resistance group is presented in the Appendix.  
Between the four South African provinces, Beijing strains were predominantly localized to the Western 
and Eastern Cape where 55% and 69% of all MDR isolates belonged to this genotype, respectively.  
Conversely, Beijing strains represented only 6% and 17% of all MDR isolates from KwaZulu-Natal and 
Gauteng, respectively (Table 2; Figure 1; p<0.001 for the pairwise comparison of the proportions 
between all provinces).  Differentiation of a subset of the Beijing isolates into the sub-families of typical 
and atypical Beijing genotypes highlighted distinct population structures in the different provinces.  In 
the Western Cape, 75% of all analyzed MDR isolates of the Beijing genotype belonged to the group of 
typical Beijing strains.  In contrast, only 8% of the analyzed Beijing isolates from the Eastern Cape were 
members of the typical group and 92% belonged to the group of atypical Beijing strains (Table 3; Figure 
1; p<0.001).  In Gauteng, 83% of the tested Beijing isolates were members of the typical Beijing 
genotype (Table 3; Figure 1).  Beijing isolates from KwaZulu-Natal were not available for further 
characterization. 
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Table 2. The frequency distribution of major MDR genotypes in four South African provinces stratified by drug resistance group. 
Province 
  Drug 
resistance 
class 
  Strain families   
Total 
    BEIJING   LAM4   S   T1   X1   Others   
    no. %   no. %   no. %   no. %   no. %   no. %   no. % 
Western Cape 
  All MDR   1174 54.7   52 2.4   51 2.4   158 7.4   181 8.4   529 24.7   2145 100.0 
  MDR s.s.   919 50.5   48 2.6   49 2.7   148 8.1   172 9.5   483 26.6   1819 100.0 
  Pre-XDR   161 72.9   4 1.8   2 0.9   6 2.7   9 4.1   39 17.6   221 100.0 
  XDR   94 89.5   0 0.0   0 0.0   4 3.8   0 0.0   7 6.7   105 100.0 
                                                
Eastern Cape 
  All MDR   348 69.2   52 10.3   10 2.0   13 2.6   0 0.0   80 15.9   503 100.0 
  MDR s.s.   144 50.5   46 16.1   9 3.2   13 4.6   0 0.0   73 25.6   285 100.0 
  Pre-XDR   115 92.7   5 4.0   0 0.0   0 0.0   0 0.0   4 3.2   124 100.0 
  XDR   89 94.7   1 1.1   1 1.1   0 0.0   0 0.0   3 3.2   94 100.0 
                                                
KwaZulu-Natal 
  All MDR   15 6.4   61 26.2   71 30.5   30 12.9   0 0.0   56 24.0   233 100.0 
  MDR s.s.   15 7.7   39 19.9   66 33.7   27 13.8   0 0.0   49 25.0   196 100.0 
  Pre-XDR   0 0.0   4 33.3   3 25.0   1 8.3   0 0.0   4 33.3   12 100.0 
  XDR   0 0.0   18 72.0   2 8.0   2 8.0   0 0.0   3 12.0   25 100.0 
                                                
Gauteng   All MDR   128 16.7   128 16.7   56 7.3   109 14.2   0 0.0   344 45.0   765 100.0 
                                                
All Provinces   All MDR   1665 45.7   293 8.0   188 5.2   310 8.5   181 5.0   1009 27.7   3646 100.0 
MDR s.s.: MDR sensu stricto; MDR cases not including identified pre-XDR and XDR-TB cases               
no.: Number of isolates belonging to a given strain family for a given drug resistance group and province         
%: Proportion of isolates belonging to a given strain family for a given drug resistance group and province         
LAM4 is also commonly referred to as F15/LAM4/KZN                               
Stellenbosch University  https://scholar.sun.ac.za




Figure 1:  Frequency distribution of major MDR genotypes in four South African provinces.  The proportion of isolates 
belonging to the Beijing, LAM4, S, T1, X1, or other genotypes is indicated in different shades of gray.  The proportion of 
typical and atypical Beijing strains among the Beijing strains in Western Cape, Eastern Cape and Gauteng Provinces is shown 
in Table 2.  Beijing strains from KwaZulu-Natal were not available for further characterization. LAM4 is also commonly 
referred to as F15/LAM4/KZN. 
 
The concept of distinct population structures within the different provinces is further supported by our 
observation that the S and LAM4 (also referred to as F15/LAM4/KZN) families together constituted 57% 
of the isolates in KwaZulu-Natal but only 5%, 12% and 24% of the isolates in the Western Cape, Eastern 
Cape and Gauteng, respectively (Table 2; Figure 1; p<0.001 for the pairwise comparison of the 
proportions between all provinces).  Interestingly, the X1 family of strains was only represented in 
isolates from the Western Cape (8% of all isolates) (Table 2; Figure 1).  The strain population structure in 
Gauteng also differed from the other provinces. This was mostly suggested by the more equal frequency 
distribution of isolates from different strain families. While the two most frequently detected MDR 
strain families in the Western Cape, Eastern Cape and KwaZulu-Natal contributed 57% and more of all 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
23 
 
isolates in these provinces, strains belonging to the two most prevalent genotypes in Gauteng only 
constituted 33% of the isolates in this province (Table 2; Figure 1). Of note, the EAI1_SOM and the H3 
lineages were significantly more frequently isolated from MDR-TB patients in Gauteng (in 7% and 12% of 
the isolates, respectively) than in the other provinces (less than 2%; p<0.001), further illustrating the 
distinct population structure in Gauteng (Appendix).  
Table 3. Proportion of typical and atypical Beijing strains.       
Province 
  Drug 
resistance 
class 
  BEIJING   
    Typical   Atypical   All   
    no. %   no. %   no. %   
Western Cape 
  All MDR   168 75.0   56 25.0   224 100.0   
  MDR s.s.   129 85.4   22 14.6   151 100.0   
  Pre-XDR   25 67.6   12 32.4   37 100.0   
  XDR   14 38.9   22 61.1   36 100.0   
                          
Eastern Cape 
  All MDR   16 7.9   186 92.1   202 100.0   
  MDR s.s.   16 32.0   34 68.0   50 100.0   
  Pre-XDR   0 0.0   85 100.0   85 100.0   
  XDR   0 0.0   67 100.0   67 100.0   
                          
Gauteng   All MDR   67 82.7   14 17.3   81 100.0   
MDR s.s.: MDR sensu stricto; MDR cases not including identified pre-XDR and XDR-TB cases 
 
Stratification of the genotyping data for the Western Cape, Eastern Cape and KwaZulu-Natal by 
phenotypic drug resistance (no second-line DST results were available for Gauteng), revealed an 
increasingly marked predomination of one or two strain families from MDR sensu stricto- (MDR s.s.) to 
pre-XDR- and XDR-TB (Table 2; Figure 2).  In the Western and Eastern Cape provinces, 90% or more of 
the XDR isolates belonged to the Beijing family of strains, representing a more than 75% increase 
compared to MDR s.s. (p<0.001 for both provinces; Table 2; Figure 2).  Notably, the extrapolated overall 
proportion of atypical Beijing strains increased from 7% in the MDR s.s. group to 55% in the XDR group 
in the Western Cape, while the overall proportion of atypical Beijing strains increased from 34% in MDR 
s.s. to 95% in the XDR group in the Eastern Cape (Tables 1 and 2; Figure 2).  Similarly, in KwaZulu-Natal, 
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the proportion of isolates belonging to the F15/LAM4/KZN family of strains increased from 20% in MDR 
s.s. cases to 72% in XDR-TB (Table 2). 
A recent study revealed an association between drug-resistance mutations in the inhA promoter and 
XDR-TB in South Africa, however, without considering the influence of transmission (29).  In a random, 
preliminary sample of XDR-TB isolates from the Western Cape, of 13 typical and 19 atypical Beijing 
isolates tested, 11 (85%) and 19 (100%) showed mutations in the inhA promoter, respectively.  In the 
Eastern Cape, 62 (95%) of 65 tested XDR strains of the atypical Beijing family of strains showed a 
mutation in the inhA promoter.  In a previous study by Ioerger et al., whole genome sequencing of 9 
randomly chosen XDR isolates of the F15/LAM4/KZN family of strains from patients from different 
regions of KwaZulu-Natal revealed an inhA promoter mutation in all of these isolates (30).  Thus, inhA 
promoter mutations are strongly linked to strains predominating in XDR-TB in at least three South 
African provinces. 
 
2.4  Discussion 
The present study represents a comprehensive description and comparison of the regional population 
structures of MDR M. tuberculosis strains in a high-burden country.  Molecular characterization of MDR 
isolates from the Western and Eastern Cape, KwaZulu-Natal and Gauteng revealed distinct MDR-TB 
strain population structures in all four provinces and the geographical localization of specific strain 
families to different regions.  In particular, typical and atypical Beijing strains are overrepresented in the 
neighboring coastal Western and Eastern Cape provinces and strains of the S and F15/LAM4/KZN family 
are present at significantly higher frequencies in KwaZulu-Natal (Table 2, Figure 1). 
Distinct population structures between different regions may be explained by the lack of strain 
exchange between geographically separated populations, resulting in a ‘disconnected’ evolution and a 
progressive differentiation of these populations over time (31).  Interestingly, the observed differences 
in the interprovincial MDR strain population structures parallel observations in the population structure 
of M. bovis in other parts of the world (31;32) but are unexpected as one might assume that internal 
migrations in South Africa could homogenize population structures between closely situated regions to a 
larger extent (33). 
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Nevertheless, our data provides evidence to suggest that limited strain exchange between different 
regions is occurring.  This is especially indicated by the presence of most of the strain families in more 
than one province.  Of all 3646 isolates analyzed within this study 3185 isolates (87%; representing 51 
spoligotype patterns) exhibited a spoligotype pattern that was present in more than one province.  
Previous analyses of South Africa’s internal migrations showed highest immigration rates for Gauteng 
(33); this is also reflected by a more equal frequency distribution of MDR-TB genotypes in this setting 
(Table 2; Figure 1).  Residents from KwaZulu-Natal mostly immigrated to Gauteng and significantly less 
often to the Western or Eastern Cape provinces, perhaps explaining the more frequent isolation of MDR 
isolates belonging to the S and F15/LAM4/KZN family of strains in Gauteng and the very distinct 
population structure between KwaZulu-Natal and the Western and Eastern Cape provinces.  Over 50% 
of the migrations to the Western Cape originated from the Eastern Cape (33), which possibly led to the 
introduction of the atypical Beijing strain genotype into the Western Cape.  It could be speculated that 
the observed evidence for strain exchange between provinces is mostly based on recent human 
migrations while the generally different population structures between provinces could reflect earlier 
periods characterized by less migration (e.g. due to a restrictive migration policy during the apartheid 
era from 1948-1994) (33).  Alternatively, the distinct population structures may be a result of multiple 
factors including geographically localized outbreaks or epidemics and distinct migration patterns in 
different settings. 
An introduction of the atypical Beijing lineage from the Eastern Cape into the Western Cape and not vice 
versa is mostly supported by the much higher overall prevalence of this lineage in the Eastern Cape 
(Figure 1), a considerably higher diversity of IS6110 RFLP patterns among the atypical Beijing strain 
population in the Eastern Cape compared to the Western Cape (data not shown) and a ten times higher 
number of human migrations from the Eastern to the Western Cape than vice versa (33).  An 
introduction from other provinces not included in this study such as the neighboring Northern Cape 
(Figure 2) is less likely considering the human migratory behaviors in South Africa (33) and a significantly 
higher TB and MDR-TB incidence in the Eastern Cape compared to the Northern Cape (24), making 
spillover to the adjacent province more likely.  Taken together, the current data suggests that the 
atypical Beijing lineage, accounting for more than 50% of all XDR-TB cases detected in the Western 
Cape, was introduced from the Eastern Cape. 
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Figure 2:  Frequency distribution of major MDR genotypes stratified by drug-resistance group for three South African 
provinces. The proportion of isolates belonging to the Beijing, LAM4, S, T1, X1 or other genotypes is indicated for MDR sensu 
stricto (MDR s.s.; not including pre-XDR and XDR isolates), pre-XDR and XDR cases (different shades of gray). The proportion 
of typical and atypical Beijing strains among the Beijing strains in the Western and Eastern Cape is extrapolated from Table 3. 
LAM4 is also commonly referred to as F15/LAM4/KZN. 
 
XDR-TB cases caused by atypical Beijing strains in the Western Cape are for the most part unlikely to be 
a result of clonal transmission of XDR strains, as recent data revealed a variety of distinct second-line 
drug resistance mutations among IS6110 RFLP clustered isolates (34).  Thus, the majority of these XDR 
cases emerged through the amplification of resistance in primary MDR s.s. or pre-XDR-TB.  The 
predominance of atypical Beijing strains in XDR-TB in the Western Cape, their significantly reduced 
contribution to MDR s.s. and pre-XDR-TB (Figure 2; Table 3) and the lack of evidence for the clonal 
transmission of XDR strains (34) suggests that a considerable amount of XDR-TB cases detected in the 
Western Cape could have developed from patients infected in the Eastern Cape who subsequently 
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migrated or returned to the Western Cape or who were seeking treatment outside their residential 
province.  It seems conceivable that in particular patients with complicated disease residing in the 
economically more depressed Eastern Cape may decide to visit health clinics in the more affluent 
Western Cape where they may expect relatively superior quality of health care services (35).  This 
situation could illustrate how relatively increased disease frequencies or shortage of access to efficient 
health care in a given region may burden health systems in adjacent areas.  Similar scenarios are found 
in other regions of the world; e.g., MDR-TB clusters identified in Europe are associated with strains 
originating in eastern European countries (36).  Equal access to functional health care services in closely 
situated regions is essential to prevent aggravation of circumstances in a given setting and the 
subsequent overload of health clinics in neighboring regions. 
This study shows an intriguing, increasingly marked predomination of one single or two strain families 
from MDR s.s. to XDR-TB in all three provinces analyzed (Table 2; Figure 2).  An association of certain 
strain families with XDR-TB could be attributed to their relatively more effective transmission as MDR 
strains, or, alternatively, may be explained by an enhanced intrinsic capacity to acquire resistance to 
second-line anti-TB drugs.  We have recently demonstrated a significant association of inhA promoter 
mutations with XDR-TB in the Western and Eastern Cape provinces of South Africa (29).  InhA promoter 
mutations confer low-level resistance to INH (used in first-line therapy for supposedly drug-sensitive TB) 
and high-level resistance to ETH (commonly used in second-line drug regimens for the treatment of 
MDR-TB) (37).  We hypothesize that MDR strains, which have acquired such mutations at a previous 
instance (e.g. when exposed to INH during first-line therapy) would show an increased probability to 
gain resistance to other second-line drugs due to the treatment regimen having one less effective drug 
(29).  Our preliminary data from the Western and Eastern Cape and a previous study in KwaZulu-Natal 
revealed that inhA promoter mutations are strongly linked to strains predominating in XDR-TB in at least 
three South African provinces.  Similarly, in a study from Portugal, all of 26 XDR-TB isolates analyzed 
showed an inhA promoter mutation (38), suggesting that this association might be of importance in 
several parts of the world.  These observations could be explained if, within the context of certain 
standardized second-line drug regimens, the presence of an inhA promoter mutation could increase the 
likelihood for a given strain to acquire additional resistance. 
We previously recommended an adapted treatment regimen not including ETH for TB patients infected 
with strains harbouring an inhA promoter mutation (29). High-dose INH may be considered for 
treatment in such cases if no additional high-level resistance mutations (e.g. mutations in katG gene 
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codon 315) are present in infecting strains.  Importantly, with the use of molecular probe assays such as 
the GenoType® MTBDRplus assay, now regularly used for genotypic DST in many settings, information 
about the presence of inhA promoter mutations in patient isolates is readily available to clinicians (29). 
The present study has certain limitations.  Most importantly, sample collection in the different provinces 
occurred during distinct time periods (Table 1), which could have caused artificial dissimilarities between 
the observed population structures.  In the Western Cape Province, where isolates were collected over 
the longest period, an extensive increase in drug-resistant TB cases due to the Beijing family of strains 
could be observed with 32% and 63% of the isolates belonging to this family in 2001 and 2009, 
respectively.  This is in accordance with previous reports from this region (10;39).  Nevertheless, no 
considerable change was evident with respect to the different strain families comprising the most 
frequently observed MDR-TB isolates (data not shown), suggesting that temporal biases were unlikely to 
artificially create distinct strain population structure between the investigated regions.  Secondly, it may 
not be able to exclude the possibility that the population bottlenecks occurring during the transitions 
from MDR s.s.- to pre-XDR- and XDR-TB could, in theory, account for the increasingly marked 
predomination of only one or two strain families from MDR s.s.- to XDR-TB.  More research is needed to 
investigate the nature of this observation. 
In conclusion, the data presented shows a distinct population structure and geographical localization of 
MDR strains of M. tuberculosis in four South African provinces.  Evidence for provincial migration and in 
particular the introduction of XDR strains from the Eastern to the Western Cape highlights the need for 
uniformly implemented TB control programs.  Only few strain families contribute to XDR-TB in South 
Africa, suggesting an enhanced ability of these strains to transmit as primary MDR strains or to acquire 
second-line resistance. In either case, inadequate diagnostic and treatment algorithms have probably 
led to the programmatic selection of these strains to become XDR strains.  South African guidelines for 
the treatment of MDR-TB have recently been amended with terizidone replacing EMB for the treatment 
of MDR-TB and capreomycin, p-aminosalicylic acid and moxifloxacin, respectively, replacing KM (or 
AMK), PZA and OFX for the treatment of XDR-TB.  It is questionable whether these changes will help 
curbing the emergence of XDR-TB or the predominance of the few transmitting MDR strains accounting 
for the majority of XDR-TB cases.  This study provides important baseline data to understand and 
monitor future changes in the population structure of M/XDR strains of M. tuberculosis and to assess 
the impact of such interventions. 
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Abstract 
SETTING: Western Cape and Eastern Cape Provinces in South Africa. 
OBJECTIVE: To assess a potential association between the evolution of extensively drug resistant 
(XDR) strains of Mycobacterium tuberculosis and mutations in katG or the inhA promoter. 
DESIGN: Analysis of a population sample of drug resistant strains of M. tuberculosis. 
RESULTS: In the Western Cape and Eastern Cape Provinces, respectively, the percentage of strains 
exhibiting inhA promoter mutations increased significantly from 47.8% and 70.7% in multidrug 
resistant (MDR) strains to 85.5% and 91.9% in XDR strains.  Data from the Western Cape revealed 
that significantly more XDR strains showed mutations in the inhA promoter than in katG (85.5% vs. 
60.9%; p<0.0001) although the respective proportions were equal for INH resistant non-MDR strains 
(~30%). 
CONCLUSIONS: InhA promoter mutations are strongly associated with XDR tuberculosis in South 
Africa.  This is most probably due to the dual resistance to ethionamide and (low-dose) isoniazid 
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conferred by inhA promoter mutations. The use of molecular probe assays such as the GenoType® 
MTBDRplus assay, which allow the detection of inhA promoter mutations, could enable adjustment 
of the treatment regimens depending on the pharmacogenetic properties of the mutations 
detected. 
 
2.6  Introduction 
Multidrug resistant tuberculosis (MDR-TB), defined by the resistance to at least isoniazid (INH) and 
rifampicin (RIF), threatens TB control programs in many parts of the world (1).  Amplification of drug 
resistance in MDR-TB can lead to virtually untreatable extensively drug resistant tuberculosis (XDR-
TB), defined as MDR-TB with additional resistance to a fluoroquinolone and one of the injectable 
second line drugs kanamycin (KAN), amikacin (AMI) or capreomycin (CAP) (2-5).  Cases of drug 
resistant TB emerge through ineffective treatment, patient non-adherence to therapy or the 
transmission of drug resistant strains of M. tuberculosis (2-4).  
In South Africa, all new cases of TB are treated with a combination of four anti-TB drugs [INH, RIF, 
pyrazinamide (PZA) and ethambutol (EMB)] in the absence of drug susceptibility testing (DST) (6;7).  
Streptomycin is added to this regimen for retreatment cases while DST is being performed.  If 
resistance to INH and RIF is detected the treatment regimen is adjusted to include second line anti-
TB drugs.  Since 2002 the treatment of MDR-TB has been largely standardized and includes a 
fluoroquinolone [mostly ofloxacin (OFX)], an aminoglycoside (AMI or KAN), PZA, EMB or cycloserine, 
and ethionamide (ETH) (6;8).  This regimen assumes that resistance to EMB and PZA is rare.  
However, there is mounting microbiological evidence to suggest a strong association between MDR-
TB and EMB and PZA resistance (6;9;10).  Furthermore, several molecular epidemiological studies 
have suggested that MDR-TB is largely transmitted (11-13).  This questions the validity of the current 
treatment guidelines (6) and calls for the development of rapid diagnostics for DST (14). 
On a molecular level, drug resistance in M. tuberculosis develops through spontaneous mutations in 
target genes followed by the natural selection of these resistant bacteria upon exposure to anti-TB 
drugs (3;4).  Various drug resistance causing mutations in M. tuberculosis have been characterized, 
to date (3;15;16).  It is well documented that mutations in the inhA promoter confer low-level 
resistance to INH and cross-resistance to ETH, while mutations in katG at codon 315 exclusively 
confer high-level resistance to INH (16-19).  Similarly, mutations in the rpoB gene account for >95% 
of RIF resistance (20).  Thus, molecular assays identifying specific drug resistance causing mutations 
may be used to accelerate DST, which is considered critical to prevent amplification and 
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transmission of drug resistance (14).  In this respect, the WHO approved GenoType® MTBDRplus 
assay has been implemented in several settings to assist culture based DST; it detects most of the 
mutations conferring RIF resistance as well as the principal mutations in the katG gene and inhA 
promoter which confer INH resistance (14). 
Considering the dual resistance to INH and ETH conferred by the inhA promoter mutation and the 
use of these drugs for first and second line treatment, respectively, this study aimed to determine 
whether M. tuberculosis strains harbouring mutations in the inhA promoter are associated with XDR-
TB, in South Africa.  Moreover, we assessed the usefulness of the GenoType® MTBDRplus assay for 
the detection of mutations conferring INH resistance in order to guide treatment regimens for MDR-
TB. 
 
2.7  Materials and Methods 
2.7.1  Data from the Western Cape Province 
Between 2001 and 2007, drug resistant isolates from patients visiting health facilities in two of the 
four health districts in the Western Cape Province were collected.  From 2008, drug resistant isolates 
from patients visiting health facilities in all of the health districts were collected.  Routine DST was 
done by the National Health Laboratory Services (NHLS) and included testing for INH, RIF and EMB 
resistance.  In 2007, routine DST was revised to include testing for OFX, AMI and ETH resistance.  
Mutation analyses of katG and the inhA promoter was done on a convenience sample of INH 
resistant non-MDR (INH mono-resistance and poly-resistant) and MDR strains.  The same mutation 
analysis was done on the complete set of XDR-TB strains.  Mutations were identified by dot-blot 
techniques or partial gene sequencing as explained elsewhere (21).  For the analysis of the frequency 
of mutations in katG and the inhA promoter of INH resistant strains (Table 1), only sequencing data 
was considered.  For the analysis of mutation patterns in different drug resistance classes (Tables 2 
and 3, Figures 1 and 2), all available data including results from dot-blot analyses was considered. 
Only one M. tuberculosis isolate per patient was integrated in our analysis. 
 
2.7.2  Data from the Eastern Cape Province 
During the period from July 2008 to November 2009, all MDR-TB isolates cultured from patients 
visiting heath facilities in the Eastern Cape Province were collected.  Routine DST was done by the 
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NHLS of the Nelson Mandela Bay Municipality, Eastern Cape.  Mutations in the inhA promoter were 
identified by DNA sequencing (21). 
 
2.7.3  Statistical analyses 
Associations between distinct drug resistance groups and the occurrence of mutations in katG or the 
inhA promoter have been tested by the Pearson’s chi-squared test.  Difference in the proportions of 
XDR strains with mutations in katG or the inhA promoter have been tested by the Mc Nemar’s test.  
Analyses have been performed in Stata/IC v10.1 
 
2.8  Results 
2.8.1  Western Cape Province 
Table 1 lists the mutations identified by sequencing of the katG gene and the inhA promoter.  KatG 
mutations at codon 315 and inhA promoter mutations at nucleotide position -15 constituted the 
majority (34.7% and 55.9%, respectively) of the observed sequence changes (Table 1).  Of all 
identified mutations, the MTBDRplus assay could potentially detect alterations in katG codon 315 
and in the inhA promoter at nucleotide positions -8, -15 and -17, either specifically through a 
mutation probe or through the absence of a hybridization signal for one of the wild-type probes.  
Consequently, in theory, the MTBDRplus assay might detect up to 96.3% of the mutation events here 
identified by sequencing (Table 1). 
To investigate any potential associations between sequence changes in katG or the inhA promoter 
and XDR-TB, we calculated the proportion of strains with mutations in these genetic regions for 
different drug resistance classes (INH resistant non-MDR strains, MDR strains and XDR strains; Table 
2, Figure 1).  The percentage of strains with an inhA promoter mutation increased significantly from 
30.1% in INH resistant non-MDR strains to 58.5% in MDR strains and 85.5% in XDR strains (overall 
2.8-fold increase, Χ2=74.6, p<0.001; Table 2, Figure 1).  Although the percentage of strains with a 
katG mutation also increased, the rate of increase was lower (2.1-fold, Χ2=28.7, p<0.001) and fully 
attributable to strains that also harboured an inhA promoter mutation (Table 2, Figure 1).  
Significantly more XDR strains showed mutations in the inhA promoter than in katG (85.5% vs. 
60.9%, p<0.0001) although the respective proportions were equal for INH resistant non-MDR strains 
(~30%; Table 2, Figure 1). 
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Table 1 Frequency of mutations identified by sequencing in katG and the inhA promoter of INH resistant strains of M. tuberculosis in the Western Cape Province 
Gene Position Mutation Present  Absent Sum % Present % Mutations % Cumulative mutations 
inhA promoter -15 point mutation 224 157 381 58.8% 55.9% 55.9% 
inhA promoter -17 point mutation 21 360 381 5.5% 5.2% 61.1% 
inhA promoter -8 point mutation 2 379 381 0.5% 0.5% 61.6% 
katG 315 point mutation 139 277 416 33.4% 34.7% 96.3% 
katG 387 point mutation 2 414 416 0.5% 0.5% 96.8% 
katG 77 point mutation 1 415 416 0.2% 0.2% 97.0% 
katG 299 point mutation 1 415 416 0.2% 0.2% 97.3% 
katG 302 point mutation 1 415 416 0.2% 0.2% 97.5% 
katG 314 insertion 1 415 416 0.2% 0.2% 97.8% 
katG 320 point mutation 1 415 416 0.2% 0.2% 98.0% 
katG 408 point mutation 1 415 416 0.2% 0.2% 98.3% 
katG 483 point mutation 1 415 416 0.2% 0.2% 98.5% 
katG 119 deletion 3 130 133 2.3% 0.7% 99.3% 
katG 76 point mutation 1 132 133 0.8% 0.2% 99.5% 
katG 137 point mutation 1 132 133 0.8% 0.2% 99.8% 
katG 198 point mutation 1 132 133 0.8% 0.2% 100.0% 
Total     401           
Position: Amino-acid positions are indicated for transcribed regions (katG) and base-pair positions are indicated for untranscribed regions (inhA promoter)  
Present: Among the INH resistant strains tested, number of strains showing a point mutation for the indicated gene at the indicated position 
Absent: Among the INH resistant strains tested, number of strains not showing a mutation for the indicated gene at the indicated position 
Sum: Number of INH resistant strains tested for a specific mutation for the indicated gene at the indicated position 
% Present: Among the INH resistant strains tested, percentage of strains showing a mutation for the indicated gene at the indicated position 
% Mutations: Number of times a specific mutation has been detected divided by the total number of detected mutation events 
Total: Total number of detected mutation events           
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Importantly, 41.7% of all INH resistant non-MDR strains did not exhibit any mutations in katG or the 
inhA promoter (Table 2, Figure 1). However, this was significantly less frequently observed in MDR- 
and not seen in XDR-TB cases. Also of note, a proportion of almost 40% of the MDR and XDR strains 




2.8.2  Eastern Cape Province 
We analyzed an extensive set of MDR-TB strains isolated from TB patients in the Eastern Cape 
Province in order to determine whether the association between the inhA promoter mutation and 
XDR-TB is restricted to the Western Cape Province.  Table 3 and Figure 2 show all mutations 
identified in the inhA promoter and their mutation frequencies in MDR and XDR strains.  
In this setting, the proportion of isolates with an inhA promoter mutation also increased significantly 
during amplification of resistance from MDR-TB (70.7%) to XDR-TB (91.9%; 1.3-fold increase; 
Χ2=13.9, p<0.001; Table 3, Figure 2).  In contrast to the Western Cape Province, the inhA promoter 
mutation at nucleotide position -17 was the predominant mutation found in this region.
Table 2 Patterns of point mutations in the inhA promoter and katG by drug resistance class in strains of M. tuberculosis in the Western 
Cape Province 
Mutation 
  non-MDR INHR   MDR   XDR 
  N % CI   N % CI   N % CI 
inhA promoter\katG   61 29.6% 23.5%-36.4%   100 39.5% 33.5%-45.8%   27 39.1% 27.6%-51.6% 
inhA promoter∩katG   1 0.5% 0.0%-2.7%   48 19.0% 14.3%-24.4%   32 46.4% 34.3%-58.8% 
katG\inhA promoter   58 28.2% 22.1%-34.8%   73 28.9% 23.4%-34.9%   10 14.5% 7.2%-25.0% 
only others   86 41.7% 34.9%-48.8%   32 12.6% 8.8%-17.4%   0 0.0% 0.0%-5.2%* 
inhA promoter   62 30.1% 23.9%-36.9%   148 58.5% 52.2%-64.6%   59 85.5% 75.0%-92.8% 
katG   59 28.6% 22.6%-35.3%   121 47.8% 41.5%-54.2%   42 60.9% 48.4%-72.4% 
Total   206 100.0% N/A   253 100.0% N/A   69 100.0% N/A 
MDR group includes XDR group                   
inhA promoter\katG: Strains with mutations detected in the inhA promoter but not in katG     
inhA promoter∩katG: Strains with mutations detected in the inhA promoter and in katG       
katG\inhA promoter: Strains with mutations detected in katG but not in the inhA promoter     
only others: Strains with no mutations detected in katG or the inhA promoter         
inhA promoter: Strains with mutations detected in the inhA promoter           
katG: Strains with mutations detected in katG                 
Total: Total number of strains tested                   
N: Number of strains of the same drug resistance group with the respective drug mutation pattern   
%: Percentage of strains of the same drug resistance group with the respective drug mutation pattern   
CI: 95% confidence intervals                   
* One-sided, 97.5% confidence interval                 
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  MDR   XDR 
    Present  Absent Sum % Present % Mutation N % CI   N % CI 
inhA   -17   134 129 263 51.0% 72.0% 134 51.0% 44.7%-57.1%   62 83.8% 73.4%-91.3% 
inhA   -15   30 233 263 11.4% 16.1% 30 11.4% 7.8%-15.9%   4 5.4% 1.5%-13.3% 
inhA   -8   22 241 263 8.4% 11.8% 22 8.4% 5.3%-12.4%   2 2.7% 0.3%-9.4% 
only others       N/A N/A N/A N/A N/A 77 29.3% 23.8%-35.2%   6 8.1% 3.0%-16.8% 
inhA   all   N/A N/A N/A N/A N/A 186 70.7% 64.8%-76.2%   68 91.9% 83.2%-97.0% 
Total       186         263 100.0%     74 100.0%   
MDR group includes XDR group                       
Position: Nucleotide positions are indicated                   
Present: Among the MDR strains tested, number of strains showing a point mutation for the indicated gene at the indicated position 
Absent: Among the MDR strains tested, number of strains not showing a mutation for the indicated gene at the indicated position 
Sum: Number of MDR strains tested for a specific point mutation for the indicated gene at the indicated position   
% Present: Among the MDR strains tested, percentage of strains with a point mutation detected for the indicated gene at the indicated position 
% Mutations: Number of times a specific mutation has been detected divided by the total number of detected mutation events 
N: Number of strains of the same drug resistance group with the respective drug mutation pattern         
%: Percentage of strains of the same drug resistance group with the respective drug mutation pattern         
CI: 95% confidence intervals                       
Total: Total number of detected mutation events or total number of MDR/XDR cases           
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Figure 1:  Patterns of point mutations in the inhA promoter and katG by drug resistance class in strains of M. 
tuberculosis in the Western Cape Province. MDR group includes XDR group; only others = isolates with no mutations 
detected in katG or the inhA promoter; katG\inhA promoter = isolates with mutations detected in katG but not in the 
inhA promoter; inhA promoter∩katG = isolates with mutations detected in the inhA promoter and in katG; inhA 
promoter\katG = isolates with mutations detected in the inhA promoter but not in katG. 
 
2.9  Discussion 
Our results show a significant association between inhA promoter mutations and the emergence of 
XDR-TB from MDR-TB in two different settings in South Africa (Table 2, Figure 1).  This suggests that 
MDR strains harbouring an inhA promoter mutation have a selective advantage to become XDR 
strains, within the current treatment regimen.  Two distinct processes may explain the observed 
accumulation of XDR-TB strains with an inhA promoter mutation.  First, a significant proportion of 
XDR-TB strains initially might have been susceptible to ETH; however, continuous exposure to this 
drug could have led to the acquisition of inhA promoter mutations and ETH resistance (3;4;15-19).  
Second, inhA promoter mutations may have evolved during exposure to INH during first line 
treatment.  MDR strains evolving from such strains also would have demonstrated cross resistance 
to ETH.  If ETH resistance remained undetected there was an increased probability for these strains 
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Figure 2: Frequency of point mutations in MDR and XDR strains of M. tuberculosis in the Eastern Cape Province.  MDR 
group includes XDR group; only others = isolates with no mutations detected in the inhA promoter; inhA -8/-15/-17 = 
isolates with mutations detected in the inhA promoter at nucleotide position -8 or -15 or -17, respectively 
 
The strong association between the presence of inhA promoter mutations and XDR-TB may also 
apply to other regions in South Africa and other parts of the world.  In a recent study in Portugal, 
98.0% of 50 tested MDR strains showed resistance to ETH and 91.4% of 58 tested MDR strains 
showed an inhA promoter mutation (22).  A retrospective study on XDR-TB isolates from four 
provinces of South Africa showed that 30 of the 41 strains tested (73.2%), were resistant to ETH (23).  
These findings may again be explained by the latter scenario described above. 
Our population study has some limitations.  Mutation analyses of katG and the inhA promoter of 
isolates from the Western Cape Province was done on a convenience sample of INH resistant non-
MDR and MDR strains.  However, the majority of the XDR strains from this setting have been 
analyzed and no bias is evident for this group of strains.  We know that the Beijing lineage of strains 
was overrepresented in our sample of the INH resistant non-MDR and MDR strains.  In the Western 
Cape Province, drug resistant Beijing strains are strongly associated with inhA promoter mutations 
[(11), unpublished results].  Therefore, our analyses overestimated the proportion of strains with an 
inhA promoter mutation in INH resistant non-MDR and in MDR strains.  Moreover, XDR strains were 
overrepresented in our sample of MDR strains of the Western Cape Province.  Therefore, the 
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strains to XDR strains is likely to be even more pronounced and our analyses have been very 
conservative with regards to this observation.  
 
 
Figure 3: Proposed guidelines for the individualized treatment of TB patients in South Africa contingent on MTBDRplus 
DST results 
 
Also, our results may have been influenced by the considerable contribution of transmission of drug 
resistant strains to MDR-TB, in South Africa (11-13).  Therefore, the percentage composition of 
distinct drug resistance mutations in different drug resistance groups may fluctuate if significant 
changes in the transmission rates of strains occur that are associated with specific mutations. 
 
Our study suggests that in principle, the MTBDRplus assay could detect 96.3% of all mutation events 
identified by sequencing of the katG gene and the inhA promoter of an extensive sample of INH 
resistant strains of M. tuberculosis (Table 1).  However, our results clearly showed that mutations in 
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Genetic region exhibiting a drug resistance mutation
Use standard first line drugs.
Do not consider INH and ETH as effective drugs for treatment. 
Use another second line drug than ETH to replace INH in the 
drug regimen. High-dose INH may be considered for 
treatment.
Do not consider INH or high-dose INH as an effective drug for 
treatment. Replace INH by an effective second line drug for 
treatment.
Do not consider INH or high-dose INH and ETH as effective 
drugs for treatment. Use another second line drug than ETH 
to replace INH in the treatment regimen.
Do not consider RIF as an effective drug for treatment.
Replace RIF by an effective second line drug for treatment.
Use second line drugs for treatment. Do not consider ETH, 
EMB and PZA as effective drugs for treatment. High-dose INH 
may be considered for treatment.
Use second line drugs for treatment. Do not consider high-
dose INH, EMB and PZA as effective drugs for treatment.
Use second line drugs for treatment. Do not consider high-
dose INH, ETH, EMB and PZA as effective drugs for treatment.
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INH resistant non-MDR and MDR cases, respectively.  This illustrates that culture based phenotypic 
DST should not be replaced but only assisted by molecular drug resistance typing techniques in order 
to achieve the highest possible sensitivity for the detection of drug resistant isolates.  Failing this will 
inevitably lead to the selection and spread of INH resistant strains with properties that remain 
undetected by the applied molecular identification methods. 
The MTBDRplus assay has been implemented for routine DST in several countries including some 
provinces in South Africa.  With the introduction of the assay to assist culture based DST, 
information on the presence of the most important drug resistance mutations in isolates of M. 
tuberculosis from TB patients becomes readily available to clinicians.  This may allow adjustment of 
the treatment regimens depending on the pharmacogenetic properties of the mutations detected 
(24). 
For TB patients infected with strains exhibiting an inhA promoter mutation, ETH must not be 
considered an effective drug of the treatment regimen.  However, because the inhA promoter 
mutation only confers low-level resistance to INH, high-dose or standard dose INH may be included 
in the treatment regimen of such cases if the infecting strains do not also exhibit any additional high-
level INH resistance mutations (24).  In many settings, the most frequently observed high-level INH 
resistance mutations are found in codon 315 of katG (3), which are detectable by the MTBDRplus 
assay (14).  The information that high-dose INH may be included in treatment regimens is 
particularly valuable in XDR-TB cases, for which only few active drugs remain available.  In this 
respect, our observation that approximately 40% of the MDR and XDR strains from the Western 
Cape Province exhibit a mutation in the inhA promoter but not in katG, is of special importance. 
In Figure 3, we propose guidelines for the individualized treatment of TB patients based on the drug 
resistance mutation patterns detected by the MTBDRplus assay.  These recommendations also 
consider our previous observations of a high percentage of EMB and PZA resistance in MDR strains 
in South Africa (6). 
 
Acknowledgments 
The authors thank C. Hayes (National Health Laboratory Service, Port Elizabeth) for sample collection 
in the Eastern Cape Province and M. Kidd for statistical support.  This study has received funding 
from the International Atomic Energy Agency (grant RAF6040) and the Wellcome Trust 
(087303/Z/08/Z).  B. Müller received financial support from the Swiss National Science Foundation.  
Stellenbosch University  https://scholar.sun.ac.za
 45 
We are indebted to the TB patients that have participated in our previous studies and allowed the 
collection of the data herein analyzed. 
 
2.10  References 
 (1)  Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-
resistant tuberculosis. J Infect Dis 2002 Apr 15;185(8):1197-202. 
 (2)  Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infectious Diseases 2009 
Jan;9(1):19-30. 
 (3)  Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. 
International Journal of Tuberculosis and Lung Disease 2009 Nov;13(11):1320-30. 
 (4)  Lobue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009 Apr;22(2):167-73. 
 (5)  Anti-tuberculosis drug resistance in the world: fourth global report. Geneva: World Health 
Organization; 2008. Report No.: 4. 
 (6)  Hoek KG, Schaaf HS, Gey van Pittius NC, van Helden PD, Warren RM. Resistance to 
pyrazinamide and ethambutol compromises MDR/XDR-TB treatment. S Afr Med J 2009;99(11):785-7. 
 (7)  The South African Tuberculosis Control Programme - Practical Guidelines 2000. 1st, 1-46. 
2000.  Department of Health of South Africa.   
 (8)  The Management of Multidrug Resistant Tuberculosis in South Africa. 2nd. 1999.  
Departement of Health of South Africa.   
 (9)  Johnson R, Jordaan AM, Pretorius L, Engelke E, van der SG, Kewley C, et al. Ethambutol 
resistance testing by mutation detection. Int J Tuberc Lung Dis 2006 Jan;10(1):68-73. 
 (10)  Louw GE, Warren RM, Donald PR, Murray MB, Bosman M, van Helden PD, et al. Frequency 
and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int 
J Tuberc Lung Dis 2006 Jul;10(7):802-7. 
 (11)  Johnson R, Warren R, Strauss OJ, Jordaan AM, Falmer AA, Beyers N, et al. An outbreak of 
drug-resistant tuberculosis caused by a Beijing strain in the Western Cape, South Africa. 
International Journal of Tuberculosis and Lung Disease 2006;10(12):1412-4. 
Stellenbosch University  https://scholar.sun.ac.za
 46 
 (12)  Victor TC, Streicher EM, Kewley C, Jordaan AM, van der Spuy GD, Bosman M, et al. Spread of 
an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. 
International Journal of Tuberculosis and Lung Disease 2007 Feb;11(2):195-201. 
 (13)  Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-
resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural 
area of South Africa. Lancet 2006 Nov 4;368(9547):1575-80. 
 (14)  Barnard M, Allbert H, Coetzee G, O'Brien R, Bosiman ME. Rapid molecular screening for 
multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. American 
Journal of Respiratory and Critical Care Medicine 2008 Apr 1;177(7):787-92. 
 (15)  Johnson R, Streicher EM, Louw GE, Warren RM, van Helden PD, Victor TC. Drug resistance in 
Mycobacterium tuberculosis. Curr Issues Mol Biol 2006 Jul;8(2):97-111. 
 (16)  Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis 
drug resistance mutation database. PLoS Med 2009 Feb 10;6(2):e2. 
 (17)  Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene 
encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994 Jan 
14;263(5144):227-30. 
 (18)  Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. Molecular characterization of isoniazid-resistant 
clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 2006 Nov;55(Pt 
11):1527-31. 
 (19)  Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of 
ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 
2003 Dec;47(12):3799-805. 
 (20)  Herrera L, Jimenez S, Valverde A, Garcia-Aranda MA, Saez-Nieto JA. Molecular analysis of 
rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new 
mutations in the rpoB gene and review of the literature. Int J Antimicrob Agents 2003 
May;21(5):403-8. 
 (21)  Victor TC, Jordaan AM, van RA, van der Spuy GD, Richardson M, van Helden PD, et al. 
Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot 
hybridization strategy. Tuber Lung Dis 1999;79(6):343-8. 
Stellenbosch University  https://scholar.sun.ac.za
 47 
 (22)  Perdigao J, Macedo R, Joao I, Fernandes E, Brum L, Portugal I. Multidrug-resistant 
tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 2008 
Jun;14(2):133-43. 
 (23)  Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of 
extensively drug-resistant tuberculosis (XDR-TB) in South Africa. International Journal of Tuberculosis 
and Lung Disease 2008;12(1):99-104. 
 (24)  Warren RM, Streicher EM, van Pittius NC, Marais BJ, van der Spuy GD, Victor TC, et al. The 
clinical relevance of Mycobacterial pharmacogenetics. Tuberculosis (Edinb ) 2009 May;89(3):199-
202.
Stellenbosch University  https://scholar.sun.ac.za
 48 
Programmatically selected multidrug-resistant strains drive the 
emergence of extensively drug-resistant tuberculosis in South 
Africa 
 
Borna Müller1,2,3,*, Violet N. Chihota1,4,*, Manormoney Pillay5, Marisa Klopper1, Elizabeth M. 
Streicher1, Gerrit Coetzee6, Andre Trollip1, Cindy Hayes7, Marlein E. Bosman8, Nicolaas C. Gey van 
Pittius1,Thomas C. Victor 1, Sebastien Gagneux2,3, Paul D. van Helden1 and Robin M. Warren1 
*These authors contributed equally to this work 
 
1DST/NRF Centre of Excellence for Biomedical Tuberculosis Research / MRC Centre for Molecular and 
Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health 
Sciences, Stellenbosch University, Cape Town, South Africa; 2Swiss Tropical and Public Health 
Institute, Basel, Switzerland; 3University of Basel, Basel, Switzerland; 4The Aurum Institute for Health 
Research, Johannesburg, South Africa; 5Medical Microbiology and Infection Control, University of 
KwaZulu-Natal, Durban, South Africa; 6National TB Reference Laboratory, National Institute for 
Communicable Diseases, National Health laboratory Services, Johannesburg, South Africa; 7National 
Health Laboratory Service, Port Elizabeth, South Africa; 8National Health Laboratory Service, Green 
Point, Cape Town, South Africa 
 
Abstract 
BACKGROUND:  South Africa shows one of the highest global burdens of multidrug-resistant (MDR) 
and extensively drug-resistant (XDR) tuberculosis (TB).  Since 2002, MDR-TB in South Africa has been 
treated by a standardized combination therapy, which until 2010 included ofloxacin, kanamycin, 
ethionamide, ethambutol and pyrazinamide.  Since 2010, ethambutol has been replaced by 
cycloserine or terizidone.  The effect of standardized treatment on the acquisition of XDR-TB is not 
currently known.   
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METHODS:  We genetically characterized a random sample of 4,667 patient isolates of drug-
sensitive, MDR and XDR-TB cases collected from three South African provinces, namely, the Western 
Cape, Eastern Cape and KwaZulu-Natal.  Drug resistance patterns of a subset of isolates were 
analyzed for the presence of commonly observed resistance mutations. 
RESULTS:  Our analyses revealed a strong association between distinct strain genotypes and the 
emergence of XDR-TB in three neighbouring provinces of South Africa.  Strains predominant in XDR-
TB increased in proportion by more than 20-fold from drug-sensitive to XDR-TB and accounted for 
up to 95% of the XDR-TB cases.  A high degree of clustering for drug resistance mutation patterns 
was detected.  For example, the largest cluster of XDR-TB associated strains in the Eastern Cape, 
affecting more than 40% of all MDR patients in this province, harboured identical mutations 
concurrently conferring resistance to isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, 
ethionamide, kanamycin, amikacin and capreomycin. 
CONCLUSIONS:  XDR-TB associated genotypes in South Africa probably were programmatically 
selected as a result of the standard treatment regimen being ineffective in preventing their 
transmission.  Our findings call for an immediate adaptation of standard treatment regimens for 
M/XDR-TB in South Africa. 
 
2.11   Introduction 
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) 
threatens disease control efforts throughout the world (1–3).  Drug-resistant TB may be acquired if 
bacteria harbouring spontaneously emerging drug resistance mutations (Table 1) are positively 
selected due to e.g. inadequate treatment regimens, poor drug quality or patient non-compliance 
(2,4–6).  Alternatively, drug-resistant TB may also occur through the transmission of already resistant 
strains; termed primary resistance.  High rates of primary resistance reflect poor transmission 
control essentially due to delays in drug susceptibility testing and initiation of appropriate treatment 
(2,5). 
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Globally, in 2011, there were an estimated 310,000 incident cases of MDR-TB among cases reported 
to have tuberculosis of which 9% were XDR-TB (3,4).  Increasing incidence rates for MDR-TB were 
recorded in several settings with South Africa being among the most severely affected countries 
(1,7,8).  In South Africa, 10% of all TB cases are believed to be MDR-TB of which again one-tenth are 
XDR-TB (1,7,8).  Highest rates of MDR and XDR-TB were notified for the Western Cape, Eastern Cape 
and KwaZulu-Natal provinces (9) with treatment success rates below 50% for MDR-TB and 
considerably poorer outcomes for XDR-TB (10,11).  There is convincing evidence that MDR-TB in 
South Africa is caused mostly by the transmission of MDR strains, as suggested by well-documented 
clonal outbreaks and elevated rates of primary resistance (in some places as high as 80%) among 
MDR-TB cases (12–17).  Similarly, transmission of MDR strains is likely to be a main driver of MDR-TB 
in many other high-burden countries (2,5,18). 
New TB patients in South Africa are treated according to WHO guidelines with isoniazid (H), 
rifampicin (R), ethambutol (E) and pyrazinamide (Z) (19).  Since 2002, MDR-TB treatment is also 
standardized and until 2010 included a fluoroquinolone (FQ; mostly ofloxacine (Ofx)), kanamycin 
(Km), ethionamide (Eto), E and Z (20).  This regimen neglected high proportions of E and Z resistance 
among MDR-TB cases and cross-resistance to Eto if infecting strains previously acquired an inhA 
promoter mutation (Table 1) (21,22).  An only marginally improved MDR-TB regimen was 
implemented in 2010, which replaced E with cycloserine or terizidone (Cs/Trd) (20).  Standardized 
chemotherapy for MDR-TB is necessary in resource-limited settings where drug susceptibility testing 
(DST) cannot be performed regularly (19).  The design of standardized regimens however, requires 
the prior determination of the spectrum of resistances present in the community (19).  Culture-
based resistance surveys not incorporating strain genotyping data do not enable examining whether 
detected resistances are transmitted jointly (by the same strain) or independently (by different 
strains).  The absence of this knowledge has important implications for the design of standardized 
treatment regimens. 
Previous studies in South Africa observed an association of specific genotypes of M. tuberculosis 
with XDR-TB (23).  Specifically, the R220 genotype, a subgroup of the typical Beijing family of strains, 
the R86 genotype, a subgroup of “atypical” Beijing strains and the F15/LAM4/KZN genotype, a 
subgroup of the LAM4 family, were identified as commonly transmitted drug-resistant strains in the 
Western Cape, Eastern Cape and KwaZulu-Natal, respectively (15,16,23–26).  In order to elucidate 
whether and how standardized treatment impacted the strain population structure of drug-sensitive 
and drug-resistant M. tuberculosis in South Africa, we characterized in detail an extensive collection 
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of clinical TB isolates from these provinces and analyzed resistance patterns of XDR-TB associated 
strains. 
 
2.12  Materials and Methods 
2.12.1  Ethics statement 
This study was approved by the Ethics Committees of Stellenbosch University and the University of 
KwaZulu-Natal.  The Stellenbosch Health Research Ethics Committee approved a waiver of consent 
for the retrospective genotypic analysis of routinely collected M. tuberculosis isolates after patient 
identifiers were removed.  The University of KwaZulu-Natal Ethic Committee approved the 
prospective collection and genotyping of M. tuberculosis isolates after obtaining written consent. 
 
2.12.2  Study population, routine culture and drug susceptibility testing 
A comprehensive sample of clinical drug-resistant TB isolates collected during different time periods 
from the whole area of the Western Cape, Eastern Cape and KwaZulu-Natal province were analysed 
(Figure 1).  Only one isolate per patient was included in the study. Subsets of this sample collection 
were used previously to describe the population structure of MDR M. tuberculosis strains in these 
provinces (23) and drug resistance mutations of strains of the Eastern Cape Province (27).  These 
isolates characterised formerly were further complemented with a comparable, random sample of 
diagnosed drug-sensitive and mono-/poly-resistant isolates in order to analyse a larger spectrum of 
resistance patterns and a wider geographical area compared to previous studies.  Routine culture 
and DST was performed at the National Health Laboratory Service (NHLS) in the respective provinces 
as described previously (23).  The location of healthcare facilities attended by the TB patients was 
recorded to analyse the geographical distribution of M. tuberculosis genotypes identified. 
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Figure 1: Selection of study population. Grey boxes indicate sample sets used to analyse the strain population structures 
in the three South African provinces. Boxes with striped pattern indicate sample sets used to characterise drug 
resistance mutation patterns among XDR-TB associated genotypes. a) Computer-based random sampling was applied. b) 
Review of an extensive collection of data generated within multiple previous studies. 
 
2.12.3  Definition of drug resistance groups 
M. tuberculosis isolates were classified into different drug resistance groups based on routine DST 
(23).  Drug-sensitive isolates were susceptible to all drugs tested (at least H and R).  Mono-/Poly-
resistant isolates were resistant to one or multiple first-line anti-TB drugs but were not MDR.  MDR 
and XDR isolates were classified according to WHO definitions (19).  Pre-XDR-TB isolates were 
defined as MDR-TB isolates with additional resistance to either a FQ or a second-line injectable drug 
(Km, amikacin (Am) or capreomycin (Cm)) but not both.  The MDR sensu stricto (s.s.) group excluded 
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2.12.4  Genotypic characterisation 
Initial genotyping of random samples of M. tuberculosis isolates was done by spoligotyping 
according to the protocol described by Kamerbeek et al (28) and the isolates were grouped into 
recognised strain families by comparison to previously reported spoligotype patterns (29,30).  A 
randomly selected subset of Beijing isolates from all drug resistance groups from the Western and 
Eastern Cape and a subset of only drug-sensitive Beijing isolates from KwaZulu-Natal were further 
differentiated into typical and “atypical” Beijing isolates by PCR (Figure 1) (14).  Computer-based 
random sampling was applied to randomly select isolates.  Based on similar IS6110 RFLP patterns 
and whole genome sequencing data it was previously established that “atypical” Beijing strains in 
the Western and Eastern Cape represent one single genotype herein referred to as R86 (14,25,31).  
Typical Beijing isolates from the Western Cape were distinguished into R220 and non-R220 isolates 
by PCR (Figure 1) (32).  LAM4 isolates from KwaZulu-Natal were differentiated into F15/LAM4/KZN 
and other LAM4 isolates by IS6110 RFLP analysis (Figure 1) (16).  A random subsample of identified 
MDR R86 isolates from the Eastern Cape was tested for the presence of drug resistance mutations in 
the inhA promoter and the genes katG, rpoB, pncA, embB, rrs and gyrA by PCR amplification of 
genetic regions commonly observed to harbour resistance mutations and subsequent sequencing of 
these PCR products (Table 1, Figure 1) (33–37).  Similarly, data from an extensive collection of drug-
resistant isolates from the Western Cape was reviewed for records on Beijing isolates tested for the 
presence of resistance mutations in the same genetic regions (Table 1, Figure 1).  However, no data 
on streptomycin resistance mutations in rrs were available (Table 1).  Isolates with identical drug 
resistance mutation patterns were grouped by pncA mutations, which are highly diverse and may 
allow identifying genetically related groups of strains (27). 
Table 1. Drug resistance-associated genetic regions analyzed 
Genetic region Region covered* No. of base-pairs Resistance 
katG gene 2154968...2155387 420 H 
inhA promoter 1673261...1673506 246 H, Eto 
rpoB gene 760822...761258 437 R 
embB gene 4247302...4247561 260 E 
pncA gene 2288652...2289266 615 Z 
rrs gene (around nucleotide position 513) 1472283...1472852 570 S 
rrs gene (around nucleotide position 1401) 1473184...1473373 190 Km, Am, Cm 
gyrA gene 7355...7698 344 Many FQs, e.g. Ofx 
*Genetic region covered by PCR with respect to nucleotide positions in H37Rv 
H: Isoniazid; Eto: Ethionamide; R: Rifampicin; E: Ethambutol; Z: Pyrazinamide; S: Streptomycin; Km: Kanamycin; Am: 
Amikacin; Cm: Capreomycin; FQ: Fluoroquinolone; Ofx: Ofloxacin 
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2.13  Results 
Molecular characterisation of a random sample of 4,667 clinical TB isolates collected from the whole 
area of the Western Cape, Eastern Cape and KwaZulu-Natal provinces of South Africa revealed an 
increasing predomination of a single genotype of strains from drug-sensitive to XDR-TB, in each of 
the three provinces (Figure 2).  In the Eastern Cape and KwaZulu-Natal, the proportion of isolates 
belonging to the R86 and the F15/LAM4/KZN genotype, respectively, underwent a 27- and 44-fold 
increase from drug-susceptible to XDR-TB and accounted for 95% and 72% of all XDR-TB cases 
(Figure 2, Table S1).  In the Western Cape, the percentage of R86 isolates also increased significantly 
from drug-sensitive to XDR-TB cases.  However, a previous study indicated that R86 isolates detected 
in the Western Cape, may to a large extent represent TB patients from the economically depressed 
Eastern Cape seeking treatment in the more affluent Western Cape (23).  Thus, if R86 isolates are 
disregarded, the R220 genotype most strongly contributes to drug-resistant TB in the Western Cape, 
in line with previous results (15).  Noteworthy, R220 isolates expand significantly in proportion (24-
fold) from drug-sensitive to mono-/poly-resistant TB (Figure 2, Table S1). 
Genotypes predominant in XDR-TB were infrequently detected among drug-sensitive TB cases 
(Figure 2).  In all three provinces investigated, R220, R86 and F15/LAM4/KZN strains accounted for 
less than 5% of the drug-sensitive TB cases, making them considerably less abundant than the typical 
Beijing, LAM3 and T1 genotypes, which each represented between 10% and 41% of all drug-sensitive 
isolates (Table S1).  Interestingly, while the strain population structure among MDR-TB isolates was 
fundamentally different between the three provinces (23), it appeared to be similar for drug-
sensitive isolates (Figure 2). 
Drug resistance patterns of XDR-TB associated genotypes were analysed by assessing the presence 
of commonly observed resistance mutations in the inhA promoter and the genes katG, rpoB, pncA, 
embB, rrs and gyrA (Table 1).  A random sample of 193 MDR isolates of the R86 genotype from the 
Eastern Cape and 41 conveniently selected MDR isolates from the Western Cape representing a 
variety of different Beijing genotypes (R86, R220 and other typical Beijing strains) were selected 
(Figures 1, 3 and 4).  Apart from H and R resistance mutations, various additional resistance-
conferring mutations were detected.  Moreover, mutation patterns were highly clustered (Figures 3 
and 4).  Most strikingly, 69% of the R86 isolates from the Eastern Cape analyzed (133/193 MDR 
isolates analyzed) harboured as many as seven identical resistance mutations in the inhA promoter 
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Figure 2: Strain population structure of drug-sensitive (DS), mono-/poly-resistant (DR), sensu stricto multidrug-resistant 
(MDR s.s.; excluding identified pre-XDR and XDR isolates), pre-extensively drug-resistant (pre-XDR) and extensively drug 
resistant (XDR) isolates in three provinces of South Africa. The R220, R86 and F15/LAM4/KZN genotypes, respectively, 
represent a subgroup of the typical Beijing, “atypical” Beijing and LAM4 family (14–16,22–24). Based on similar IS6110 
RFLP patterns and whole genome sequencing data it was previously shown that “atypical” Beijing strains in the Western 
and Eastern Cape, unlike in other parts of the world, represent one single genotype herein referred to as R86 (23,25,27). 
The specific presence of R220 and F15/LAM4/KZN genotypes was only assessed in the Western Cape and KwaZulu-Natal, 
respectively, where these genotypes were known to be frequent among XDR-TB cases (22). 
 
and the genes katG, rpoB, pncA, embB and rrs suggesting that this cluster represents a commonly 
transmitted pre-XDR strain resistant to at least H, R, Z, E, S, Eto, Km, amikacin (Am) and capreomycin 
(Cm) (Table 1, Figure 3) (23,27).  XDR-TB cases that have emerged from infection with this strain 
showed a variety of different gyrA mutations, suggesting that FQ resistance was acquired 
subsequently and perhaps due to the mismanagement of primary pre-XDR-TB.  Nevertheless, a sub-
group of 44 isolates showed for example an identical gyrA D94G mutation, potentially indicating 
community spread of XDR strains (Figure 3). 
A second cluster representing 17% of the R86 isolates from the Eastern Cape (32/193 MDR isolates 
analyzed), was characterized by identical mutations in katG, rpoB, pncA, embB and rrs conferring 
resistance to H, R, Z, E and S (Table 1; Figure 3) (27).  Presumably, a sub-branch of this strain 
subsequently acquired resistance to Eto through an inhA promoter mutation (38), to Km, Am and Cm 
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Figure 3: Drug resistance mutation pattern in a random selection of 193 MDR R86 isolates from the Eastern Cape. 
Different colours indicate different drug resistance associated genes. The area of the circles is proportional to the 
number of isolates (indicated in the centre of each circle) harbouring an identical drug resistance mutation for the 
respective resistance gene as well as all circles connected to the left. Principal branches of the tree were defined by 
resistance mutations in pncA. Other first-line drug resistance mutations were connected by logical deduction to 
maximize clustering and were followed by second-line resistance mutations. However, the order of acquisition of 
resistance mutations may remain debatable in some cases. 
 
through an additional mutation in rrs (39,40) and finally to FQs due to the acquisition of a gyrA A90V 
resistance mutation (Figure 3) (6,41). 
Analysis of the drug resistance mutation patterns of a convenience sample of 41 MDR Beijing 
isolates from the Western Cape, revealed that the two major R86 clusters detected in the Eastern 
Cape were also present in this province, albeit at a different relative frequency (Figures 3 and 4).  For 
the remaining R220 and other typical Beijing isolates analyzed, clustered mutation patterns for at 
least pncA and embB were found in 8 out of 16 cases (Figure 4), indicating a widespread combined 
presence of Z and E resistance among these strains, in the Western Cape. 
The clusters of strains defined above by genotype and drug resistance mutation patterns (Figures 3 
and 4) were geographically widespread within the Eastern and Western Cape (Table 2), indicating 
historical spread.  In the Eastern Cape, the two predominant clusters among MDR isolates of the R86 
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genotype were detected in four and three different municipal districts, respectively.  In the Western 
Cape, despite the small sample size, isolates of four out of five clusters as defined by distinct pncA 
mutations were identified in more than one district (Table 2). 
 
 
Figure 4: Drug resistance mutation pattern in a convenience sample of 41 MDR Beijing isolates from the Western Cape. 
No data was available for the streptomycin resistance determining region in rrs (Table 1). For more information see 
figure legend of Figure 3. 
 
2.14  Discussion 
The present data shows a strong association between distinct strain genotypes and the emergence 
of XDR-TB in three neighbouring provinces of South Africa (23).  XDR-TB associated genotypes were 
infrequently found among drug-sensitive TB cases, of which typical Beijing, LAM3 and T1 were the 
most prevalent genotypes in all three provinces (Figure 2).  This observation is counterintuitive, if it 
was supposed that the proportion of genotypes causing XDR-TB was a result of random fluctuations.  
Under such conditions it would be plausible to assume that genotypes predominant among drug-
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sensitive TB cases would have been more likely to become overrepresented among XDR-TB cases 
(Table 2, Figure 2).  Instead, the association of the R220, R86 and F15/LAM4/KZN genotypes with 
XDR-TB suggests an increased ability of these strains to acquire multiple drug-resistance mutations 
or to transmit as drug-resistant strains.  However, the relatively distant phylogenetic relationship of 
these XDR-TB associated strain genotypes (42,43) argues against the possibility of genetic 
background accounting for this observation. 
Table 2. Geographical distribution of selected clusters of isolates 
Province Genotype Drug resistance mutation pattern Municipal District NIsolate % 
EC R86 
katG S315T/rrs 513 A→C/pncA C14R/rpoB 
S531L/embB M306I 
Amathole 19 59.4 
Nelson Mandela Bay 12 37.5 
OR Tambo 1 3.1 
EC R86 
katG S315T/rrs 513 A→C/pncA C14R/rpoB 
S531L/embB M306I/inhA promoter -15 
C→T/rrs 1401 A→G/gyrA A90V 
Amathole 7 70.0 
Nelson Mandela Bay 2 20.0 
OR Tambo 1 10.0 
EC R86 
katG S315T/rrs 513 A→C/pncA 172 G 
insertion/inhA promoter -17 G→T/embB 
M306I/rpoB D516V/rrs 1401 A→G 
Amathole 30 22.6 
Cacadu 12 9.0 
Chris Hani 1 0.8 
Nelson Mandela Bay 90 67.7 
EC R86 
katG S315T/rrs 513 A→C/pncA 172 G 
insertion/inhA promoter -17 G→T/embB 
M306I/rpoB D516V/rrs 1401 A→G/gyrA D94G 
Amathole 9 20.5 
Cacadu 3 6.8 
Chris Hani 1 2.3 
Nelson Mandela Bay 31 70.5 
WC R86 
pncA C14R/inhA promoter -15 C→T/rpoB 
S531L/embB M306I/katG S315T/rrs 1401 A→G 
Cape Town 12 92.3 
Eden 1 7.7 
WC R86 
pncA 172 G insertion/inhA promoter -17 
G→T/rpoB D516V/embB M306I/katG 
S315T/rrs 1401 A→G 
Cape Town 3 75.0 
Eden 1 25.0 
WC R220 
inhA promoter -15 C→T/rpoB S531L/pncA 
Y103Stop 
Cape Town 2 66.7 
Overberg 1 33.3 
WC R220 
inhA promoter -15 C→T/pncA 153 large 
deletion/embB M306V 
Cape Town 2 66.7 





katG S315T/rpoB S531L/pncA T100I/embB 
M306I 
Cape Town 3 100.0 
EC: Eastern Cape Province   
WC: Western Cape Province   
Nisolate: Number of isolates of a cluster detected in the municipal district indicated 
%: Proportion of isolates of a cluster detected in the municipal district indicated 
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Figure 5: Model for the evolution of XDR-TB associated strain families. 
Drug resistance mutation patterns of isolates of XDR-TB associated genotypes in the Eastern and 
Western Cape provinces were highly clustered (Figure 3).  Unfortunately, isolates of the XDR-TB 
associated F15/LAM4/KZN genotype in KwaZulu-Natal were not further characterised within this 
study and therefore the relationship between genotype and clustering could not be evaluated.  
However, in line with our observations for the Western and Eastern Cape, a previous whole genome 
sequence analysis of nine XDR F15/LAM4/KZN isolates from patients of different settings in KwaZulu-
Natal revealed nearly identical genome sequences including matching drug resistance mutations 
(26).  Together, this data suggests that in South Africa, XDR-TB emerges mainly due to ongoing 
transmission of specific MDR s.s. or pre-XDR genotypes that are sub-optimally treated by 
programmatic treatment regimens, or partly, directly through the transmission of XDR strains of 
these genotypes (11,25,27). 
It is likely however, that our analyses convey a relative overestimate of the proportion of 
transmission of primary pre-XDR and XDR strains as the Km/Am/Cm resistance mutation (rrs 1401 
A→G) and the FQ resistance mutations (gyrA D94G and the gyrA A90V) detected among the largest 
clusters of isolates, belong to the most frequently observed resistance mutations for these drugs 
(6,44).  Indeed, for the Km/Am/Cm resistance mutations observed in rrs, only a very low diversity 
was observed (Figures 3 and 4) (39,40).  Thus, it is likely that these mutations have been acquired 
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independently multiple times among clustered isolates and clustering may not (or to a lesser extent) 
represent the clonal spread of pre-XDR and XDR strains. 
Even if FQ and Km/Am/Cm resistance mutations in gyrA and rrs are disregarded, 72% (139/193) and 
8% (15/193) of the MDR R86 isolates from the Eastern Cape belonged to one of two major clusters 
of isolates harbouring identical resistance mutations to at least H, R, Z, E, S and Eto (Figure 3).  
Similarly, altogether 63% (26/41) of the MDR Beijing isolates from the Western Cape tested 
belonged to one of altogether five clusters of isolates with identical resistance mutations to at least 
H, R, Z, E, and Eto (Figure 4).  Given this data and the frequency distribution of different genotypes 
among MDR-TB cases (Table 2), we can estimate that at least 48% and 28% of all MDR-TB cases in 
the Eastern and Western Cape, respectively, were caused by a strain resistant to at least H, R, Z, E, S 
and Eto at the time of infection.  Considering published whole genome sequences of XDR 
F15/LAM4/KZN isolates (26) and if FQ and Km/Am/Cm resistance mutations are disregarded, this 
genotype also shows primary resistance to at least H, R, E, Z, S and Eto and accounts for 26% of all 
MDR-TB cases in KwaZulu-Natal (Table 2).  Importantly, since only specific XDR-TB associated 
genotypes were analyzed, the proportion of MDR-TB cases with resistances to additional anti-TB 
drugs than H and R may be even higher. 
Given the standard MDR-TB drug regimens in South Africa (currently consisting of Ofx, Km, Eto, 
Trd/Cs and Z) and if excluding rrs and gyrA mutations, TB patients infected with these strains are 
exposed to three effective drugs only (Ofx, Km and Cs/Trd); this is less than the four effective drugs 
recommended by the WHO (45).  If many of these transmitting strains in fact also harboured a 
primary rrs 1401 A→G mutation, the treatment regimen would consist of two effective drugs only.  
Under these conditions, even the standardized XDR-TB treatment regimen in South Africa, currently 
consisting of moxifloxacin, Cm, Eto, para-aminosalicylic acid and Cs/Trd would be inappropriate to 
treat infected patients (20).  Noteworthy, the previous MDR-TB regimen endorsed until 2010, which 
used E instead of Cs/Trd, resulted in an even higher chance of resistance development as it consisted 
of only two or one effective drug, respectively.  This clearly demonstrates the inadequacy of current 
treatment regimens in South Africa to prevent spread of XDR-TB associated strains and calls for an 
immediate adaptation of MDR treatment algorithms.  Moreover, our findings highlight the urgent 
need for rapid first- and second-line DST for all TB cases at treatment onset. 
A likely scenario for the evolution of XDR-TB associated strains in South Africa is depicted in Figure 5.  
It could be speculated that the use of non-standardized drug regimens before 2002 facilitated the 
emergence and transmission of strains with different resistance patterns.  Possibly, the 
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implementation of standardized MDR-TB treatment subsequently promoted the spread of strains 
harbouring resistances against which the regimen was less effective.  These strains could have 
emerged originally as early as in the 1950’s when TB treatment was not well controlled and mostly 
included H, S and para-aminosalicylic acid only (46).  This is supported by the very widespread 
presence of identical H and S resistance mutations in isolates from the Eastern Cape, indicating that 
these mutations were acquired at an initial stage (Figure 3).  However, importantly, improved TB 
control and standardized MDR-TB treatment probably curbed the emergence of new resistant 
strains and transmission of strains harbouring unfavourable resistance patterns.  Thus, the 
programmatic use of an only variably effective MDR-TB treatment regimen could explain the 
predomination of only a few strain families among XDR-TB cases.  Although an impact of strain 
genetic background on the propensity to develop MDR/XDR-TB has been suggested (47), according 
to this model, the acquisition of advantageous resistance patterns would have occurred by chance 
and independent of strain genetic background, explaining the association of different, distantly 
related genotypes with XDR-TB in different provinces.  Associations of a few specific genotypes with 
MDR and XDR-TB were observed in several countries throughout the world (48–51), suggesting 
similar mechanisms for the emergence of XDR-TB. 
This work highlights the value of molecular epidemiological tools to perform drug resistance surveys 
and to decipher how individual resistances may be linked and transmitted.  Moreover, this data will 
help designing more effective and urgently needed MDR-TB treatment regimens for South Africa.  




We are indebted to the patients, public health practitioners and laboratory technicians who have 
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Table S1. Strain population structure in the Western Cape, Eastern Cape and KwaZulu-Natal Provinces of South Africa.
All
N % 95%CI N % 95%CI N % 95%CI N % 95%CI N % 95%CI N % 95%CI N
BEIJING All 34 35,1 25.6-45.4 782 44,9 42.5-47.3 743 56,0 53.3-58.7 133 73,9 66.8-80.1 67 87,0 77.4-93.6 943 59,5 57.1-62.0 1759
BEIJING R220
a 1 3,3 0.1-17.2 54 60,7 49.7-70.9 63 64,3 54.0-73.7 12 21,4 11.6-34.4 9 18,0 8.6-31.4 84 41,2 34.4-48.3 139
BEIJING Typical (excl. R220)
a 25 83,3 65.3-94.4 28 31,5 22.0-42.2 28 28,6 19.9-38.6 5 8,9 3.0-19.6 4 8,0 2.2-19.2 37 18,1 13.1-24.1 90
BEIJING R86
a 4 13,3 3.8-30.7 7 7,9 3.2-15.5 7 7,1 2.9-14.2 39 69,6 55.9-81.2 37 74,0 59.7-85.4 83 40,7 33.9-47.8 94
BEIJING R220
b 1 1,2 N/A 474 27,2 N/A 478 36,0 N/A 29 15,8 N/A 12 15,7 N/A 518 32,7 N/A 994
BEIJING Typical (excl. R220)
b 28 29,2 N/A 246 14,1 N/A 212 16,0 N/A 12 6,6 N/A 5 7,0 N/A 230 14,5 N/A 504
BEIJING R86
b 5 4,7 N/A 62 3,5 N/A 53 4,0 N/A 93 51,5 N/A 50 64,4 N/A 195 12,3 N/A 261
LAM4 All 1 1,0 0.0-5.6 19 1,1 0.7-1.7 42 3,2 2.3-4.3 4 2,2 0.6-5.6 0 0,0 0.0-4.7 46 2,9 2.1-3.9 66
LAM4 F15/LAM4/KZN
c 0 0,0 0.0-3.7 6 0,3 0.1-0-7 37 2,8 2.0-3.8 3 1,7 0.3-4.8 0 0,0 0.0-4.7 40 2,5 1.8-3.4 46
LAM4 Non-F15/LAM4/KZN c 1 1,0 0.0-5.6 13 0,7 0.4-1.3 5 0,4 0.1-0.9 1 0,6 0.0-3.1 0 0,0 0.0-4.7 6 0,4 0.1-0.8 20
LAM3 All 11 11,3 5.8-19.4 164 9,4 8.1-10.9 85 6,4 5.1-7.9 2 1,1 0.1-4.0 2 2,6 0.3-9.1 89 5,6 4.5-6.9 264
T1 All 12 12,4 6.6-20.6 218 12,5 11.0-14.2 112 8,4 7.0-10.1 6 3,3 1.2-7.1 4 5,2 1.4-12.8 122 7,7 6.4-9.1 352
S All 5 5,2 1.7-11.6 73 4,2 3.3-5.2 31 2,3 1.6-3.3 2 1,1 0.1-4.0 0 0,0 0.0-4.7 33 2,1 1.4-2.9 111
Others All 34 35,1 25.6-45.4 486 27,9 25.8-30.1 314 23,7 21.4-26.0 33 18,3 13.0-24.8 4 5,2 1.4-12.8 351 22,2 20.1-24.3 871
Total All 97 100,0 N/A 1742 100,0 N/A 1327 100,0 N/A 180 100,0 N/A 77 100,0 N/A 1584 100,0 N/A 3423
BEIJING All 111 38,5 32.9-44.4 34 47,9 35.9-60.1 144 50,5 44.6-56.5 115 92,7 86.7-96.6 89 94,7 88.0-98.3 348 69,2 64.9-73.2 493
BEIJING Typical a 101 91,0 84.1-95.6 29 93,5 78.6-99.2 17 32,7 20.3-47.1 0 0,0 0.0-3.9 0 0,0 0.0-5.1 17 7,9 4.7-12.3 147
BEIJING R86 a 10 9,0 4.4-15.9 2 6,5 0.8-21.4 35 67,3 52.9-79.7 93 100,0 96.1-100.0 71 100,0 94.9-100.0 199 92,1 87.7-95.3 211
BEIJING Typical b 101 35,1 N/A 32 44,8 N/A 47 16,5 N/A 0 0,0 N/A 0 0,0 N/A 47 9,4 N/A 180
BEIJING R86 b 10 3,5 N/A 2 3,1 N/A 97 34,0 N/A 115 92,7 N/A 89 94,7 N/A 301 59,8 N/A 313
LAM4 All 6 2,1 0.8-4.5 0 0,0 0.0-5.1 46 16,1 12.1-20.9 5 4,0 1.3-9.2 1 1,1 0.0-5.8 52 10,3 7.8-13.3 58
LAM4 F15/LAM4/KZN c 2 0,7 0.1-2.5 0 0,0 0.0-5.1 45 15,8 11.8-20.6 5 4,0 1.3-9.2 1 1,1 0.0-5.8 51 10,1 7.6-13.1 53
LAM4 Non-F15/LAM4/KZN c 4 1,4 0.4-3.5 0 0,0 0.0-5.1 1 0,4 0.0-1.9 0 0,0 0.0-2.9 0 0,0 0.0-3.8 1 0,2 0.0-1.1 5
LAM3 All 66 22,9 18.2-28.2 10 14,1 7.0-24.4 24 8,4 5.5-12.3 0 0,0 0.0-2.9 0 0,0 0.0-3.8 24 4,8 3.1-7.0 100
T1 All 38 13,2 9.5-17.7 3 4,2 0.9-11.9 13 4,6 2.5-7.7 0 0,0 0.0-2.9 0 0,0 0.0-3.8 13 2,6 1.4-4.4 54
S All 7 2,4 1.0-4.9 5 7,0 2.3-15.7 9 3,2 1.5-5.9 0 0,0 0.0-2.9 1 1,1 0.0-5.8 10 2,0 1.0-3.6 22
Others All 60 20,8 16.3-26.0 19 26,8 16.9-38.6 49 17,2 13.0-22.1 4 3,2 0.9-8.1 3 3,2 0.7-9.0 56 11,1 8.5-14.2 135
Total All 288 100,0 N/A 71 100,0 N/A 285 100,0 N/A 124 100,0 N/A 94 100,0 N/A 503 100,0 N/A 862
BEIJING All 50 41,3 32.4-50.6 4 13,8 3.9-31.7 15 7,7 4.4-12.4 0 0,0 0.0-26.5 0 0,0 0.0-13.7 15 6,5 3.7-10.4 69
BEIJING Typical a 41 100,0 91.4-100.0 N/D N/A N/A N/D N/A N/A N/D N/A N/A N/D N/A N/A N/D N/A N/A 41
BEIJING R86 a 0 0,0 0.0-8.6 N/D N/A N/A N/D N/A N/A N/D N/A N/A N/D N/A N/A N/D N/A N/A 0
BEIJING Typical b 50 41,3 N/A 4 13,8 N/A 15 7,7 N/A 0 0,0 N/A 0 0,0 N/A 15 6,5 N/A 69
BEIJING R86 b 0 0,0 N/A 0 0,0 N/A 0 0,0 N/A 0 0,0 N/A 0 0,0 N/A 0 0,0 N/A 0
LAM4 All 4 3,3 0.9-8.2 6 20,7 8.0-39.7 39 20,0 14.6-26.3 4 33,3 9.9-65.1 18 72,0 50.6-87.9 61 26,3 20.7-32.5 71
LAM4 F15/LAM4/KZN 2 1,7 0.2-5.8 6 20,7 8.0-39.7 39 20,0 14.6-26.3 4 33,3 9.9-65.1 18 72,0 50.6-87.9 61 26,3 20.7-32.5 69
LAM4 Non-F15/LAM4/KZN 2 1,7 0.2-5.8 0 0,0 0.0-11.9 0 0,0 0.0-1.9 0 0,0 0.0-26.5 0 0,0 0.0-13.7 0 0,0 0.0-1.6 2
LAM3 All 19 15,7 9.7-23.4 2 6,9 0.8-22.8 10 5,1 2.5-9.2 1 8,3 0.2-38.5 2 8,0 1.0-26.0 13 5,6 3.0-9.4 34
T1 All 12 9,9 5.2-16.7 3 10,3 2.2-27.4 27 13,8 9.3-19.5 1 8,3 0.2-38.5 2 8,0 1.0-26.0 30 12,9 8.9-17.9 45
S All 8 6,6 2.9-12.6 3 10,3 2.2-27.4 66 33,8 27.2-41.0 3 25,0 5.5-57.2 2 8,0 1.0-26.0 71 30,6 24.7-37.0 82
Others All 28 23,1 16.0-31.7 11 37,9 20.7-57.7 38 19,5 14.2-25.8 3 25,0 5.5-57.2 1 4,0 0.1-20.4 42 18,1 13.4-23.7 81
Total All 121 100,0 N/A 29 100,0 N/A 195 100,0 N/A 12 100,0 N/A 25 100,0 N/A 232 100,0 N/A 382
All Total All 506 N/A N/A 1842 N/A N/A 1807 N/A N/A 316 N/A N/A 196 N/A N/A 2319 N/A N/A 4667
DS: Drug-sensitive; DR: Non-multidrug-resistant drug-resistant isolates (also commonly referred to as mono- and poly-resistant isolates);
MDR s.s. : Multidrug-resistant sensu stricto  (excluding all identified pre-extensively drug-resistant and extensively drug-resistant isolates);
pre-XDR: Pre-extensively drug-resistant isolates; XDR: Extensively drug-resistant isolates; MDR: Multidrug-resistant (including MDR s.s. , pre-XDR and XDR-TB cases).
N: Number of isolates; %: Proportion of isolates; 95% CI: 95% confidence interval N/A: Not applicable; N/D: No data;
MDR s.s. pre-XDRFamily Subfamily DS DR XDR MDR





aA subset of Beijing strains was further categorized. The number of isolates identified as members of the typical or atypical Beijing subfamily is indicated. Proportions in this case relate to the number of Beijing isolates characterized.
bExtrapolated number for typical and atypical Beijing isolates. The sum of the extrapolated number of isolates corresponds to the total number of Beijing isolates.
Drug resistance group
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Chapter 3   Emergence and spread of extensively and totally drug-
resistant tuberculosis in the Eastern Cape 
 
This work was published as: 
Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. 
Klopper M, Warren RM, Hayes C, Gey van Pittius NC, Streicher EM, Müller B, Sirgel FA, Chabula-
Nxiweni M, Hoosain E, Coetzee G, David van Helden P, Victor TC, Trollip AP. 
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What has been is what will be, and what has been done is what will be done and there is nothing 
new under the sun. – Ecclesiastes 1:9  
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Abstract  
Factors driving the increase in drug-resistant tuberculosis (TB) in the Eastern Cape, South Africa are 
not understood.  A convenience sample of 309 drug-susceptible and 342 multidrug-resistant (MDR)-
TB isolates, collected between July 2008 and July 2009, were characterised by spoligotyping, DNA 
fingerprinting, insertion site mapping and targeted DNA sequencing.  Analysis of the molecular-
based data showed diverse genetic backgrounds among drug-sensitive and MDR sensu stricto 
isolates, as opposed to restricted genetic backgrounds among pre-extensively drug-resistant (pre-
XDR)-TB and XDR-TB isolates.  Second-line drug resistance was associated with the atypical Beijing 
genotype (p<0.001). DNA fingerprinting and sequencing demonstrated that the pre-XDR and XDR 
atypical Beijing isolates had evolved from a common progenitor with 85% and 92%, respectively, 
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being clustered, indicating transmission.  Ninety-five percent of the atypical XDR Beijing isolates had 
mutations known to confer resistance to 10 anti-TB drugs, while additional resistance to para-
aminosalicylic acid suggests emergence of totally drug-resistant TB.  
 
3.1  Introduction 
The emergence of drug-resistant tuberculosis (TB) is of major concern to TB control in South Africa.  
A country-wide survey in 2002 revealed that 1.8% of all new TB cases and 6.7% of previously treated 
TB cases had multidrug-resistant (MDR)-TB (resistant to at least isoniazid and rifampicin) (1).  This 
translates to an estimated annual case load of 13 000 MDR-TB cases, placing South Africa fourth 
among the world’s high-burden MDR-TB countries (1).  However, this may be an under-estimation as 
two recent studies (2, 3) suggested that the proportion of MDR-TB cases may be significantly higher 
than the WHO estimate (3).  Alarmingly, only 4143 of the 9070 patients (46%) diagnosed with MDR-
TB in 2009 were started on treatment, possibly due to resource constraints, creating a situation 
where control was bound to fail (4).  This is supported by the diagnosis of 594 extensively drug 
resistant (XDR)-TB cases (MDR plus additional resistance to a fluoroquinolone and any second-line 
injectable drug) in that year (4).  The cure rate of patients with drug-resistant TB is less than 50% for 
MDR-TB cases (5), while culture conversion was observed in only 19% of XDR-TB cases during the 
follow-up period, irrespective of HIV status (6). 
The majority of MDR-TB and XDR-TB cases in South Africa are detected in KwaZulu-Natal, the 
Western Cape and the Eastern Cape provinces (4).  Statistics from the Eastern Cape showed the 
largest increase in the number of MDR-TB cases, rising from 836 cases in 2006 to 1858 cases in 2009 
(2.2 fold increase) (4).  The reason for this dramatic increase in MDR-TB cases remains to be 
determined. 
Molecular epidemiological data from the neighbouring Western Cape province have demonstrated 
that MDR-TB is primarily transmitted (7, 8), accounting for nearly 80% of reported MDR-TB cases (2).  
To date, only one molecular epidemiological study has been reported for the Eastern Cape (9), 
showing that 50% of rifampicin-resistant TB isolates (including MDR-TB cases) belonged to the 
Beijing genotype with “atypical” Beijing strains being significantly overrepresented.  These strains 
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harboured rare mutations in the inhA promoter (G-17A) and rpoB gene (GAC516GTC), which have 
previously been associated with a high fitness cost (10).  The authors demonstrated that the spread 
of these strains was facilitated by HIV co-infection, thereby raising concern for the spread of drug-
resistant strains in vulnerable populations (9). 
A recent epidemiological study conducted in the Eastern Cape estimated that 75.6% of XDR-TB cases 
with complete data were due to on-going transmission (11).  Treatment outcomes were dismal with 
58% of cases dying within one year, while culture conversion was observed in only 8.4% of cases 
after 143 days of treatment (11), raising concern that these patients are infected with an untreatable 
form of TB.  This situation is similar to the Tugella Ferry outbreak in KwaZulu-Natal (12), which 
emphasised the need for improved basic control measures, including rapid diagnostics and infection 
control (13). 
This study aimed to describe the Mycobacterium tuberculosis strain population structure among 
MDR-TB and XDR-TB cases in the Eastern Cape Province of South Africa in order to determine 
whether the epidemic is driven by acquisition or transmission of resistance and to describe the 
extent of resistance within these strains. It is envisaged that these findings will inform TB control to 
implement measures to curb either emergence or spread of drug-resistance.  
 
3.2  Materials & Methods 
3.2.1  Study population 
Sputum specimens were collected from high risk TB suspects (previously treated cases and close 
contacts of known drug resistant cases) in accordance with the National TB Control program.  
Specimens that were collected at health care facilities in the Eastern Cape were submitted to the 
National Health Laboratory Service (NHLS) in Port Elizabeth for TB drug susceptibility testing (DST).  
From July 2008 to July 2009 a convenience sample of sputum cultures shown to be either fully drug-
susceptible or resistant to at least isoniazid and rifampicin (MDR-TB) by the NHLS were submitted to 
Stellenbosch University for subsequent genotyping.  Only limited demographic and clinical data was 
available for each patient: unique identifier (assigned by the NHLS), sputum date, clinic/hospital of 
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origin and routine DST pattern. The unique identifier was used to identify the first available isolate 
from 309 drug-susceptible and 342 MDR-TB cases included in the study.  This study was approved by 
the ethics committee of Stellenbosch University, Faculty of Health Sciences (N09/11/296).  
 
3.2.2  Drug susceptibility testing 
Sputum samples were processed by the NHLS for routine TB diagnosis by smear microscopy and 
culture.  Each sputum specimen was decontaminated using the standard NALC-NaOH method and 
cultured in MGIT960 medium until a positive growth index was observed.  The presence of M. 
tuberculosis was confirmed by spoligotyping (see below).  DST was done by the indirect proportion 
method using the BACTEC MGIT 960 system (BD Bioscience, Sparks, MD) according to the 
manufacturer’s instructions.  Initially, resistance against isoniazid and rifampicin was tested, 
followed by testing for streptomycin and ethambutol resistance if the isolate was resistant to either 
isoniazid or rifampicin.  Second-line drug susceptibility testing was done on 7H10 medium containing 
2µg/ml ofloxacin, 4µg/ml amikacin or 5µg/ml ethionamide.  DST for para-aminosalicylic acid was 
done at Stellenbosch University in MGIT 960 medium containing 4.0µg/ml, 8µg/ml and 16µg/ml 
para-aminosalicylic acid (14). 
 
3.2.3  Molecular-based analysis 
Crude DNA was prepared by boiling a 200µl aliquot of a positive MGIT culture and this was used as 
template for subsequent PCR analysis (15).  Each isolate was spoligotyped using the internationally 
standardized method (16) and grouped into genotypes according to previously described 
spoligotype signatures (17).  Beijing genotype strains were sub-classified as either “typical” or 
“atypical” according to the presence or absence of an IS6110 insertion in the NTF region (18),(19).  
The atypical Beijing genotype strains were further classified by using the internationally standardized 
IS6110 DNA fingerprinting method (20).  In atypical Beijing strains that were drug-sensitive according 
to DST, sensitivity to isoniazid and rifampicin was confirmed by sequencing of the katG and rpoB 
genes.  In MDR atypical Beijing strains, mutations conferring resistance to isoniazid, rifampicin, 
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ethambutol, pyrazinamide, ofloxacin, streptomycin, amikacin, kanamycin and capreomycin were 
identified by sequencing of the inhA promoter, katG, rpoB, embB, pncA, gyrA, and rrs genes, 
respectively (21, 22).  Isolates were grouped as either MDR-TB sensu stricto (s.s., MDR strains  






















1 11 (3.6) 41 (27.0) 98 (92.5) 
78 
(92.9) 
29 (22.5) 85 (87.6) 103 (95.4) 








66 (21.4) 12 (7.9) 2 (1.9) 0 (0) 12 (9.3) 0 (0) 0 (0) 
LAM4 60; 811 6 (1.9) 32 (21.1) 4 (3.8) 2 (1.9) 29 (22.5) 3 (3.1) 2 (1.9) 
LAM (other) 
4; 20; 42; 
398 
7 (2.3) 1 (0.7) 0 (0) 1 (1.2) 1 (0.8) 0 (0) 1 (0.9) 
MANU2 1247 0 (0) 0 (0) 0 (0) 2 (2.4) 1 (0.8) 0 (0) 1 (0.9) 





















34 (11.0) 14 (9.2) 1 (0.9) 0 (0) 11 (8.5) 2 (2.1) 0 (0) 
Total  309 152 106 84 129 97 108 
Total MDR    342   334#  
* ST - Shared Type (17); † MDRs.s. – Multidrug-resistant sensu strictu; ‡ Pre-XDR – Pre-extensively drug-resistant; § XDR – 
extensively drug-resistant; ¶ For Beijing isolates a distinction was made between typical and atypical based on the 
presence or absence of an IS6110 insertion in the NTF region (18),(19); # Molecular-based DST total differs from culture-
based DST total, because some results were not available. 
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excluding identified pre-XDR (MDR plus additional resistance to either a fluoroquinolone or any 
second-line injectable anti-TB drug) (23) and XDR strains), pre-XDR-TB or XDR-TB according to high 
confidence mutations.  This method of grouping was selected given that routine drug susceptibility 
testing was not done for all of the anti-TB drugs on all of the isolates.  Furthermore, a poor 
correlation was observed between high confidence mutations and routine second-line DST (see 
Results).  Isolates were considered to belong to the same cluster (implying on-going transmission) if 
identical mutations were observed in all of the genes sequenced. 
 
3.3  Results 
A convenience sample of 309 drug-sensitive and 342 MDR-TB isolates from patients from the 
Eastern Cape Province was collected during the study period.  These were submitted to Stellenbosch 
University for molecular-based analysis.  Analysis of the population structure of these isolates by 
spoligotyping identified 52 and 29 different spoligotype patterns among drug-sensitive and MDR-TB 
strains, respectively.  Among drug-sensitive and MDR isolates, 22/52 and 14/29 spoligotype patterns 
were previously recorded in the SpolDB4 database.  These represented 275/309 (89.0%) of drug-
sensitive and 327/342 (95.6%) of MDR isolates.  It is noteworthy that 84% of MDR isolates 
constituted only 3 different spoligotypes (Table 1), namely Beijing, LAM3 and LAM4.  This is an 
indication of transmission of these strains.  
Table 1 shows the breakdown of spoligotypes against the degree of drug resistance, where drug 
resistance is expressed as either culture-based or molecular-based DST.  In this study, we used 
molecular-based DST to define the extent of drug-resistance in routinely diagnosed MDR-TB isolates.  
The katG or rpoB regions of 8 isolates could not be amplified and could therefore not be classified 
according to molecular based DST.  Accordingly, 119 (38.5%) drug-sensitive and 236 (69%) of the 
MDR-TB patients were infected with a Beijing genotype strain.  Sub-classification of Beijing genotype 
strains showed that 11/119 (9.2%) drug-sensitive and 217/236 (91.9%) MDR strains belonged to the 
“atypical” subgroup of the Beijing genotype as indicated by the absence of an IS6110 element in the 
NFT region. 
Analysis of mutations conferring resistance to first and second-line anti-TB drugs allowed grouping of 
the MDR isolates: 136 MDR s.s., 98 pre-XDR and 108 XDR.  Using these groupings, isolates with a 
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higher degree of resistance, were more likely to have an atypical Beijing genotype (drug sensitive: 
11/309 (3.6%, 95% CI: 1.8%-6.3%); MDR s.s.: 29/136 (21.3%, 95% CI: 14.8%-29.2%) vs pre-XDR: 85/98 
(86.7%, 95% CI: 78.4%-92.7%) vs XDR: 103/108 (95.4%, 95% CI: 89.5%-98.5%)).  
DNA sequencing data for the first available isolate from each patient infected with an MDR atypical 
Beijing strain (n = 217) and IS6110 fingerprinting for a subset of these isolates (n = 110) was analysed 
to establish whether the over-abundance of the atypical Beijing genotype among patients with pre-
XDR-TB and XDR-TB strains reflected on-going transmission.  IS6110 DNA fingerprinting showed that 
all of these patients were infected with closely related atypical Beijing strains with only minor 
differences in the banding patterns (Figure 1 and 2), thereby suggesting clonal dissemination. 
Table 2 shows that 216/217 (99.5%) of the MDR atypical Beijing genotype strains harboured an 
identical katG (AGC315ACC) mutation, while 209/217 (94.9%) had a distinctive rrs (A513C) gene 
mutation.  This suggests that these mutations were acquired prior to dissemination.  Subsequently, 
resistance to rifampicin, ethambutol, pyrazinamide, amikacin and ofloxacin was acquired in various 
combinations.  Of the 29 atypical Beijing MDR s.s. isolates, 22 (75.9%) were grouped into 4 clusters 
according to mutations (mutation pattern, MP) in the inhA promoter and katG, rpoB, embB, pncA, 
rrs and gyrA genes (cluster size ranged from 3 to 12 cases; Table 2: MP2, MP17, MP32, MP34) while 
7 had unique mutation patterns (Table 2: MP23, MP25, MP30, MP31, MP41, MP44, MP48).  
Similarly, the 85 atypical pre-XDR Beijing isolates showed 11 different mutation patterns, of which 
81 (95.3%) were clustered into 7 clusters (cluster size ranged from 2 to 62 cases; Table 2: MP3, MP5, 
MP18, MP26, MP28, MP35, MP38).  The genotype of the largest pre-XDR-TB cluster was 
characterised by an inhA promoter mutation at position -17 and the katG AGC315ACC, rpoB 
GAC516GTC, embB ATG306ATA, rrs A513C and rrs A1401G nucleotide substitutions as well as an 
insertion in the pncA gene at position 172G.  This mutation pattern was characteristic of 79% 
(81/103) of the atypical Beijing XDR-TB isolates and for ease of reference will be called MP5 (see 
Table 2).  By contrast, only 3 of the 29 atypical Beijing MDR s.s. isolates showed the same mutation 
pattern for these genes excluding the rrsA1401G mutation (MP2).  Ten different atypical XDR Beijing 
mutation patterns emerged from the MP5 progenitor by mutation in the gyrA gene.  Of these, 6 
mutation patterns showed clustering (cluster size ranged from 2 to 46 cases, MP6-11) and 4 had 
unique mutations conferring ofloxacin resistance (MP12-16).  The presence of clustering among both 
the pre-XDR and XDR genotypes suggests transmission following acquisition of additional resistance.  
Of the remaining 22 atypical XDR Beijing isolates, 12 distinct resistance mutation patterns were 
observed, of which 11 isolates were clustered (MP27) and 11 had unique genotypes (MP19-22, 
MP24, MP29, MP39-40, MP42-43, MP47). 
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Table 2: Geographical distribution of atypical Beijing genotype isolates and their mutation patterns 
 
*WT – Wild Type; †MP – mutation pattern; ‡DR – Drug-resistance; §XDR – extensively drug-resistant tuberculosis; ¶MDR – 
mutidrug-resistant tuberculosis; # AM – Amathole; **NMB - Nelson Mandela Bay; ††CC – Cacadu; ‡‡CH - Chris Hani; §§OT - 
OR Tambo              Continued… 
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Table 2 continued: Geographical distribution of atypical Beijing genotype isolates and their mutation patterns 
 
*WT – Wild Type; †MP – mutation pattern; ‡DR – Drug-resistance; §XDR – extensively drug-resistant tuberculosis; ¶MDR – 
mutidrug-resistant tuberculosis; # AM – Amathole; **NMB - Nelson Mandela Bay; ††CC – Cacadu; ‡‡CH - Chris Hani; §§OT - 
OR Tambo 
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Figure 1: IS6110 DNA fingerprint patterns of a subset (63/85) of atypical Beijing pre-XDR-TB isolates and their 
geographical origin. MP, Mutation pattern; NMB, Nelson Mandela Bay; AM, Amathole; CC, Cacadu; OT, Oliver Tambo 
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Figure 2: IS6110 DNA fingerprint patterns of a subset (81/103) of atypical Beijing XDR-TB isolates and their geographical 
origin. MP, Mutation pattern; NMB, Nelson Mandela Bay; AM, Amathole; CC, Cacadu; OT, Oliver Tambo 
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Figure 3: Map showing district municipalities in the Eastern Cape. 
 
Spatial analysis of the patient origins showed that pre-XDR and XDR isolates with an atypical Beijing 
genotype were present in 5 of 8 district municipalities (Figure 3, Table 2).  The largest atypical pre-
XDR Beijing genotype cluster (MP5) was identified in 4 adjacent district municipalities (Table 2), 
while the largest XDR-TB cluster (MP6) was identified in 3 of these districts as well as an additional 
district, suggesting historic spread of these genotypes.  
 
Table 3: Correlation of culture-based and molecular-based Drug-susceptibility testing among atypical Beijing isolates 
* CB-DST – culture-based drug susceptibility testing; †R – resistant; ‡MB-DST – molecular-based DST; §S – sensitive; ¶INH – Isoniazid; #RIF 













INH¶/katG 217 9 1 0 227 99.6% 
RIF#/rpoB 219 9 0 0 228 100% 
STR**/rrs500 191 6 2 16 215 91.60% 
EMB††/embB 56 5 2 152 215 28.40% 
ETH‡‡/inhA 
promoter 
76 25 5 86 192 52.60% 
OFL§§/gyrA 78 93 0 29 200 85.50% 
AMK¶¶/rrs1400 167 32 7 9 215 92.60% 
CAP##/rrs1400 21 38 1 155 215 27.40% 
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The presence of mutations in target genes known to confer resistance with high confidence 
suggested 95.1% (98/103) of the atypical XDR Beijing isolates were resistant to at least ten anti-TB 
drugs: isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, amikacin, kanamycin, 
capreomycin, ethionamide and ofloxacin.  The extent of drug resistance in these isolates was under-
estimated by routine DST (Table 3).  The correlation between molecular-based drug-resistance and 
routine culture-based DST was 99.6% for isoniazid, 100% for rifampicin, 28% for ethambutol, 92% for 
streptomycin, 93% for amikacin, 27% for capreomycin, 52% for ethionamide and 86% for ofloxacin 
(Table 3).  Routine DST for pyrazinamide, kanamycin, cycloserine and para-aminosalicylic acid was 
not determined.  DST for para-aminosalicylic acid was done at Stellenbosch University on 45 isolates 
of which 9 showed resistance at a level of > 4.0µg/ml. 
 
3.4  Discussion 
Review of routine DST results highlights the severity of the drug-resistant TB epidemic in South 
Africa (4), and thereby emphasises the urgent need to curb the rising incidence of drug resistance in 
the country.  This can only be achieved by the implementation of appropriate intervention strategies 
which are based on knowledge of the mechanisms fuelling this epidemic.  Recently, molecular 
epidemiological techniques have been used in combination with classical epidemiological data to 
enhance our understanding of the TB epidemic in different settings.  Those studies have quantified 
the relative proportion of acquisition versus transmission, and have described the population 
structure of M. tuberculosis over time (7, 9, 21, 23, 24).  Using these approaches we show that 
patients with MDR-TB in the Eastern Cape could be divided into two distinct groups: patients 
infected with MDR-TB s.s. showed diverse genetic backgrounds, while patients infected with pre-
XDR-TB and XDR-TB showed restricted genetic backgrounds.  
The finding that the pre-XDR-TB and XDR-TB strains are genetically distinct when compared to the 
MDR-TB s.s. strains is counterintuitive as we would expect all MDR-TB strains to have had an equal 
chance of acquiring resistance to second-line anti-TB drugs.  The absence of second-line resistance 
among a large number of different MDR-TB genotypes suggests that under the current MDR-TB 
treatment regimen acquisition of additional resistance in MDR s.s. strains is reduced.  Conversely, 
analysis of the DNA sequencing data showed a significant association between the atypical Beijing 
genotype and mutations conferring second-line resistance.  This demonstrates that this genotype 
has acquired resistance to the level of pre-XDR-TB, which in turn has spread and thereafter has 
acquired additional resistance to the level of XDR-TB followed again by transmission.  An alternative 
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explanation would be that the atypical Beijing genotype acquires resistance conferring mutations 
more readily than other genotypes.  However, it is highly unlikely that the convergent evolution of 
seven different mutations would occur within a single genotype.  
Spatial analysis of the pre-XDR-TB cases infected with this clone shows a wide distribution suggesting 
that this genotype has been in circulation for an extended period.  This was further supported by the 
analysis of the evolutionary order in which resistance was acquired (Table 2) which showed that the 
ancestral clone first acquired resistance to isoniazid and streptomycin.  This could be explained by 
the treatment regimen used in the early 1960s, which was based on the combination of isoniazid 
and streptomycin (26).  A similar conclusion was drawn from whole genome sequence data, which 
predicted that mutations conferring resistance to isoniazid and streptomycin were deeply rooted in 
the atypical Beijing genotype (27). 
Given the extent of resistance in pre-XDR-TB strains and the extremely limited treatment options 
available, it is inevitable that the emergence of ofloxacin resistance would follow.  This was 
supported by our molecular-based analysis of the XDR-TB isolates which demonstrates that 
resistance to a fluoroquinolone had been acquired independently on a number of different 
occasions (several different gyrA mutations were observed) followed by amplification through 
transmission (clustering of XDR phenotypes was observed).  However, the true extent of acquisition 
may be higher than predicted given that the XDR-TB isolates were cultured from patients who 
resided in different district municipalities and contact was unlikely due to the long distances. 
We suggest that the absence of routine second-line drug susceptibility testing and treatment of 
MDR-TB with an inadequate standardized regimen according to the 2002 guidelines (6 months 
intensive phase: kanamycin, ethionamide, pyrazinamide, ofloxacin, and cycloserine or ethambutol; 
12–18 months continuation phase: ethionamide, ofloxacin and cycloserine or ethambutol) (28) may 
have led to the inappropriate treatment of undiagnosed pre-XDR-TB cases.  This would have 
prolonged the period of infectiousness leading to transmission to close contacts as well as increasing 
the risk of amplification of resistance (28,29).  This has been recently addressed with the 
implementation of a revised treatment regimen (28) as well as routine second-line DST which is now 
done on all isolates shown to be resistant to rifampicin.  However, these tests are culture-based, 
exacerbating diagnostic delay and possible transmission.  This can be partially resolved with the 
implementation of a genetic-based second-line drug susceptibility test (29).   However, the extent of 
resistance associated with the atypical Beijing genotype makes treatment options extremely difficult 
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as these isolates are resistant to all first-line anti-TB drugs (isoniazid, rifampicin, ethambutol, 
pyrazinamide and streptomycin) and many of the second-line drugs (amikacin, kanamycin, ofloxacin, 
ethionamide capreomycin).  A limited number of isolates were also resistant to para-aminosalicylic 
acid.  This suggests that the atypical Beijing genotype clone is evolving towards total drug resistance 
(TDR, defined as in vitro resistance to all first-line drugs, as well as aminoglycosides, cyclic 
polypeptides, fluoroquinolones, thioamides, serine analogues and salicylic acid derivatives (30)).  
Our molecular-based results are in accordance with a recent study from the Eastern Cape, which 
documented extremely poor treatment outcomes for XDR-TB cases (11).  The authors showed high 
mortality (58.4%) and low culture conversion rates (8.4%) over a follow-up period of 143 days.  They 
concluded that only 1.7 drugs per patient was regarded as “effective”, based on DST results and/or 
previous treatment records.  Given that this study was conducted concurrently with ours, it is highly 
likely that a large proportion of their patients were also infected with XDR-TB strains with an atypical 
Beijing genotype.  Thus the poor treatment outcome may be related to the extent of drug-
resistance, however, we cannot exclude the possibility that the atypical Beijing genotype contributes 
to morbidity and mortality.  A further concern is the observation that this clone is now spreading to 
other provinces in South Africa, possibly due to migration.  In the Western Cape, an estimated 55% 
of XDR-TB cases harbour isolates with the atypical Beijing genotype (32).  
We acknowledge that this study has a number of limitations.  Firstly clinical data was not available 
for this study and therefore it was not possible to establish the impact of drug resistance on 
treatment outcome.  However, we do not believe that the strains reported by Kvasnovsky et al (11) 
differ from those analysed in this study as both studies were conducted concurrently.  Secondly, our 
analysis of a convenience sample may have led to an over estimation of the proportion of pre-XDR-
TB and XDR-TB cases in the Eastern Cape Province.  Thirdly, our use of mutational data to categorise 
patients as MDR s.s., pre-XDR and XDR is not the accepted standard.  However, genetic DST has been 
endorsed by the WHO for first-line anti-TB drugs and there is mounting evidence that high 
confidence mutations accurately predict second-line drug resistance (33).   
The diagnostic dilemma facing TB control managers in the Eastern Cape is how to rapidly identify 
cases at risk of harbouring the atypical Beijing genotype to prioritize DST, ensure isolation and 
administer appropriate treatment.  Previous studies have shown a strong association between inhA 
promoter mutations and preXDR-TB and XDR-TB (34).  Given that the Genotype® MTBDRplus test 
(35) has been implemented as the diagnostic standard in most NHLS laboratories in South Africa we 
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propose that this test could be used as a rapid screening tool to identify patients harbouring drug 
resistant atypical Beijing strains (34).  It is therefore essential that TB control managers make use of 
this information in an attempt to contain the spread of this virtually untreatable form of TB. 
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Chapter 4   The value of selected drugs in the treatment of XDR-TB 
patients in the Eastern Cape 
 
The work in this chapter has been published as two peer-reviewed publications. 
 
1.  Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and 
capreomycin in Mycobacterium tuberculosis. 
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G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A. 
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2. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. 
Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD. 
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It’s the little details that are vital.  Little things make big things happen. – John Wooden  
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Abstract 
The availability of antituberculosis drugs to treat extensively drug-resistant tuberculosis is limited.  The 
aminoglycosides amikacin and kanamycin, and the cyclic polypeptide capreomycin are important 
injectable drugs in the treatment of multidrug-resistant tuberculosis.  Capreomycin is recommended 
as a substitute for amikacin or kanamycin if resistance to either of them is suspected.  However, cross-
resistance between amikacin/kanamycin and capreomycin in Mycobacterium tuberculosis was 
observed in clinical isolates and laboratory-generated mutants that contain single nucleotide 
polymorphisms.  In this study, the genetic mechanisms that confer phenotypic levels of resistance to 
amikacin and capreomycin in 50 clinical isolates of M. tuberculosis were investigated.  The isolates 
were cultured from patients resident in the Eastern Cape Province of South Africa and then subjected 
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to DNA sequencing of the rrs- (1400-1500 region) and the tlyA- (entire region) genes.  The phenotypic 
resistance of each isolate was quantified in MGIT 960 and compared to the sequenced data.  All 
isolates with a nucleotide substitution at position 1401 (A→G) in the rrs gene showed high-level 
resistance (>20 µg/ml) to amikacin.  A 100% correlation was also found between the presence of the 
rrs(A1401G) mutation and decreased phenotypic susceptibility to capreomycin at MICs of 10 to 15 
µg/ml.  No other mutations in either the rrs or tlyA genes were detected.  Complete (100%) cross-
resistance between amikacin and capreomycin in M. tuberculosis isolates with an A-to-G change at 
position 1401 of the rrs gene was therefore observed in this study.  Our findings provide important 
information that could be used to guide the management of drug resistant tuberculosis.  
 
4.1  Introduction 
Therapeutic options in the treatment of pulmonary tuberculosis (TB) are limited and this is a major 
concern in view of the increasing incidence of drug resistant M. tuberculosis.  Drug susceptible M. 
tuberculosis infections are treated with a combination of first-line drugs: isoniazid (INH), rifampicin 
(RIF), pyrazinamide (PZA), and ethambutol (EMB).  Therapy with all 4 drugs is administered for an 
initial intensive phase of 2 months followed by a 4 month continuation phase with only INH and RIF 
(16, 17).  Lengthy dosing regimens with multiple drugs increase the risk of non-adherence and this is 
often the reason for treatment failure.  Patients may thus acquire drug resistance during therapy or it 
may arise in previously treated individuals due to relapse of the initial infection (4, 7).  Primary drug 
resistance may also occur as a result of drug resistant strains that are transmitted to treatment-naïve 
patients.  First-line drugs, especially INH and RIF, are the most effective and best tolerated amongst 
the antituberculosis drugs.  Resistance to at least INH and RIF indicates that multidrug-resistant TB 
(MDR) has emerged (7).  Effective treatment of MDR-TB requires prolonged administration of 
expensive and less potent second-line drugs that are often poorly tolerated (4).  MDR-TB patients are 
thus at increased risk of acquiring additional resistance, eventually giving rise to extensively drug 
resistant TB (XDR-TB).  XDR-TB has emerged independently worldwide and is defined as MDR-TB that 
has acquired additional resistance to any fluoroquinolone such as ofloxacin (OFX) and at least 1 of the 
3 injectable second-line drugs: amikacin (AMK) kanamycin (KAN) or capreomycin (CAP) (4, 16, 17).  
XDR-TB is extremely difficult to cure because of limited and expensive treatment options.  Delays in 
the detection and therapy of infected individuals are further complications as M(X)DR strains are 
expected to spread readily in vulnerable communities (5).  The transmission of XDR-TB especially 
amongst individuals co-infected with the human immunodeficiency virus could easily develop into 
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XDR-TB epidemics with devastating public health consequences (5).  The standard MDR-TB treatment 
regimen used in South Africa is based on the recommended guidelines of the World Health 
Organization (WHO) and includes the following drugs: KAN or AMK (injectable); OFX; terizidone; 
ethionamide (ETH) and PZA (16, 17). AMK and KAN are aminoglycosides with a high level of cross-
resistance between them, while CAP is a structurally unrelated cyclic polypeptide antibiotic (3).  
However, cross resistance in M. tuberculosis between AMK/KAN and CAP has been observed in both 
clinical isolates and laboratory-generated mutants that contain single nucleotide polymorphisms 
(SNPs) in the rrs gene between nucleotides 1400 and 1500 (9, 13, 15).  AMK/KAN and CAP primarily 
affect protein synthesis in M. tuberculosis and resistance to these drugs is associated with changes in 
the 16S rRNA (rrs) (2, 8, 9, 12).  Mutations in the 1400 region of the rrs gene and in particular those at 
positions 1401, 1402 and 1484 are somehow linked with cross-resistance between CAP, AMK and KAN 
(1, 2, 9, 13, 15).  Resistance to CAP has also been associated with mutations in the tlyA gene, although 
such mutants are less often seen as those with an A-to-G substitution at position 1401 in the rrs gene 
(9, 12, 13).  The tlyA gene encodes a putative rRNA methyltransferase and mutations that inactivate 
this gene in M. tuberculosis results in CAP and viomycin resistance (8, 12).  
Between June 2008 and November 2009, 310 M(X)DR M. tuberculosis clinical isolates, cultured by the 
National Health Laboratory Services (NHLS) in the Eastern Cape of South-Africa were sent to 
Stellenbosch University for genotyping.  This cohort of strains was subjected to DNA sequencing of the 
rrs and tlyA genes to establish the mutational mechanisms responsible for AMK and CAP resistance.  
A subset of these strains was then selected for quantitative drug susceptibility testing (QDST) against 
AMK and CAP.  The objectives of the study were (i) to correlate the susceptibility levels of M. 
tuberculosis isolates against AMK and CAP with the molecular mechanisms that cause drug resistance; 
(ii) to determine whether the rrs and tlyA genes of isolates displaying resistance to both AMK and CAP 
contain specific mutations that mediate cross-resistance between the two drugs; and (iii) to consider 
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4.2  Methods 
4.2.1  Clinical isolates 
The M(X)DR clinical isolates of M. tuberculosis used in this study were obtained from the NHLS in Port 
Elizabeth (Eastern Cape Province, South Africa) where they were collected during the period June 2008 
to November 2009.  A total of 310 isolates were initially cultured and subjected to routine DST of first- 
and second- line drugs by the NHLS laboratory.  The BD BACTEC MGIT 960 SIRE system (BD Bioscience, 
Sparks, MD) was used for DST of first-line drugs at critical concentrations (CCs) of 1.0 µg/ml for SM; 
0.1 µg/ml for INH; 1.0 µg/ml for RIF; and 5.0 µg/ml for EMB (17).  DST of the second-line drugs was 
determined according to the 7H11-agar proportional method at CCs of 10.0 µg/ml for AMK; 2.5 µg/ml 
for ETH; 2.0 µg/ml for OFX and 10 µg/ml for CAP (17).  Subsequently, the isolates were sent to 
Stellenbosch University where they were subjected to DNA sequencing of the rrs (1400-1500 region) 
and the tlyA genes as previously described (10).  A subset of 50 M(X)DR isolates was randomly selected 
from the above group with each isolate representing a separate patient.  The cohort included strains 
that were: susceptible to both AMK and CAP; resistant to AMK; and resistant to both drugs (see Table 
1).  The test isolates were sub-divided according to their drug susceptibility patterns into three groups: 
MDR; pre-XDR and XDR (15).  Twenty strains were MDR (19 of these showed additional resistance to 
1 or more of the alternative antituberculosis drugs, excluding the fluoroquinolones and the injectable 
drugs); 15 pre-XDR (MDR with additional resistance to either a fluoroquinolone or an injectable); and 
15 XDR (MDR with additional resistance to both a fluoroquinolone and an injectable).  Among the test 
strains 20 were susceptible to both AMK and CAP; 17 were resistant to both AMK and CAP; while 13 
were resistant to AMK, but susceptible to CAP when tested on Middlebrook 7H11-agar medium (see 
Table 1).  Each of the 50 isolates was re-tested by QDST to quantify the level of AMK and CAP 
resistance.  The automated BACTEC MGIT 960 instrument equipped with the TBeXiST application and 
EpiCentreTMV5.69A software (BD Bioscience, Erebodegem, Belgium) was used for QDST as previously 
described (14).  AMK was tested at 1.0 µg/ml, 4.0 µg/ml and 20.0 µg/ml, and CAP at 2.5 µg/ml, 5.0 
µg/ml, 10.0 µg/ml, 15.0 µg/ml, and 25.0 µg/ml.  M. tuberculosis strain H37Rv (ATCC 27294) was 
included as a control and subjected to all the relevant drug concentrations.  The MICs were 
determined with the MGIT 960 according to the proportion method that defines resistance as the 
ability of 1% of the strains (inoculum) to grow at a particular drug concentration.  Strains with MICs of 
≥ 1.0 µg/ml for AMK and ≥ 2.5 µg/ml for CAP were considered as resistant based on the CCs suggested 
by the WHO (17). 
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4.2.2  Antimicrobial agents used for QDST 
AMK and CAP were obtained from Sigma Aldrich South Africa.  Stock solutions of AMK at 1680 µg/ml 
and CAP at 2100 µg/ml were respectively prepared in distilled water.  The drugs were then sterilised 
by filtration through a Millex-GV syringe-driven filter with a membrane pore size of 0.22 µm.  Aliquots 
of stock solutions were stored at -80°C in screw-cap polypropylene cryovials up to 6 months.  Stock 
solutions were further diluted in sterile distilled water as required.  AMK was diluted 1:5 and 1:20 for 
a concentration range of 1680 µg/ml, 336 µg/ml and 84 µg/ml.  From each of the latter dilutions, 100 
µl was respectively added into 8.3 ml MGIT medium for a final drug concentration range of 20.0 µg/ml, 
4.0 µg/ml and 1.0 µg/ml.  From the CAP stock solution, four additional dilutions: 1:1.67 µg/ml, 1:2.5 
µg/ml, 1:5 µg/ml and 1:10 µg/ml were prepared to provide a concentration range of 2100 µg/ml, 1260, 
µg/ml, 840 µg/ml, 420 µg/ml and 210 µg/ml.  From each of these 100 µl was transferred into 8.3 ml 
MGIT tubes to obtain a final drug concentration range of 25.0 µg/ml, 15.0 µg/ml, 10.0 µg/ml, 5.0 µg/ml 
and 2.5 µg/ml.  
 
4.3  Results 
4.3.1  Molecular detection of mutations  
During a period of 18 months, 310 M(X)DR-TB isolates were received from NHLS in Port Elizabeth.  
DNA sequencing of the rrs gene detected the A1401G mutation in 181 of the isolates (58%).  Amongst 
the 50 selected test isolates, 35/35 (100%) of the AMK/CAP resistant strains as determined by QDST, 
were identified with the rrs(A1401G) SNP.  The remaining 15 strains lacked the latter mutation and 
were susceptible to both AMK and CAP (see Table 1).  Alternative mutations that are linked to 
AMK/KAN or CAP resistance in either the rrs or tlyA genes were not observed in any of the 50 test 
strains.  
 
4.3.2  QDST of clinical isolates against AMK and CAP 
The control strain H37Rv (ATCC 27294) was susceptible to AMK and CAP in both routine DST and QDST, 
as expected.  According to routine DST, 20 of the selected 50 M(X)DR strains tested susceptible to 
both AMK and CAP on Middlebrook 7H11-medium at CCs of 4.0 µg/ml and 10.0 µg/ml, respectively 
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Table 1: Mutations and susceptibility profiles of amikacin and capreomycin in clinical isolates of M. tuberculosis 
Resistance 
classification 
Routine DST profile QDST MGIT 960b  
No. of clinical 
isolates 
(7H11-agar)a MIC in µg/mlc Gene mutationsd 
AMK CAP AMK CAP rrs gene 
tlyA 
gene 
XDR        
6 R S >20 (R) 10 (R) A1401G None 
7 R R >20 (R) 10 (R) A1401G None 
2 R R >20 (R) 15 (R) A1401G None 
Pre-XDR     A1401G None 
6 R S >20 (R) 10 (R) A1401G None 
1 R S >20 (R) 15 (R) A1401G None 
7 R R >20 (R) 10 (R) A1401G None 
1 R R >20 (R) 15 (R) A1401G None 
MDR       
5 S S >20 (R) 10 (R) A1401G None 




Control       
H37Rv (ATCC 
27294) 






a Critical concentrations on 7H11 agar: AMK, 4.0mg/L; CAP, 10mg/L. 
b QDST, quantitative drug susceptibility testing. 
c Critical concentrations in MGIT 960 medium: AMK, 1.0mg/L; CAP, 2.5mg/L. 
d The entire tlyA gene and region 1400-1500 of the rrs gene were sequenced. 
DST, drug susceptibility testing; QDST, quanititative DST; MIC, minimum inhibitory concentration; AMK, 
amikacin; CAP, capreomycin; S, susceptible; R, resistant. 
 
(see Table 1).  However, in this study and by QDST in MGIT 960 at CCs of 1.0 µg/ml for AMK and 2.5 
µg/ml for CAP, 5 of the 20 strains were found to be resistant to both drugs while the other 15 were 
truly susceptible.  The remaining 30 strains also tested resistant to both AMK and CAP by QDST.  
Routine DST on the other hand, only found 17 of these 30 strains resistant to both AMK and CAP, while 
13 showed resistance to AMK only (Table 1).  The agreement between routine DST and QDST results 
regarding the detection of both AMK and CAP susceptibility was 15 out of 20 isolates (75%); AMK 
resistance was 30 out of 35 strains (85.7 %); and both AMK and CAP resistance was 17 out of 35 strains 
(48.60%).  However, the QDST findings correlated with molecular data which indicated an A-to-G 
nucleotide change at position 1401 of the rrs gene in all 35 isolates that were resistant to both AMK 
and CAP.  Our results therefore showed a 100% correlation between the presence of the A1401G 
mutation and cross-resistance between AMK and CAP. 
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4.4  Discussion 
The aminoglycosides AMK or KAN and the cyclic polypeptide CAP together with fluoroquinolones play 
an important role in the treatment of MDR-TB (7, 17).  Evidence that CAP is bactericidal against non-
replicating M. tuberculosis has renewed interest in this drug despite its limitations due to renal and 
auditory toxicities (6, 7).  It has also been demonstrated that the risk of treatment failure and mortality 
increases when CAP resistance emerges among MDR-TB cases (11).  High levels of cross-resistance 
between the closely related aminoglycosides AMK and KAN have previously been reported (2, 9).  CAP 
has therefore been recommended as the preferred choice to replace AMK or KAN if resistance to 
either of them is suspected as cross-resistance across drug classes may only in part be expected (7, 
17).  The introduction of CAP therapy may be based on the treatment history of the patient when DST 
results are still pending.  However, a relationship between AMK/KAN and CAP resistance due to the 
presence of either an A1401G (referred to as A1400G in ref 2), C1402T or a G1484T rrs mutation in M. 
tuberculosis strains (13) may compromise the use of CAP in M(X)DR treatment.  In this study, the 
occurrence of cross-resistance between AMK and CAP in clinical isolates obtained from the Eastern 
Cape Province of South Africa was examined.  Phenotypic and genotypic resistance to AMK and CAP 
were respectively determined by QDST and compared to DNA sequencing of the rrs (1400-1500 
region) and tlyA genes.  QDST in MGIT 960 showed high-level AMK resistance (>20 µg/ml) in 35 of the 
50 M(X)DR isolates while a lower level of CAP resistance was observed in the same isolates (MICs of 
10 to 15 µg/ml).  A nucleotide substitution at position 1401(A→G) in the rrs gene was present in all of 
the 35 AMK-CAP resistant strains.  No mutations were detected in the 1400-1500 region of the rrs 
gene in any of the 15 AMK-CAP susceptible isolates, while all 50 isolates had wild-type tlyA genes.  
These results agree with previous findings that a mutation at rrs position 1401 not only confers high-
level AMK/KAN resistance in M. tuberculosis, but also mediates CAP resistance.  In contrast, mutation 
C1402T is associated with CAP-resistance (also viomycin), low-level KAN resistance and no resistance 
to AMK, whereas mutation G1484T is linked to high-level AMK and CAP resistance (also KAN and 
viomycin) in M. tuberculosis (13)).  The absence of mutations C1402T and G1484T in the rrs gene 
further supports the QDST findings.  Mutations in the tlyA genes that are associated with CAP 
resistance (but no resistance to AMK or KAN) were also not detected (8, 12, 13).  Discrepancies 
between routine DST and QDST results were probably due to the different techniques that were used.  
QDST was done in MGIT 960 as opposed to Middlbebrook 7H11-agar that was used for routine DST.  
A 100% correlation between the QDST results and the mutational data regarding AMK-and CAP- 
susceptibilities were obtained and these findings were considered to be more accurate than 
Stellenbosch University  https://scholar.sun.ac.za
 98 
conventional DST on 7H11-agar plates.  The agreement between routine DST and mutational findings 
of AMK and CAP resistance was 86% and 49%, respectively.  
The presence of high level AMK resistance as opposed to a relatively low level of CAP resistance among 
the test strains reflect a history of AMK/KAN usage prior to CAP treatment (15).  It is likely that 
decreased susceptibility to CAP occurred even before it was included in the treatment regimen.  The 
pre-selection of low-level CAP resistance as a result of AMK/KAN therapy may imply that the drug has 
no further clinical relevance in the treatment of XDR patients.  The possibility of administering CAP at 
increased dosages to eliminate low-level CAP-resistant mutants is not an option because of toxicity 
considerations (7).  DST is however, based on a single critical concentration which does not necessarily 
reflect clinical resistance (14).  Peak serum concentration levels of 20–47 µg/ml for CAP are achieved 
between 1 and 2 hours after a single daily dosage of 15-20 mg/kg by intramuscular injection (3, 7).  In 
this study the MICs (10 to 15 µg/ml) of the CAP resistant isolates were above the CC of 2.5 µg/ml, but 
substantially below the achievable peak serum levels.  Protein binding of CAP is relatively low at 20% 
and the concentration of free drug at the point of infection may be sufficient for an adequate 
therapeutic effect when patients are infected with low-level CAP resistant mutants (3).  Therapeutic 
options for M(X)DR-TB are severely restricted and the omission of CAP based on the current DST 
criteria needs to be considered with caution.  
This study supports existing data that the A1401G mutation in the rrs gene mediates cross-resistance 
between AMK and CAP and that it could be regarded as a genetic marker to demonstrate resistance 
to both drugs (2, 9).  Rapid and accurate detection of AMK/KAN and CAP resistance is important to 
guide treatment regimens and to improve infection control measures that may limit the spread of 
M(X)DR-TB.  Our findings have significant implications on the management of XDR-TB in the Eastern 
Cape as nearly 60% of MDR cases in the region harbour the rrs A1401G mutation.  Therefore, we 
propose that clinical studies be carried out to establish a clear correlation between the current critical 
concentration, quantitative susceptibilities, mutational data, pharmacokinetics and clinical outcome 
as a basis for a realistic DST interpretation.  
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Abstract 
Genetically related Mycobacterium tuberculosis strains with alterations at codon 516 in the rpoB 
gene were observed amongst a substantial number of patients with drug resistant tuberculosis in 
the Eastern Cape Province (ECP) of South Africa.  Mutations at codon 516 are usually associated with 
lower level rifampicin (RIF) resistance, while susceptibility to rifabutin (RFB) remains intact.  This 
study was conducted to assess the rationale for using RFB as a substitution for RIF in the treatment 
of MDR and XDR tuberculosis outbreaks.  Minimum inhibitory concentrations (MICs) of 34 drug 
resistant clinical isolates of M. tuberculosis were determined by MGIT 960 and correlated with rpoB 
mutations.  RFB MICs ranged from 0.125 to 0.25 μg/ml in the 34 test isolates thereby confirming 
phenotypic susceptibility as per critical concentration (CC) of 0.5 μg/ml.  The corresponding RIF MICs 
ranged between 5 and 15 μg/ml, which is well above the CC of 1.0 μg/ml.  Molecular-based drug 
susceptibility testing provides important pharmacogenetic insight by demonstrating a direct 
correlation between defined rpoB mutation and the level of RFB susceptibility.  We suggest that 
isolates with marginally reduced susceptibility as compared to the epidemiological cut-off for wild-
type strains (0.064 μg/ml), but lower than the current CC (≤0.5 μg/ml), are categorised as 
intermediate.  Two breakpoints (0.064 μg/ml and 0.5 μg/ml) are recommended to distinguish 
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between susceptible, intermediate and RFB resistant strains.  This concept may assist clinicians and 
policy makers to make objective therapeutic decisions, especially in situations where therapeutic 
options are limited.  The use of RFB in the ECP may improve therapeutic success and consequently 
minimise the risk of ongoing transmission of drug resistant M. tuberculosis strains.  
 
4.6  Introduction 
Mutations within an 81-bp fragment of the rpoB gene that encodes the ß subunit of DNA-dependent 
RNA polymerase are responsible for RIF resistance in M. tuberculosis [1–4].  This domain is found 
between rpoB codons 507 and 533 and is referred to as the Rifampicin Resistance Determining 
Region (RRDR).  More than 95% of RIF-resistant isolates have been shown to possess mutations 
within the RRDR of the rpoB gene [1–7].  Mutations in the RRDR at codons 531, 526 and 513 are 
generally associated with high-level RIF-resistance [2–4].  In contrast, amino acid substitutions 
resulting from specific changes at codons 511, 514, 515, 516, 518, 521, 522 and 533 are correlated 
with lower levels of RIF-resistance [2,8,9].  Mutations in the rpoB gene that confer high-level RIF-
resistance (MICs, ≥32 μg/ml) in M. tuberculosis have been associated with cross-resistance to RFB 
(MIC, ≥4.0 μg/ml) (2,8,9).  Conversely, isolates that exhibit lower levels of RIF-resistance MICs (≤16 
μg/ml) were found to remain phenotypically susceptible to RFB based on a CC of 0.5 μg/ml [2,8,9].  
Single nucleotide polymorphisms (SNPs) outside the RRDR near the beginning of the rpoB gene have 
also been described to be associated with RIF resistance [5].  This region has recently been 
suggested for inclusion as an additional target for the detection of cross-resistance between RIF and 
RFB [5].  High-level RIF-resistance is almost always encountered in clinical practice, while mutants 
with lower levels of resistance are less frequently reported [10].  The clinical impact of low-level RIF-
resistance in multidrug-resistant (MDR) tuberculosis (TB) and extensive drug-resistant (XDR) TB, 
collectively referred to as M(X)DR-TB, is less well-studied and understood.   
Epidemiological data based on molecular methods demonstrated that large numbers of M(X)DR 
patients in the Eastern Cape Province (ECP) of South Africa are infected with similar M. tuberculosis 
isolates of the atypical Beijing genotype [11].  These isolates had comparable sequence alterations in 
the inhA promoter, katG, rpoB, pncA, embB and rrs (500 and 1400 regions) genes which mediate 
isoniazid (INH), RIF, pyrazinamide, ethambutol (EMB), streptomycin and amikacin/kanamycin 
resistance, respectively (11).  These similarities suggest genotypic clustering of circulating strains 
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which are likely responsible for wide-spread transmission of M(X)DR-TB in the ECP.  Of particular 
interest is the high proportion (77%) of the atypical Beijing isolates harbouring SNPs at codon 516 in 
the rpoB gene (11), which is expected not to mediate RFB-resistance [2,9,12].  Based on these 
observations, it was decided to investigate the possibility of using RFB as a substitute for RIF to treat 
these M(X)DR TB-infected patients.  Hence, our objectives: (i) to correlate the MICs of RIF and RFB in 
a subset of M(X)DR M. tuberculosis isolates (ii) to analyse the MIC data to establish whether cross-
resistance occurs between RIF and its analogue RFB and, (iii) to translate the gained knowledge into 
clinical practice for further assessment concerning RFBs potential to improve clinical outcome. 
 
4.7  Materials and Methods 
4.7.1  Clinical Isolates  
Amongst a collection of 342 M(X)DR M. tuberculosis clinical isolates obtained from patients resident 
in the ECP, South Africa, 217 (63%) were previously characterised as members of the atypical Beijing 
lineage [11].  Within this group, 77% (168/217) harboured a mutation at codon 516 in the rpoB gene 
and 151/168 (90%) of these had an Asp516Val (GAC→GTC) alteration.  A convenience sample of 
34/217 isolates (Table 1) with SNPs in the rpoB gene at codon 516 was selected for this study.  The 
isolates had known sequence alterations in the inhA promoter, katG (315), rpoB (516), pncA (Ins172) 
and embB (306) genes [11].  In addition, high confidence drug-resistance conferring mutations were 
observed in the rrs (500 and 1400 regions) and gyrA genes.  H37Rv (ATCC 27294) and 27 M. 
tuberculosis clinical isolates were included for quality control purposes.  Two of the isolates were 
genotypically and phenotypically resistant and 25 susceptible to RIF (Table 1). 
 
4.7.2  MIC determinations 
MICs for all selected isolates were determined for RIF and RFB by quantitative drug susceptibility 
testing (QDST) in BACTEC MGIT 960 eXtended individual  Susceptibility Testing (TB eXiST) for 
EpiCenter TM 92 V5.75A, (BD Bioscience, Erembodegem, Belgium) as previously described (13).  The 
drugs were purchased from Sigma-Aldrich, South Africa.  RIF and RFB were dissolved in dimethyl 
sulfoxide and then diluted in sterile distilled water.  Stock solutions of each drug were prepared at 
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concentrations that were at least 84 times higher than the highest test concentration used.  The 
stock solutions were filter sterilized and small aliquots were then stored at -80°C.  The MICs for RIF 
were determined at 0.5 μg/ml,1.0 μg/ml, 10.0 μg/ml, 15.0 μg/ml and 20.0 μg/ml and for RFB at 0.03 
μg/ml, 0.06 μg/ml, 0.125 μg/ml, 0.25 μg/ml, 0.5 μg/ml and 1.0 μg/ml. CCs of 1.0 μg/ml and 0.5 
μg/ml were used to determine the susceptibilities of the strains against RIF and RFB, respectively 
[14].  The relative resistance (RR) of the isolates against the drugs was measured by: Mutant 
MICs/Wild-type MICs.  
Table 1:  MICs and relative resistance of rifampicin an rifabutin in M. tuberculosis 
Genotype rpoB Rifampicin  Rifabutin  
 Mutants (n) MIC µg/ml bRR MIC µg/ml RR 
Atypical Beijing D516T (1) 5.0 10 0.125 2 
 D516S (4) 5.0-15 10-30 0.125-0.25 2-4 
 D516V (29) 10-15 20-30 0.125-0.25 2-4 
Undetermined aWild-type (26) ≤0.5 - ≤0.06 - 
Typical Beijing S531L (1) >10 >20 >1.0 >16 
Atypical Beijing Q510P (1) >10 >20 >1.0 >16 
a Twenty-five clinical isolates with unknown genotype plus one H37Rv strain were included as controls. 
b RR indicates relative resistance: Mutant MIC/Wild-type MIC. 
 
4.8  Results  
The MICs for RIF and RFB as determined in this study are summarised in Table 1.  The selected 34 
isolates possessed either an Asp516Tyr (n = 1), Asp516Ser (n = 4) or an Asp516Val (n = 29) rpoB 
mutation.  The RIF MICs for these isolates were 5 μg/ml (n =2) and 10 – 15 μg/ml (n = 32), which 
clearly distinguished them from H37Rv and the 25 wild-type strains which displayed MICs of ≤0.5 
μg/ml.  The level of RIF resistance were thus 5- to 15-fold above the CC, but much lower than those 
generally displayed by strains harbouring mutations at codons 526 and 531 (MICs, ≥50 to ≥250 
μg/ml) [7,10].  However, the corresponding MICs for RFB ranged between 0.125 and 0.25 μg/ml, 
which was 2- to 4- fold below its CC of 0.5 μg/ml [14].  The MICs for the 26 wild-type strains ranged 
from ≤0.03 to≤0.06 μg/ml for RFB.  Two mutant control strains with SNPs at codons Ser531Leu and 
Gln510Pro in the rpoB gene had MICs of >10 μg/ml and >1.0 μg/ml for RIF and RFB, respectively. 
These susceptibility levels were well within the resistance ranges of the respective drugs.  
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4.9  Discussion 
The 34 clinical isolates were phenotypically susceptible to RFB as per CC, despite of their resistance 
to RIF and the presence of SNPs at codon 516 in the rpoB gene (Table 1).  However, a shift in the RFB 
MICs, from ≤0.03–0.06 μg/ml for wild-type strains to 0.125–0.25 μg/ml for the mutant isolates was 
observed.  The corresponding MIC shift for RIF was from ≤ 0.5 μg/ml to 5.0–15.0 μg/ml.  Based on 
these findings, the relative resistance of the drugs (Table 1) shows that RFB was less affected by the 
mutations at codon 516 in the rpoB gene as compared to RIF [2,8,9].  The decreased susceptibility to 
RFB may not predict clinical resistance, but indicate that mutations at codon 516 in the RRDR are 
associated with incomplete cross-resistance between RIF and RFB.  More recently, an 
epidemiological cut-off (ECOFF) concentration of 0.064 μg/ml was proposed for RFB based on the 
Middlebrook 7H10 dilution method [15]. T he ECOFF is defined as the highest concentration within 
the MIC distribution of wild-type strains (i.e. isolates lacking resistance mechanisms) [15].  A 
breakpoint for RFB, based on clinical evidence has not yet been established.  According to the CC 
(0.5 μg/ml) endorsed by the World Health Organization [14], our results suggest that a substantial 
proportion M(X)DR TB patients in the ECP may benefit from a treatment regimen that substitute RIF 
for RFB.  This strategy is feasible only if the strains that remain susceptible to RFB are readily 
detectable.  Molecular assays are therefore useful to assist culture-based drug susceptibility testing 
(DST) in identifying isolates with specific mutations that are associated with RIF-resistance, while 
they remain susceptible to RFB.  The GenoType® MTBDplus assay (Hain LifeScience GmbH, Nehren, 
Germany) is designed to detect most of the mutations that confer RIF- and INH- resistance and has 
been suggested to be an important tool to define RFB susceptibility [16].  However, molecular assays 
with enhanced discriminating capacity are needed for identifying mutations that confer low-level or 
incomplete cross-resistance to analogue drugs.  This information is crucial, particularly for the 
rifamycins, INH, the fluoroquinolones and the injectable drugs as the definition of MDR- and XDR- TB 
is based on these compounds (17).  Furthermore, mutations outside the RRDR, in the beginning of 
the rpoB gene, have also been associated with resistance to both RIF and RFB, while others confer 
resistance only to RIF [5].  Molecular assays that exclude this region and only target the RRDR in the 
rpoB gene may give a genotypic susceptible result which does not match the resistance phenotype 
[5].  
Previous studies reported on borderline RIF-resistance, missed by standard DST [10,18].  The 
particular isolates possessed rpoB mutations that were associated with low-level RIF-resistance as 
confirmed by their MICs [10,18].  In another study, isolates from an outbreak of MDR-TB were 
identified with low-level RIF-resistance [9].  All the isolates harboured an Asp516Tyr mutation in the 
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rpoB gene and displayed MICs of 0.5–2 μg/ml for RIF and 0.2–0.5 μg/ml for RFB [9]. These studies 
suggest that low-level RIF-resistance can be overcome by the use of higher RIF doses or alternatively, 
by replacing RIF with RFB [9,10].  A retrospective study in South Korea showed an 85.7% (12/14) 
treatment success in patients with RFB-susceptible MDR-TB infections who received RFB as an 
additional drug [19].  In our study, the MIC distribution for RFB was above the ECOFF, but below the 
standard CC.  Using of the ECOFF as clinical breakpoint for RFB as recently suggested [15] may be 
misleading as strains with decreased susceptibility that remain treatable may be overlooked.  M. 
tuberculosis strains with moderate decreases in susceptibility to RFB should rather be classified as 
intermediate. Clinical isolates in this category can be distinguished from those that are clearly 
susceptible or resistant by introducing a second breakpoint and/or by the use of a molecular assay.  
Our results and existing data [9,10,14,15,18] suggest an intermediate classification that 
encompasses MICs above the ECOFF (0.6 μg/ml), but below or equal to the current CC (0.5 μg/ml). 
The peak serum concentration of RFB at a single dosage of 300 mg ranges from 0.4 μg/ml to 0.6 
μg/ml [20].  Increased RFB dosages may not be an option to increase these levels due to possible 
toxicity issues.  However, the pharmacokinetics of RFB are in part misleading as its blood levels do 
not reflect the concentrations that are attained in infected cells and tissues where the drug tends to 
accumulate [20].  Furthermore, a twofold reduction in the MICs of both RFB and EMB has previously 
been indicated owing to synergy between these two drugs when used together [20].   
Our study reinforces the notion that the heterogeneous MIC levels observed in drug resistant M. 
tuberculosis strains may have important therapeutic implications [21–24].  Of particular relevance is 
the presence of mutations that confer low-level drug-resistance as it offers possibilities for more 
effective treatment of drug resistant TB [21–24].  Knowledge of incomplete cross-resistance 
between the rifamycins and the identification of isolates with intermediate RFB susceptibility should 
assist clinicians to make objective therapeutic decisions regarding its potential use in M(X)DR-TB 
treatment-regimens. Designing a treatment regimen for M(X)DR-TB is challenging and the 
substitution of one or two drugs in a failing regimen must be done with caution to avoid the 
development of further resistance.  Relevant clinical studies are thus imperative to establish 
appropriate RFB-based regimens that warrant favourable clinical outcome. 
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Chapter 5   In-depth analysis of the epidemiologically dominant TB 
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Abstract 
The drug-resistant TB epidemic in the Eastern Cape is out of control.  We have previously shown 
programmatic selection of the Atypical Beijing genotype to be the dominant strain type among pre-
XDR-TB, and XDR-TB in the region.  Inappropriate treatment of these cases continues amplify 
resistance resulting in untreatable TB which is resistant to up to 11 anti-TB drugs.  Contrary to 
dogma these highly resistant strains have retained their ability to transmit and cause disease.  
However, the evolutionary mechanisms underlying the retention of virulence remains unknown.  In 
this study, we employed next generation sequencing to determine the evolutionary history of the 
Atypical Beijing genotype strains from the region, and to investigate molecular features that may 
predispose these strains to become increasingly drug-resistant, and to efficiently spread.  
Phylogenetic analysis confirmed the evolution and sequential acquisition of resistance markers.  
These strains initially evolved resistance to isoniazid and streptomycin in response to historic 
inadequate treatment regimens before acquiring resistance to EMB, PZA, RIF and second-line 
injectable drugs in two distinct branches of the Atypical Beijing genotype, each harbouring unique 
features.  Furthermore, we show that all representative Atypical Bejing strains – including those 
diagnosed as pan-susceptible – harbour a mutation in ethA, which has been associated with 
ethionamide (ETH) resistance.  This result may explain the apparent increased ability of the Atypical 
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Beijing strains to evolve higher drug-resistance.  RNA sequencing confirmed the distinct nature of 
the two groups of drug-resistant isolates, and revealed the massive up-regulation of the InhA operon 
in isolates with an inhA promoter mutation, suggesting a mechanism of resistance.  Furthermore, 
the toxin-antitoxin pair vapBC was affected by a DNA mutation that resulted in altered RNA 
expression. The effect of this change on the cell needs to be investigated further. 
 
5.1  Introduction 
There is growing acknowledgement of the problem of tuberculosis (TB) with drug resistance beyond 
the four drugs that define extensively drug-resistant (XDR) TB, unofficially called totally drug-
resistant TB (TDR-TB).  Evidence suggest that TDR-TB may be the result of acquisition of resistance 
(1–3) or it may be due to primary resistance (4) or a combination thereof (5).  A recent report 
documented the widespread transmission of a highly resistant Mycobacterium tuberculosis strain 
with an Atypical Beijing genotype in the Eastern Cape (EC) Province of South Africa (4).  The Beijing 
genotype has previously been associated with increased ability to spread and with multidrug-
resistance (MDR) (6,7).  However, the Atypical subgroup – distinguished from Typical Beijing 
primarily through the absence of an IS6110 in the NTF region – is not frequently observed world-
wide, with the exception of countries in the Far East (8–10).  Atypical Beijing strains are usually also 
seen at low frequency in South African settings (11).  However, in the EC, Atypical Beijing strains are 
overrepresented among pre-extensively drug-resistant (pre-XDR) and XDR (93%) isolates, as well as 
multidrug-resistant (MDR, 48%) TB isolates.  In contrast, it is seen at relatively low frequency (4%) 
among drug susceptible isolates) (4).  Furthermore, recent figures suggest an increasing incidence of 
Atypical Beijing strains in the Western Cape Province (WC), in particular among XDR-TB patients (11), 
suggesting an influence through migration from the EC, with additional local transmission (Streicher, 
personal communication).  It is therefore important to investigate the molecular mechanisms driving 
the epidemic in order to understand the reasons for this strain’s increased transmissibility.   
A range of molecular techniques are available to assess transmission, as well as other specific 
features of the genome.  These include spoligotyping (12), Mycobacterial Interspersed Repetitive 
Units – Variable Number Tandem Repeat (MIRU-VNTR) typing (13) and IS6110 DNA fingerprinting 
(14).  However, none of these methods provide a complete catalogue of genomic variation as they 
target a limited set of repeat sequences.  Furthermore, results from the different methods may yield 
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discrepant results, as evolution of these features are independent of each other (15).  Similarly, 
targeted Sanger sequencing only reveals a small portion of the genome, and is therefore only 
suitable to evaluate specific areas of the genome.  A more thorough understanding of transmission 
and evolution can be facilitated through the application of whole genome sequencing (WGS). This 
technology has the potential to identify variants that may contribute to a given phenotype.   
In this study, we aimed to interrogate the genomes of highly resistant Atypical Beijing strains 
(resistant to up to 11 drugs) from the EC through high resolution next-generation sequencing.  
Through this analysis we aimed to infer evolutionary relationships, as well as to investigate genetic 
variation among individual isolates in order to find genetic traits that may be responsible for their 
increased transmissibility. We also sought to discover a novel mechanism of PAS resistance, as six 
isolates were phenotypically resistant to PAS, but did not have mutations known to be associated 
with this phenotype. 
 
5.2  Materials and methods 
5.2.1  Strain selection 
Twenty-nine Atypical Beijing genotype isolates originating from health care facilities from across the 
EC and processed by the National Health Laboratory Services in Nelson Mandela Metropole were 
selected.  This selection was based on resistance profiles obtained through phenotypic drug 
susceptibility testing (DST) as well as targeted DNA sequencing.  The selection included 11 pan-
susceptible, 4 MDR-TB, 4 pre-XDR-TB and 10 XDR-TB isolates (including 6 TDR-TB isolates - resistant 
to 11 of the available first-and second line drugs).  Twenty-seven of these isolates were shown by 
RFLP to belong to strain family 31, a sub group of the Atypical Beijing genotype.  The remaining two 
isolates were both drug-sensitive, one belonging to a different Atypical Beijing sub-group, family 27, 
and the other could not be assigned to a known strain family. 
A group of unrelated strains (n = 93, 42 genotypes), originating from the Western Cape (including 
Atypical Beijing strains) and Kwa-Zulu Natal, as well as published genomes and M. bovis strains 
originating from the Kruger National Park, Western Cape and Kwa-Zulu Natal were included in 
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phylogenetic analysis.  These strains were selected to represent a variety of strains seen in South 
Africa, to improve the robustness of the phylogenetic analysis, and to determine the uniqueness of 
certain variants within the Atypical Beijing genotype.  
Ethical approval has been obtained from the Ethics Committee of Stellenbosch University. 
 
5.2.2  DNA sequencing 
Each of the selected strains was cultured under biosafety level 3 conditions on 7H10 media, and 
grown to confluence.  The bacteria were heat-killed prior to standardised phenol/chloroform DNA 
extraction (16).   
Purified DNA from each isolate was used to prepare paired-end genomic libraries using TruSeq DNA 
Sample Preparation Kits V2 (Illumina Inc, San Diego, CA, USA).  Each library was sequenced on an 
Illumina HiSeq2000 to a pre-calculated theoretical depth of coverage of 150x. 
 
5.2.3  DNA sequence analysis 
Next-generation sequencing data obtained from the Illumina HiSeq2000 platform was analysed 
using a pipeline that was developed by our research group (Van der Merwe, manuscript in 
preparation).  Briefly, reads are assessed with FastQC (17), followed by trimming with Trimmomatic 
(18).  The latter assesses each read individually with a sliding-window approach and trims 
accordingly.  The average quality of the bases considered needs to be above 20 and a read may not 
be shorter than 36 bases.  The processed reads are subsequently used as input in three different 
open source alignment tools, namely Burrows-Wheeler Aligner (BWA) (19), Novoalign (20), and 
SMALT (21), using M. tuberculosis H37Rv (GenBank NC000962.2) as a reference genome (19,21).  
Trimmed reads were used as input in each alignment tool with standard parameters.  The alignment 
files were assessed with Qualimap (22) to determine the number of reads that mapped to the 
reference genome and the depth of coverage.  A summary of these statistics are given in Table 2. 
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Considering indels only in isolates from the EC, a total of 5208 indels (excluding changes in PE/PPE 
genes and highly repetitive regions) were called in 29 isolates by Unified Genotyper.  Of the 5208 
indels, 3018 were called with high confidence (i.e. by all three alignment algorithms, namely, BWA, 
Novoalign and SMALT).  Indels occurring in only 1-6 isolates were regarded as unlikely to confer any 
significant change in terms of evolution of drug resistance and were disregarded, given that no clear 
pattern in terms of drug resistance could be discerned (i.e. there was a mixture of drug-resistant and 
-susceptible isolates in each group of isolates with the same indel).  Similarly, indels present in all 
isolates (n=117 indels) or in a proportion of isolates that represent both drug-sensitive and drug-
resistant strains were disregarded, based on the observation that such events were not unique to 
drug-resistant isolates and thereby could not explain a fitness advantage.   
The Genome Analysis Tool Kit (GATK) (23) was used as recommended in the user documentation to 
call single nucleotide polymorphisms (SNPs) in the alignment files from the different mapping 
algorithms used. 
Only variants (SNPs) identified by GATK in all of the alignments that overlap in both position and base 
identity were written to a high-confidence SNP file with the use of an in-house script, for each isolate 
analysed.  SNPs were filtered for PE/PPE family genes, repeat regions and SNPs with a quality value 
below 200.  These high-confidence variants were used in further analyses. 
 
5.2.4  Phylogeny 
A concatenated sequence containing high-confidence variable sites (coding and non-coding SNPs) 
for each isolate was prepared.  These sequences were written to a single multi-FASTA file and were 
used as input in Modelgenerator (24) to determine the optimal substitution model that fits the data 
structure.  The general time reversal (GTR) model with gamma (G) distribution scored the lowest in 
the hierarchical likelihood ratio test (Bayesian information criterion (BIC)), and thus described the 
substitution pattern occurring in the dataset most accurately.  The GTR+G model of substitution was 
subsequently applied to construct a maximum likelihood or minimum evolution phylogeny of the 
isolates included in this analysis with MEGA 6 (25), RaxML (26) and PhyML (27) with 1000 bootstrap 
pseudo-replicates.  In a separate phylogeny, known drug-resistance causing SNPs (Table 1) were 
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removed from the SNP string before tree construction in an attempt to improve the resolution of the 
tree by reducing homoplasy.  In further selected analyses, TT147 was omitted due to inferior 
sequencing quality (Table 2) which may contribute noise to the phylogeny.  The robustness of the 
different trees and branches were assessed by comparing the topologies of trees generated by 
different methods. 
Table 1:  Known drug-resistance causing single nucleotide polymorphisms (SNPs) that were excluded from relevant 
phylogenies 






gyrA Rv0006 FQ 90 7570 
gyrA Rv0006 FQ 91 7572 
gyrA Rv0006 FQ 94 7581 
gyrA Rv0006 FQ 94 7582 
rpoB Rv0667 RIF 516 761110 
rpoB Rv0667 RIF 531 761155 
rrs MTB000019 SM pos 513 1472359 
rrs MTB000019 AM/KAN/CAP pos 1401 1473246 
inhA promoter pre-Rv1483 INH,ETH pos -17 1673423 
inhA promoter pre-Rv1483 INH,ETH pos -15 1673425 
katG Rv1908c INH 315 2155168 
pncA Rv2043c PZA 14 2289202 
embB Rv3795 EMB 306 4247431 
*Refers to genomic position relative to H37Rv (GenBank NC000962.2) 
 
5.2.5  RNA sequencing  
The selected strains were grown in supplemented 7H9 media to OD 0.6-0.7 in biosafety level 3 
conditions, prior to RNA extraction with the FastRNA ProTM Blue Kit (MP Biomedicals).  All extractions 
were done in biological triplicate.  Total RNA extraction was followed by DNase (Promega, Madison, 
WI) treatment in technical duplicate and the purified RNA was stored at -80°C.  The selected samples 
were prepared for shipment at ambient temperature by preservation in RNAstable (Biomatrica) 
tubes. 
The quantity and quality of RNA was assessed using a Nanodrop (ND-1000, Labtech) and the Agilent 
2100 Bioanalyzer (Agilent; Palo Alto, CA, USA) per manufacturer's recommendation. 
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A subset of the purified RNA samples were selected for RNA sequencing, including 3 biological 
replicates of 2 drug-susceptible (TT372, TT700), 3 MDR-TB (TT50, TT248, TT321, TT648), 3 Pre-XDR-
TB (TT57, TT145, TT160), 4 XDR-TB (TT48, TT99, TT154, TT219) and 6 TDR-TB (TT46, TT61, TT62, 
TT98, TT135, TT147) isolates. 
Ribosomal RNA depletion was done using the RiboMinus-based rRNA depletion kit (Invitrogen).  For 
mRNA enrichment, Invitrogen's RiboMinusTM Prokaryotic kit was used according to manufacturer's 
instructions. 
Construction of double-stranded cDNA libraries was done using Illumina TruSeqTM RNA sample 
preparation kit V2 (Low-Throughput protocol) according to manufacturer's protocol.  Briefly, first 
strand cDNA was synthesized from enriched and fragmented RNA using SuperScript III Reverse 
Transcriptase (Invitrogen).  The first strand cDNA was further converted into double stranded (ds) 
cDNA.  Ampure XP beads (Beckman Coulter) were used to separate the ds cDNA from the 2nd strand 
reaction mix as per the manufacturer’s instructions, and the resultant ds cDNA was subjected to 
library preparation according to Illumina TruSeqTM RNA protocol.  cDNA fragments were end-
repaired and phosphorylated, followed by adenylation of 3′ends and adapter ligation.  Twelve cycles 
of Polymerase Chain Reaction (PCR) amplification were then done, and the library was finally 
purified with AMPure XP beads (Beckman Coulter) according to the manufacturer’s 
recommendations.  A small aliquot (1 µl) was analyzed on Invitrogen Qubit and Agilent Bioanalyzer. 
The bar-coded cDNA libraries were pooled in equal concentrations before sequencing on Illumina 
HiSeq2000 using the TruSeq SR Cluster Generation Kit v3 and TruSeq SBS Kit v3.  Data were 
processed with the Illumina Pipeline Software v1.82. 
 
5.2.6  RNA-seq analysis 
Similar to whole genome sequencing analysis, reads were assesed by FastQC, followed by quality 
trimming with Trimmomatic (18).  Subsequently, trimmed reads were imported into the Lasergene 
12 ArrayStar® software package (DNASTAR®, Inc. Madison, WI).  H37Rv (GenBank NC000962.2) was 
used as a reference genome, and normalization by reads per kilobase per million reads (RPKM) was 
chosen.  Scatterplots of the forward versus reverse reads, as well as biological replicates of each 
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sample were viewed, and R2 statistics were used in validation, where samples with R2 < 0.9 were 
discarded. Subsequently, the retained reads from each original isolate were grouped together in 
replicate sets.  The two drug-susceptible isolates were used individually and together as controls in 
separate analyses.  Drug-resistant strains were grouped together as experiments, based on 
phylogenetic relationships and the hypothesis that certain groups of strains posess a fitness 
advantage.  Student’s t-test was done for each experiment to determine statistical significance of 
up- or down-regulation, as well as the effect-size of the difference.  Gene sets for analyses were 
created of all genes in an experiment that were at least two-fold up- or down-regulated, compared 
to the control, and at 99% confidence. 
 
5.3  Results and discussion 
5.3.1  Whole genome sequencing coverage and quality 
To assess the coverage of WGS data, we utilised Qualimap (22) to analyse Novoalign-generated 
binary alignment map (BAM)-files.  Coverage in excess of 100X was obtained for the majority of the 
isolates (Table 2).  Only isolate TT564 had a mean coverage below 100.  In this study, >90% of reads 
were mapped for all isolates, except TT50, TT147 and TT719, for which <79% of reads were mapped 
to the reference genome.  Caution should be applied when interpreting the analysis of strains TT50, 
TT147, TT719 and TT564 as spurious results may occur due to the low sequencing quality.  WGS data 
of the different strains were compared to identify SNPs and small insertions and deletions (indels, up 
to 50bp) that distinguish different groups of Atypical Beijing genotype isolates.  Comparing all F31 
isolates (isolates identified by IS6110 RFLP to belong to Family 31, n= 29, including 27 EC and 2 WC 
strains) to the non-Atypical Beijing genotype strains in Figure 3, yielded 222 SNPs that were unique 
to F31, and present in all investigated F31 strains.  The distribution of these SNPs in terms of 
functional category is shown in Figure 1.  Genes involved in intermediary metabolism, respiration, 
the cell wall and cell processes were most polymorphic, followed by conserved hypothetical genes 
and intergenic regions. 
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Table 2: Quality and coverage values as reported by Qualimap 
Isolate No. of reads 
% mapped 
reads 
Mean depth of Coverage 
(Std dev) 
TT46 21,165,367 98.21 400.87 (95.05) 
TT48 18,282,314 98.25 346.69 (82.77) 
TT50 11,378,772 78.92 191.04 (41.93) 
TT57 20,173,554 98.23 381.93 (88.64) 
TT61 20,868,422 98.23 395.77 (90.11) 
TT62 20,623,626 98.20 392.57 (91.67) 
TT98 19,076,063 98.18 362.07 (86.33) 
TT99 17,921,992 98.20 341.67 (84.01) 
TT135 21,115,670 98.20 394.39 (89.89) 
TT145 18,411,02 98.27 348.95 (82.11) 
TT147 9,407,868 65.08 127.47 (31.56) 
TT154 18,529,430 98.26 352.57 (81.29) 
TT160 15,656,017 98.25 293.61 (70.45) 
TT219 18,767,531 98.24 356.27 (82.48) 
TT248 16,477,473 98.26 311.15 (73.59) 
TT321 10,993,557 96.74 224.66 (44.46) 
TT372 7,474,841 97.42 153.72 (32.87) 
TT508 6,427,782 97.59 131.88 (28.91) 
TT545 10,083,571 97.71 208.15 (43.25) 
TT564 4,349,139 95.63 89.10 (25.37) 
TT574 10,210,547 97.76 212.43 (50.08) 
TT589 9,020,067 98.16 187.63 (38.69) 
TT606 9,966,248 98.25 206.94 (45.43) 
TT607 12,216,968 97.45 247.33 (84.83) 
TT622 20,866,766 98.26 396.31 (91.28) 
TT648 5,637,053 94.50 112.32 (28.72) 
TT679 11,056,373 97.68 228.13 (48.96) 
TT700 8,885,047 97.78 182.53 (44.14) 
TT719 9,596,258 74.97 152.23 (37.12) 
Average 13,793,868 95.00 267.00 (63.00) 
min 4,349,139 65.08 89.10 
max 21,165,367 98.26 400.87 
 
Further quality assurance was built into the analysis pipeline by the use of 3 different alignment 
algorithms (BWA (19), Novoalign (20) and SMALT (21)).  Only variants that were called by all 3 
algorithms (high confidence variants) were used in further analyses. 
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Figure 1:  Distribution of SNPs that are unique to Atypical Beijing F31 strains and present in all these isolates 
Each of the EC isolates was investigated for the number of SNPs relative to H37Rv, as well as the 
number of drug-resistance conferring SNPs (Table 1) present in each isolate.  Drug-resistance 
associated SNPs were removed for phylogenetic analyses, as these SNPs could be acquired in parallel 
and could distort the phylogenetic interpretation.  These results are presented in Table 3. 
Considering indels only in isolates from the EC, a total of 5208 indels (excluding changes in PE/PPE 
genes and highly repetitive regions) were called in 29 isolates by Unified Genotyper.  Of the 5208 
indels, 3018 were called with high confidence (i.e. by all three alignment algorithms, namely, BWA, 
Novoalign and SMALT).  Indels occurring in only 1-6 isolates were regarded as unlikely to confer any 
significant change in terms of evolution of drug resistance and were disregarded, given that no clear 
pattern in terms of drug resistance could be discerned (i.e. there was a mixture of drug-resistant and 
-susceptible isolates in each group of isolates with the same indel).  Similarly, indels present in all 
isolates (n=117 indels) or in a proportion of isolates that represent both drug-sensitive and drug-
resistant strains were disregarded, based on the observation that such events were not unique to 
drug-resistant isolates and thereby could not explain a fitness advantage.   
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5.3.2  Phylogeny 
WGS of a selection of Mycobacterium tuberculosis complex (MTBC) isolates (n = 93) reflecting 
different strain families were included in a comprehensive phylogenetic reconstruction (Figure 2) to 
indicate the relative phylogenetic position of the Atypical Beijing genotype strains among other 
mycobacterial strains.  As expected, this phylogeny demonstrates that Beijing genotype strains 
(IS6110 families 27, 29 and 31, denoted F27, F29, and F31) are closely related, compared to strains 
from other genotypes.  All of the included strains from the Eastern Cape belonged to the F31 group 
(marked in red, Figure 2), with the exception of two drug-susceptible strains - TT508 (F29) and TT564 
(unassigned to a specific genotype).  The latter two (blue boxes) were shown by RFLP as well as 
several methods of phylogenetic analysis to be outliers to the EC Atypical Beijing genotype.  
The phylogeny depicted in Figure 2 was generated using RaxML v 8.0 (26).  The evolutionary history 
was inferred by using the Maximum Likelihood method based on the General Time Reversible model 
with a Gamma distribution (28).  1000 pseudo-replications were done.  All of the EC Atypical Beijing 
genotype strains with resistance profiles ranging from pre-XDR to “TDR” cluster closely together.  It 
should be noted that within the Atypical Beijing genotype sub-lineage the bootstrap values were low 
despite the use of different models and predictive algorithms (also see Figure 3 and Figure 4).  This 
may be due to the high level of similarity as well as recent parallel evolution events.  The notion of 
high similarity was supported by the observation that the number of SNPs that differentiated 
isolates from their nearest putative common ancestor was consistently below 23 (average 8.5).  In 
addition, a detailed analysis of one branch (Group B, Figure 3), revealed 48 SNPs that were subjected 
to either reversion or homoplasy within these isolates.  Interestingly, a subsequent investigation 
revealed that 40 of these events were also present in the non-Atypical Beijing genotype strains used 
in the phylogeny illustrated in Figure 2 (positions not indicated), indicating that these positions are 
prone to change.  This needs further investigation and may contribute to our knowledge of positions 
that are not informative to the evolution of M. tuberculosis strains.  Interestingly, this sub-lineage 
lacked the SNP 1548149 reported by Hanekom et al. (29) to be an evolutionary event that was 
specific to the Beijing genotype and common to both the Typical and Atypical sub-lineages.  This 
implies that these strains branched off from the clade earlier than any of the strains investigated by 
those autors.  The presence of SNP 909166, which was hypothesised to be more modern than SNP 
1548149 suggests that the SNP 909166 is subject to homoplasy. 
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Table 3: Number of SNPs, non-drug-resistance SNPs and drug-resistance SNPs removed for phylogenies, relative to 
H37Rv 
Group Isolate All SNPs Non-DR SNPs DR SNPs removed 
Group A 
TT46 1245 1238 7 
TT135 1264 1256 8 
TT622 1249 1242 7 
Group B 
TT48 1232 1225 7 
TT57 1240 1234 6 
TT61 1237 1230 7 
TT62 1247 1240 7 
TT98 1246 1239 7 
TT99 1235 1228 7 
TT145 1236 1229 7 
TT147 1211 1204 7 
TT154 1243 1236 7 
TT160 1235 1229 6 
TT219 1238 1230 8 
TT248 1227 1221 6 
Group C 
TT50 1239 1237 2 
TT321 1271 1268 3 
TT648 1189 1187 2 
TT372 1228 1228 0 
TT545 1249 1249 0 
TT574 1248 1248 0 
TT589 1243 1243 0 
TT606 1254 1254 0 
TT607 1210 1210 0 
TT679 1254 1254 0 
TT700 1240 1240 0 
TT719 1227 1227 0 
Other 
TT508 1309 1309 0 
TT564 1228 1228 0 
SNP = single nucleotide polymorphism;  DR= drug-resistance;  Groups A, B, C derived from 
Figure 3. 
 
Figure 3 shows the evolutionary history inferred using the Minimum Evolution (ME) method (30) as 
analysed in MEGA6 (25). The tree is drawn to scale, with branch lengths in the same units as those of 
the evolutionary distances used to infer the phylogenetic tree.  The evolutionary distances were 
computed using the Maximum Composite Likelihood method (31) and are in the units of the number 
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of base substitutions per site.  The ME tree was searched using the Close-Neighbor-Interchange (CNI) 
algorithm (28).  The Neighbor-joining algorithm (32) was used to generate the initial tree.  The 
analysis included 35 nucleotide sequences.  All positions containing gaps and missing data were 
eliminated.  There were a total of 3794 positions in the final dataset. This phylograph is the closest 
to what was expected, separating the strains according to known drug-resistance groups.  Both 
Group A and Group B include strains that are resistant to more drugs than the strict definition of 
MDR-TB.  Furthermore, each group has a distinct set of mutations relative to each other, including 
drug-resistance causing mutations (detailed in Table 8), suggesting clonal expansion of two variants 
of the Atypical Beijing genotype.  Group A consists exclusively of strains that harbour the pncA 14 
mutation and other associated mutations, while Group B harbours a distinct set of mutations in 
these same genes (Figure 4 and Table 8). 
The phylograph depicted in Figure 4 was inferred by using the Maximum Likelihood method based 
on the General Time Reversible model (28) as analysed using MEGA6 (25).  Bootstrap values are 
shown next to the branches (black figures).  Initial tree(s) for the heuristic search were obtained by 
applying the Neighbor-Joining method to a matrix of pairwise distances estimated using the 
Maximum Composite Likelihood (MCL) approach.  A discrete Gamma distribution was used to model 
evolutionary rate differences among sites.  The tree is drawn to scale, with branch lengths measured 
in the number of substitutions per site.  The analysis involved 28 nucleotide sequences, excluding 
the Typical Beijing genotype strains, and TT147 which had questionable sequencing quality (Table 2).  
All positions containing gaps and missing data were eliminated.  There were a total of 2145 positions 
in the final dataset.  The evolutionary position of the removed drug-resistance causing mutations are 
indicated on the tree in circled red figures.  A legend of these changes is provided in Figure 4.  GyrA 
mutations are not indicated, as there is a variety of mutations present among these strains, all 
occurring at the termini of the branches, suggesting independent acquisition.  The assigned positions 
of TT607 (drug-susceptible) and TT160 (exactly the same pattern of mutations seen in Group B) are 
thought to be unlikely, although these positions are supported by high bootstrap values.  This 
phylogenetic prediction suggest that katG mutation was deeply rooted implying that this event was 
the initial event causing drug resistance to isoniazid.  This corresponds to the chronology in which 
patients were treated.  During the period from the mid 1950’s to the late 1960’s patients were 
treated with acombination of SM, INH, PAS (33).  The rpoB 531 and inhA promoter -15 mutations, 
which are seen both in strains with higher resistance (Group A), as well as unrelated MDR-TB strains 
(in Group C), suggesting that these mutation were acquired on different occasions.   
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Figure 2: Maximum likelihood phylogeny of representative strains from a range of different strain families.  Atypical 
Beijing strains of family 31 are indicated in red; Atypical Beijing strains of other sub-classifications are indicated in blue; 
H37Rv is indicated in green.  
Comparison of F31 strains of Groups A and B (higher drug-resistance) with drug-susceptible and 
MDR sensu stricto (Group C) as per Figure 3, yields 127 SNPs that were unique to the higher 
resistance group (i.e. not present in MDRss or susceptible).  Two of these SNPs were common to all 




Figure 3: Evolutionary history of Beijing genotype strains, inferred by the Minimum evolution method.  Group A, including isolates with pncA 14GCG mutation is indicated in green; Group 
B, consisting of isolates with pncA ins172G is indicated in purple; Group C, consisting of durg-sensitive and MDRss isolates is indicated in blue  
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Figure 4: Evolutionary history of Beijing genotype strains inferred by the Maximum Likelihood method, without drug-resistance causing SNPs 
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to all isolates in the higher drug-resistance groups but not present in Group C, namely rrs513, 
conferring resistance to streptomycin (SM), and rrs1401, conferring resistance to amikacin, 
kanamycin, and capreomycin.  These SNPs may have occurred early in the evolution of these strains, 
which is plausible for rrs513, given that SM was administered as monotherapy in the early years of 
TB chemotherapy and it is unlikely that many of these patients would have been exposed to SM.  
However, it is not possible to determine whether rrs1401 occurred early in the evolution of these 
strains, or whether it evolved in parallel, this being only one of two mutations conferring resistance 
to amikacin, kanamycin, and capreomycin.  Furthermore, when these drugs are prescribed for TB it is 
only as second-line therapy, implying that exposure to the drug should have been after diagnosis of 
initial resistance, although aminoglycosides are also prescribed for non-tuberculous infections.   
Additional resistance was acquired after transmission of the progenitor strains.  This is evident from 
the presence of a variety of gyrA mutations (conferring fluoroquinolone resistance) in different 
isolates (Table 4).  Furthermore, phenotypic PAS resistance was shown in some strains that are not 
directly related (not situated on the same sub-branch of the tree).  No mutation that was called with 
high confidence was specific to all PAS resistant isolates.  This may be explained by a few possible 
scenarios:  PAS resistance may not be attributable to a single mutation, but rather any of a range of 
mutations involved in the metabolism or efflux of the drug, or epigenetic factors may play a role.  
Alternatively, some isolates may have been false-positives or false-negatives for PAS resistance, or 
PAS resistance has not fully emerged (i.e. only a portion of reads may have had the mutation) 
causing it to be missed by our stringent NGS data analysis algorithm.  Our current knowledge of PAS 
resistance is limited to high confidence SNPs situated in tlyA (34), which was not observed in any of 
these isolates.  
The number of SNPs that differentiate strains within a group from each other was investigated in 
order to determine transmission events.  Previously published whole genome sequencing studies 
investigating transmission events suggest that a transmission event could be defined when the 
genome sequences of M. tuberculosis isolates differ by a maximum of 15 SNPs (35–37).  The number 
of SNPs found in each isolate in this study, relative to other isolates within its group are shown in 
Table 5-7.  Each cell represents the number of SNPs that are unique to the isolate in the header row, 
compared to the isolate in the leading column.  Therefore, e.g. from Table 5, TT46 harbours 13 SNPs 
that are not present in TT135, whereas TT135 harbours 32 SNPs that are not present in TT46.  Like-
coloured cells represent isolates from the same health district in the header rows or leading 
columns, whereas the cells highlighted in yellow shows the variation among isolates taken from 
patients within the same in-patient facility within a month of each other (Table 6) or isolates taken 
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from the same patient on the same day (Table 7).  The tables are organised according to groups 
based on drug-resistance mutations, and therefore such mutations are not necessarily reflected in 
the numbers.  These results imply that the isolates selected for next generation sequencing are not 
all reflective of recent  







TT46 TDR Group A 91CCG 
TT48 XDR Group B 94AAC 
TT62 TDR Group B 94AAC 
TT99 XDR Group B 90GTG 
TT98 TDR Group B 90GTG 
TT135 TDR Group A 90GTG 
TT154 XDR Group B 94GGC 
TT61, TT147 TDR Group B 94GGC 
TT219 TDR Group B 91GCG/94AAC 
 









JP 0 32 19 
TT135 
SH 13 0 10 
TT622 
FH 15 25 0 
Health districts are colour coded 
Abbreviations represent health care facilities 
 
transmission events.  Although direct transmission cannot be ruled out based on geographic 
location, it certainly decreases the likelihood of transmission, especially in this setting where rural 
areas are very remote and residents tend not to travel far from their hometowns (personal 
communication, Dr Kate Mekler, Beyond Zero).  Therefore our results question the definition of 
transmission as isolates from patients from different regions of the EC in some instances showed less 
than 15 SNP variations.  This was further exemplified when the genomes from isolates TT606 and 
TT607 were compared (Table 7).  These isolates were taken from the same patient, on the same day.  
From our analysis it is clear that these isolates are evolving independently within a single host with 
TT607 gaining only 3 SNPs with respect to TT606, while TT606 gained 47 SNPs with respect to TT607.  
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Even considering the possibility of mixed infection, it is implied that with respect to the common 
progenitor, one strain gained many SNPs while the other gained only a few.  Further examples of 
such unequal evolution are evident from Tables 5-7.  These results are in accordance with studies 
which showed stability within the M. tuberculosis genome, as well as evolutionary bursts, concluding 
that genetic distance alone cannot be used to infer transmission (15,38).  In addition, in an endemic 
setting such as the EC, inference of transmission may be even further confounded by extended 
networking among cases as well as patients not included in the study.  
 







































KzC 0 11 10 8 16 14 25 25 17 14 15 22 
TT160 
PMT 3 0 10 8 14 13 24 23 15 12 13 20 
TT147 
KxC 26 34 0 31 37 35 47 43 35 30 32 39 
TT48 
JP 3 11 10 0 11 11 22 21 13 11 12 19 
TT219 
PE 5 11 10 5 0 10 22 18 10 12 12 19 
TT99 
FG 6 13 11 8 13 0 20 18 14 10 9 16 
TT98 
GC 6 13 12 8 14 9 0 20 13 9 10 17 
TT62 
JP 5 11 7 6 9 6 19 0 4 5 4 12 
TT57 
JP 4 10 6 5 8 9 19 11 0 5 5 13 
TT145 
NC 5 11 5 7 14 9 19 16 9 0 4 11 
TT61 
WT 5 11 6 7 13 7 19 14 8 3 0 8 
TT154 
CC 6 12 7 8 14 8 20 16 10 4 2 0 
Health districts are colour coded 
Abbreviations represent health care facilities 
Cells representing data from patients from the same facility, and collected within one month are highlighted  
 
5.3.3  Variants: SNPs  
All F31 Atypical Beijing strains, including those that were thought to be pan-susceptible based on 
drug-susceptibility testing for first-line drugs, were found to harbour mutations in ethA, as well as in 
Rv1772.  The mutation in Rv1772 was a synonymous mutation in codon 61, and as such, has not 
been implicated in resistance.  However, previous studies have reported an association between 
Stellenbosch University  https://scholar.sun.ac.za
 131 
Rv1772 mutations and INH resistance (39).  The ethA mutation (A381P) has previously been 
associated with resistance to ethionamide (ETH) (40), a second-line TB drug that was historically 
used in dual therapy.  This ETH resistance could also explain the vastly different distribution of 
Atypical Beijing genotype isolates seen in different classes of drug-resistance:  4% among “pan-
susceptible” TB; 27% among MDR s.s.-TB and 93% among pre-XDR- and XDR-TB (4).  ETH resistance 
would remain undetected among otherwise drug-susceptible isolates, without conferring a selective 
advantage.  However, once INH and RIF resistance has been acquired (or with current guidelines, 
once RIF resistance is acquired (41)) and the patient was treated with an ETH-containing second-line 
regimen, these strains would acquire additional resistance more readily due to the regimen 
inadvertently being compromised.  Preliminary DST results suggest that ethA mutations confer a 
relatively lower level of ETH-resistance (unpublished data), therefore the bacilli “require” an 
additional mutation in the inhA promoter for full resistance, which contributes to development of an 
XDR-TB phenotype (42). 




























TC 0 50 69 58 59 101 85 69 78 79 74 84 
TT607 
PMT 29 0 50 41 38 80 47 55 57 59 54 61 
TT50 
SAP 19 21 0 25 30 44 45 39 38 40 36 43 
TT372 
KzC 19 23 36 0 22 56 39 22 27 29 21 31 
TT719 
LBD 21 21 42 23 0 62 37 35 42 40 35 45 
TT321 
SAP 19 19 12 13 18 0 19 17 19 15 12 16 
TT606 
PMT 20 3 30 13 10 36 0 17 20 19 12 20 
TT700 
GMC 18 25 38 10 22 48 31 0 24 23 15 24 
TT574 
LP 19 19 29 7 21 42 26 16 0 13 6 13 
TT545 
GP 19 20 30 8 18 37 24 14 12 0 8 12 
TT589 
FH 20 21 32 6 19 40 23 12 11 14 0 13 
TT679 
KzC 19 17 28 5 18 33 20 10 7 7 2 0 
Health districts are colour coded 
Abbreviations represent health care facilities 
TT606 and TT607 were isolated from the same patient on the same day (highlighted) 
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When isolates from Group B was compared to Group A and Group C, seven SNPs were common to 
all strains of Group B and not present in any other strain.  These SNPs are located in mmaA4, rpoB, 
murA, Rv2019, viuB, embB, and inhA promoter, as detailed inTable 8.   
MmaA4 
MmaA4 encodes methoxy mycolic acid synthase 4, which is involved in the production of 
hydroxymycolic acid, a component of the bacterial cell envelope.  Mycolic acids have been shown to 
play a role in virulence through their influence on the permeability of the cell envelope – decreased 
permeability is hypothesised to restrict the entry of nutrients and antibiotics, thereby increasing 
intrinsic resistance.  Furthermore, mycolic acids were shown to be essential for viability, drug 
resistance and cell wall integrity (43) and they play a role in immune modulation of IL-12 (44), 
affirming a different mechanism of virulence mediated by the same gene product.  In vitro 
generated thiacetazone (a repurposed drug used in the treatment of XDR-TB) resistant mutants 
harboured a SNP in the mmaA4 gene (45).  However, none of the mutants had the specific mutation 
seen in this study.  Taken together, this evidence provides support for further investigation of the 
functionality mmaA4 and its products in these isolates.  Even though the mutation seen in this 
instance is a synonymous SNP, it may be important, as recent findings have shown that synonymous 
SNPs may play a role in drug resistance, for instance, a silent mutation in mabA acts as an enhancer 
of inhA transcription, leading to isoniazid resistance (46). 
MurA 
The product of the gene murA, UDP-N-acetylglucosamine enolpyruvyle transferase (MurA) is 
involved in the first reaction in the biosynthesis of peptidoglycan.  The coding region of the gene also 
contains the transcription starting point of the rrnA operon (47), and the two transcripts have been 
shown to form a hybrid (protein coding-rRNA coding) operon, although the patterns of expression 
during the growth cycle were different for murA and rrnA (47). 
ViuB 
ViuB encodes a probable mycobactin utilization protein, involved in iron acquisition, which is 
essential for mycobacterial survival and growth.  This protein has been shown to be over expressed 
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in macrophages (48), although a recent study showed that the protein was dispensable to M. 
tuberculosis for growth (49).  
Rv2019 
A SNP was also present in Rv2019, encoding a conserved hypothetical protein. The role of this gene 
is discussed under large deletions (section 5.3.5). 
Isolates from Group A harboured 5 unique SNPs, namely in Rv0785 (encoding a conserved 
hypothetical protein); pncA (14GCG), associated with pyrazinamide resistance; embB (306ATC), 
associated with EMB resistance; mez and in an intergenic area located between Rv3144c (PPE52) 
and nuoA (Table 8) that was not present in any other group.   
Mez 
The protein encoded by mez is an NAD dependent malate oxidoreductase, which is involved in the 
formation of pyruvate, and as such forms part of the intermediary metabolism of M. tuberculosis 
(50). 
NuoA and PPE52 
The intergenic SNP at genomic position 3511368 lies 51 bp upstream from PPE52 (reverse 
orientation), and 314 bp upstream from nuoA (forward orientation), and could therefore form part 
of either gene’s promoter region.  The function of PPE52 is currently unknown, and it is 
hypothesised to be non-essential (50).  NuoA is a probable NADH dehydrogenase I, involved in 
respiration (50).   
The variants in the inhA promoter (42,51,52), embB (53,54), katG (55), rpoB (56,57), rrs (58,59), and 
pncA (60,61) are well-described, and known to be involved in drug-resistance as indicated in Table 8. 
These changes indicate a fundamental difference between Group A and B, and suggest their 
independent evolution.  The two groups can also be distinguished by their rpoB mutations: all 
isolates in Group A have a mutation in codon 531, whereas all isolates in Group B have a mutation in 
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codon 516.  However, both these mutations are also present in the MDR isolates from group C.  
Furthermore, an rpoC mutation in codon 483 is present in all Group A isolates, as well as in one of 
the MDR isolates (TT648, group C).  This isolate also harbours the rpoB 531 mutation as well as the 
inhA promoter -15 mutation that is present in Group A.  TT50 (rpoB 531) harbours a different rpoC 
mutation (codon 521), suggesting that rpoB 531 mutations predisposes the bacilli to acquire rpoC 
mutations (62).  Neither TT321 (rpoB 516) nor any of the Group B isolates harbours rpoC mutations. 
 
5.3.4  Variants: Indels 
Two insertions (Table 8) were present in all isolates of Group B, and in no other isolate, warranting 
further investigation.  The first was a known insertion in the pncA gene (ins172G), associated with 
pyrazinamide resistance.  This insertion causes a frame-shift leading to the elongation of the 
transcript to include Rv4042c, a hypothetical conserved protein which is situated immediately 
downstream from pncA.   
The second indel was a T-insertion in codon 12 of the vapC22 gene, leading to a frame shift.  This 
gene encodes a possible toxin involved in virulence, detoxification or adaptation (63).  VapC22 is part 
of a toxin-antitoxin system – one of many of its kind found in M. tuberculosis.  The toxin is 
hypothesised to be induced under stress conditions, acting as a ribonuclease and leading to arrested 
cell growth, which has been implicated in dormancy and persistence (63).  Co-expression of its 
cognate antitoxin (vapB22) ensures binding of the two proteins in a complex that inhibits the action 
of the toxin, while also inhibiting translation of the operon by binding to its promoter region.  
Although the exact function of this specific toxin is still unclear, evidence suggest that vapC22 
inhibits cell growth in the absence of its cognate antitoxin (64).  
Present in all Group A and B isolates, as well as two MDR s.s. isolates, was a 1bp deletion (del671G) 
in Pks9, thought to be involved in the synthesis of a polyketide molecule, which may be involved in 
secondary metabolism. 
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Table 8: Variants as called by GATK for three alignment algorithms (BWA, Novoalign and SMALT) 
Gene Function Isolates affected 
Nucleotide 
change 





promoter of inhA (NADH-
dependent enoyl 




rpoB RNA polymerase Group B GAC516CTC 
D516V  
Rifampicin resistance 
embB Arabinan synthesis Group B ATG306ATA 
M306I 
Ethambutol resistance 
murA peptidoglycan synthesis Group B GGC385GAC G385D 
Rv2019 unknown Group B ATC109ACC I109T 
inhA 
promoter 








rpoB RNA polymerase Group A; 2 MDR TCG531TTG 
S531L  
Rifampicin resistance 








Converts amides to 






dehydrogenase Group A CAT350TAT H350Y 
mez 
probable malate 
oxidoreductase Group A GCA15ACA A15T 
genomic 
position 
3511368 intergenic Group A G-->T 
unknown;51bp 
upstream of Rv3144c 
(PPE52) or 314bp 
upstream of nuoA 
rrs 16S RNA 
Group A, Group 
B A513C Streptomycin resistance 
rrs 16S RNA 














viuB iron acquisition Group B CCG176CCA P176P 
Insertions 
pncA 
Converts amides to 
corresponding acid Group B ins172C 
Frame shift; extension 
by 265 amino acids; PZA 
resistance 
vapC22 toxicity Group B ins12T Frame shift 
Deletions 
pks9 polyketide synthesis All DR strains del671G 
truncation of protein at 
codon 673 
Group A and Group B derived from Figure 3; All DR strains = all drug-resistant strains, including MDR 
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5.3.5 Variants: large deletions 
GATK was used to identify areas of zero coverage, implying that these areas are deleted from the 
genome.  Files of the different strains were inspected visually.  These deletions were used as a 
starting point to verify the absence of coverage by viewing the alignments in Artemis (Sanger 
Istitute).  Isolates from this study were also compared to three additional Atypical Beijing (F31) 
strains, 4 Typical Beijing (F29) strains and one non-Beijing strain.  As the purpose of the study was to 
identify genetic elements that may confer an advantage to the strains of interest, deletions that 
were present in all of the above strains were disregarded.   
A number of areas were deleted from all F31 isolates but not any of the other strains.  These include 
1207bp from the region GlnA - Rv1879 (previously described as RD163 (65)); 80bp from Rv1841c and 
7bp from esxP.  A 2390bp deletion starting in Rv2016 and ending in Rv2019 includes the previously 
described RD175a (65), and is also found in all F31 isolates, but none of the other isolates. Rv2016, 
Rv2018 and Rv2019 are conserved hypothetical proteins that are deemed to be non-essential in M. 
tuberculosis H37Rv.  Rv2019 is postulated to be involved in information pathways (50), while Rv2017 
is thought to be a transcriptional regulator, and essential for in vitro growth (50).  This observation 
questions the definition of essentiality defined by Himar1 transposon mutagenesis (66).  These four 
deletions may prove useful markers for the classification of these Atypical Beijing strains. The 
physiological impact of these deletions remains to be determined. 
Deletions constituting other previously described Beijing-specific RDs include RD105 (Rv0071-
Rv0074), RD131e (Rv0795-Rv0796), RD149 (Rv1573-Rv1588c), RD152 (Rv1754c-Rv1765c).  Deleted in 
all strains (including non-Beijing) was Rv2278-Rv2279, which falls within RD182 and Rv2648-Rv2649, 
within RD198a (65). 
 
5.3.6  RNAseq analysis 
In order to identify differential gene expression (≥2-fold change in RNA abundance with a 99% 
confidence interval) of the Group A or Group B isolates we compared RNA abundance relative to the 
pan-susceptible Atypical Beijing genotype strains.  
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Table 9: Table of the top 10 up-regulated genes for Group A and Group B, relative to drug-susceptible TT372 















proT - 55.9 up 0.048 
12.4-
162.4 up 








22.9 up 0.010 
7.2-63.5 
up 























21.9 up 0.039 
14.9-30.5 
up 















































































When comparing Group A or Group B to TT372 (drug-susceptible), 423 and 721 genes were 
differentially expressed, respectively.  For each of these two groups, the top-ten up-regulated genes 
are presented in Table 9.  Very similar results were obtained when the groups were compared to 
TT700 (drug-susceptible).  This suggests that both groups of drug resistant isolates differs 
fundamentally from the respective drug-susceptible isolates, and each drug-resistance group differs 
from each other.  Interestingly, in Groups A or B compared to drug-susceptible, only 2 genes were 
down-regulated (Rv3395c and moaC1), as opposed to the many genes that were up-regulated (423 
and 719, respectively).   
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Table 10: Top 10 genes significantly up-regulated in both Group A and Group B 
 
In order to investigate similarities between the drug-resistance groups (Group A and B) relative to 
drug-susceptible (TT372), the 34 most differentially expressed genes (at statistical significance) in 
each of the groups was compared.  The overlap consisting of 10 genes is presented in Table 10.   
Genes affected by the variants listed in Table 8 were investigated to identify an association with RNA 
abundance (presented in Table 11).   Interestingly, the genes with known drug-resistance causing 
mutations were all up-regulated in Groups A or B, but no more than 1.8 fold, with the notable 
exception of embB (2.1 and 2.4 fold up) and inhA (7.4 and 22.1 fold up) (all statistically significant 
(p<0.05), except rrs).  In fact, inhA was one of the most severely affected genes in both Group A and 
B, but more pronounced in Group A.  Further investigation revealed that the genes surrounding inhA 
were also up-regulated.  The effect was most pronounced in fabG1 and hemZ – the genes 
immediately up- and down-stream from inhA (Figure 5), and part of the same operon.  The up-
regulation of genes within the same operon in isolates with inhA promoter mutations is not 
surprising, as promoter mutations have the potential to alter expression levels of the genes they 
regulate.  It is, however, unexpected that genes adjacent to the operon is also up-regulated, possibly 
suggesting their co-regulation, although these genes were not up-regulated to the same extent as 
the fabG1-hemZ operon. It is unclear why these three genes are regulated as an operon, as fabG1  
 





















9.4 up 0.044 9.7-11.6 up 9.8 up 0.015 6.0-12.6 up 

















9.0 up 0.039 6.7-11.6 up 5.9 up 0.037 3.6-10.7 up 
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Table 11: RNA abundance in the relevant groups for genes affected by small mutations (SNPs or indels) 










inhA C-15A 22.1 up 0.002 12.8-30.1 up G-17A 7.4 up <0.001 
5.3-10.0 
up 
rpoB TCG531TTG 1.8 up 0.010 1.6-2.2 up GAC516CTC 1.4 up 0.003 
1.0 down-
2.1 up 
embB ATG306ATC 2.1 up 0.045 1.4-3.1 up ATG306ATA 2.4 up <0.001 1.8-3.4 up 
murA N/A 2.2 up 0.006 2.0-2.8 up GGC385GAC 1.7 up <0.001 1.4-2.0 up 
Rv2019 N/A 2.3 up 0.028 1.7-3.0 up ATC109ACC 1.9 up 0.011 
1.1 down-
2.9 up 
rpoC GTG483GGG 2.1 up 0.007 1.8-2.6 up N/A 1.6 up <0.001 1.1-2.1 up 
pncA AGC14CGC 1.1 up 0.624 
1.1 down – 
1.2 up 
is172C 1.4 up 0.002 1.0-1.9 up 
Rv0785 CAT350TAT 1.5 up 0.190 1.2-2.0 up N/A 1.8 up 0.008 
1.0 down-
2.3 up 














1.4 up 0.105 1.0-1.8 up 
A513C; 
A1401G 
1.3 up <0.001 
1.1 down-
1.8 up 
katG AGC315ACC 1.6 up 0.009 1.5-1.8 up AGC315ACC 1.3 up 0.027 
1.2 down-
1.4 up 
mmaA4 N/A 2.0 up 0.022 1.4-2.5 up CTG63CTA 1.9 up <0.001 1.4-2.8 up 
viuB N/A 1.4 up 0.161 1.2-1.8 up CCG176CCA 1.6 up 0.011 1.0-2.3 up 
vapC22 N/A 1.3 up 0.238 1.1-1.7 up ins12T 17.8 up <0.001 
7.6-27.5 
up 
pks9 del671G 1.7 up 0.028 1.3-2.1 up del671G 1.6 up <0.001 1.2-2.6 up 
 
and inhA are components of the fatty acid synthase (FAS) II enzyme system, involved in mycolic acid 
synthesis (67), whereas hemZ is a ferrochelatase (68).  It is also interesting to note that both the -15 
and -17 mutations in the promoter-region leads to up-regulation of the operon, but that the -15 
mutation has a much greater effect.  This needs further investigation, as the apparent effect may be 
the result of pooling of data. 
Of the genes that were shown by WGS to harbour SNPs or indels but are not known to cause drug-
resistance, only vapC22 was significantly up-regulated, in the relevant group (Group B).  Similar to 
inhA, this was one of the most highly up-regulated genes in the group, and again, other genes in 
close proximity were also highly up-regulated, reaching statistical significance in each case (Figure 6). 
Again, several genes up-and down-stream from this operon (vapBC) were similarly up-regulated, 
possibly suggesting some common involvement.  
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Under normal conditions, formation of the vapBC complex inhibits the action of the toxin, and binds 
to the promoter of the operon, inhibiting translation of both proteins.  In the case of the Group B 
isolates, we hypothesise that the disruption of the vapC22 protein through the nucleotide insertion 
prevents complex formation with vapB22.  This in turn prevents the inhibition of translation through 
binding with the promoter, explaining the massive up-regulation of vapB22 and vapC22.   
Furthermore, we hypothesise that the alteration of the protein abrogates its putative toxic effect, 
allowing the cells to be fully functional despite the inability of vapB22 to inhibit the toxin.  However, 
this needs validation through protein studies. 
 
Figure 5: inhA operon showing relative upregulation in relation to TT372, for both Group A and Group B isolates.  Genes 
immediately up- and downstream of the operon were also up-regulated. 
 





















Group A relative to TT372: 
22.1  12.1  8.5  2.6  2.1  2.0  3.1  2.56  
7.4  4.4  7.3  1.8  1.6  1.5  2.1 1.82  
Group B relative to TT372: inhA promoter 
Conserved hypothetical 
Lipid metabolism 
Cell wall and cell processes 










Group B relative to TT372: 
9.4   7.0   28.9   17.8  8.2   11.2  3.7  1.7  
Conserved hypothetical 
Lipid metabolism 
Cell wall and cell processes 
Virulence, adaptation, detoxification 
Rv2827c 
1.7 
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5.3.7  Limitations 
It is unknown at what point in the evolution of atypical Beijing strains the development of increased 
fitness occurred – if at all.  Therefore, by looking for variants that are only present in drug-resistant 
strains, those changes that are also present in (some) drug-susceptible isolates will be missed.  More 
isolates, preferably serial isolates from the same patient, and powerful statistics will be needed to 
elucidate this. 
 
5.4  Conclusion 
Our molecular epidemiological data reveals that the Atypical Beijing genotype strains from the 
Eastern Cape Province are closely related, and that the majority of the selected strains belong to the 
F31-subgroup.  The whole genome sequencing data suggest that existing phylogenies of Beijing 
genotype strains need to be revisited as these isolates lack a specific SNP that was thought to be 
common to all Atypical and Typical Beijing genotype strains, while possessing another SNP that was 
thought to be evolutionarily more recent.  Furthermore, the presence of certain large deletions 
could be applied as markers to distinguish between F31 and other Atypical and Typical Beijing 
genotype strains.  However, the deletion of Rv2017, which was thought to be essential by Himar1-
transposon mutagenesis, questions the definition of essentiality. 
SNP and indel data show that apparently two separate genotypes (Group A and Group B) of drug-
resistant Atypical Beijing genotype strains have evolved historically, each with distinctive features, 
including specific drug-resistance mutations.  However, careful consideration of additional data 
suggest that Group A may be more diverse than what is evident by the WGS of only three strains.  
Both these genotypes have subsequently spread throughout the Province and is currently endemic.  
Relatively little variation is observed between some isolates that are not epidemiologically linked, 
suggesting a low mutation rate.  In contrast, more variation exist between other isolates with proven 
epidemiological links than what is considered the maximum amount indicative of a transmission 
event.  This confirms findings of other studies (15,38) that although the genome seems to be stable 
in most cases, the number of SNPs difference alone cannot be used to infer transmission events and 
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that the rate of mutation of M. tuberculosis may not be fixed.  Taken together, these results 
question the validity of quantifying transmission events in terms of SNPs. 
RNA abundance studies confirmed that both Group A and Group B are distinct from drug-susceptible 
isolates, as well as from each other.  Further investigation into the roles of other abundantly 
expressed RNA, especially those of the altered vapBC22 is needed to determine their role in the 
metabolism, virulence and adaptation of these highly resistant strains. 
However, some similarities between the drug-resistance groups exist.  For example, the the inhA 
promoter mutations in both Group A and Group B-isolates has a profound effect on the RNA 
abundance of the genes that forms part of the operon regulated by that promoter.  InhA is the 
target of both ETH and INH (in their activated forms).  The massive up-regulation of InhA ensures 
that there is an over-abundance of the target of these drugs, depleting the drug before all of the 
target is bound, effecting drug-resistance.  This is in accordance with the INH and ETH resistant 
phenotypes observed when InhA is overexpressed (69)   
A concerning finding was the presence of a mutation in ethA in all F31 isolates, including those that 
were regarded pan-susceptible, based on standard first line DST and Sanger sequencing of katG and 
rpoB.  This mutation has previously been linked with resistance to ETH (40).  Preliminary quantitative 
DST results suggest that these isolates are indeed ETH resistant.  This implies that the standard 
second-line regimen may be compromised for individuals infected with Atypical Beijing genotype 
strains.  Further validation is required to prove the causality of the mutation for ETH resistance. 
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Chapter 6   Literature review 
 
This literature review will be presented to the WHO Bulletin for publication. 
 
Diagnosis and management of drug-resistance beyond XDR-TB: lessons from the South African 
context 
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Abstract 
Drug-resistant Tuberculosis (TB) is a world-wide problem that is growing not only in numbers of 
cases affected, but also in numbers of drugs lost to resistance.  Amplification of drug-resistance, 
where the bacilli become resistant to an increasing number of drugs, is facilitated through 
inadequate drug-susceptibility testing (DST), concomitant with inappropriate treatment.  In South 
Africa, several iterations of testing algorithms and treatment regimens have not improved the 
situation due to a knowledge gap in understanding the repertoire of resistance circulating.  
Currently, many patients are infected with TB strains that are resistant to all drugs used in the 
standardised MDR-TB regimen as well as drugs used to treat XDR-TB.  These patients are put on 
salvage regimens without knowing their resistance profiles, which often leads to treatment failure 
and death.  When all treatment options are exhausted, these infectious patients may be sent home, 
potentially perpetuating the epidemic by allowing other members of the community to be infected 
with these highly resistant TB strains.  This problem can only be addressed by ensuring adequate 
treatment regimens consisting of at least 4 effective drugs are always given.  With the available anti-
TB drugs, this can only be achieved by testing all drugs intended for inclusion in the regimen before 
treating.  Effective treatment of highly resistant TB will depend on the development of new drugs, 
new drug combinations in association with comprehensive rapid DST.  In the interim, palliative care 
facilities for patients without adequate treatment options need to be built within the communities 
where such patients reside.   
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6.1  Introduction 
Tuberculosis (TB) control is a global problem, most severely affecting resource-poor countries.  A key 
concern has been the rise in drug-resistant TB (DR-TB), which first emerged shortly after the 
introduction of the first anti-TB drug.  Since its emergence, it has been a constant battle to keep 
ahead of the evolution of DR-TB.  In the mid-1970s, short course treatment regimens including 
rifampicin (RIF) were initiated and have subsequently been adopted by the WHO to threat TB on a 
global scale.  However, this strategy is threatened by the emergence and spread of multi-drug 
resistance (MDR-TB, resistant to isoniazid (INH) and RIF).  The loss of these two most potent anti-TB 
drugs severely compromises treatment outcome and has become a measure of the efficacy of TB 
control programs worldwide.  Globally, there were estimated to be 480,000 incident cases of MDR-
TB in 2013 (1).  Only 97,000 detected MDR-TB cases were started on treatment and less than half of 
these patients have favourable outcomes.   
In 2006, the severity of the drug resistant TB epidemic was brought to the attention of the world by 
a report documenting the spread and high mortality of a highly resistant form of TB in HIV-infected 
patients in South Africa.  This culminated in the WHO definition of extensively drug-resistant (XDR-) 
TB – resistance to INH, RIF, second-line injectables and fluoroquinolones (FQ) (2).  Global 
surveillance now reports XDR-TB in 100 countries, affecting an estimated 43,000 patients (1).  This 
indicates that XDR-TB is a problem that is not restricted to high TB-burden countries, and that it is 
emerging repeatedly.   
The application of comprehensive drug-susceptibility testing (DST) has identified patients with TB 
that was resistant to more drugs than those that strictly define XDR-TB.  These cases have been 
controversially referred to as XXDR-TB, totally drug-resistant (TDR)-TB or super-XDR-TB (3–7).  In 
addition, several publications from around the world report TB with resistance beyond XDR, but do 
not differentiate such resistance from XDR by the use of a special term (8–12).  
 
6.2  Historic drivers of DR-TB in South Africa 
Chemotherapy of TB in South Africa started soon after the discovery of streptomycin (SM) and 
largely followed recommended regimens used throughout the world.  In 1965, surveillance showed 
that primary and acquired resistance to INH was as high as 14% and 54% respectively, in newly 
admitted adult black tuberculosis patients.  By 1988, these figures had declined to 9% and 15%, 
respectively (13).  This was ascribed to the implementation of treatment guidelines and the 
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introduction of RIF into the regimen.  Although the emergence of MDR-TB was first noted in the 
early 1980’s, the 1992-1993 Western Cape drug resistance survey (14) highlighted the emergence of 
the MDR-TB epidemic in South Africa (1.1% in new cases and 4.0% in retreatment cases).  These 
statistics reflect the drug-resistant TB epidemic prior to the rise of the HIV pandemic.   
The first national drug-resistance survey, conducted in 2002, showed MDR-TB rates of 1.6% in new 
and 6.6% in retreatment cases (15).  Resistance to ethambutol (EMB) and SM was present in 25% of 
these cases (15).  By 2011, MDR-TB had increased dramatically to 7.8% of new TB cases while 5.7% 
of all MDR-TB cases were found to be XDR-TB (16).    
 
6.3  The South African response plan 
Since the recognition of MDR-TB, control policies, including that of South Africa, have been a few 
steps behind the epidemic due to inadequate data, insufficient resources and the dogma that drug-
resistant strains were less likely to transmit.  Despite these shortcomings, and in response to the 
2002 drug-resistance surveillance data, a standardized MDR-TB treatment regimen was 
implemented.  At that time, financial constraints limited drug-resistance testing to high-risk cases 
and treatment failures (17).  These patients received DST for INH, RIF and EMB only, despite the 
unreliability of EMB DST.  All patients were placed on standard first-line treatment prior to obtaining 
DST results.  New cases received INH, RIF, EMB and pyrazinamide (PZA) during the intensive phase 
and INH and RIF during the continuation phase.  Retreatment cases received an additional drug (SM) 
during the intensive phase and the treatment duration was extended.  This strategy created an 
opportunity for amplification of resistance to include PZA and EMB resistance if undiagnosed MDR-
TB was present.  Once diagnosed with MDR-TB, standardised MDR treatment was initiated.  
However, this MDR-TB regimen failed to recognize the fact that the MDR-TB strains may have been 
resistant to EMB and PZA (18–20).  This, together with high default rates, could explain the poor 
treatment outcomes (treatment success rate below 48%) (21). 
The Tugela Ferry outbreak in Kwa-Zulu Natal (KZN), which lead to the definition of XDR-TB, was 
ascribed at the time to a failing health system and poor infection control (2).  The South African 
Department of Health’s response was to bolster the treatment regimen by the inclusion of two 
additional drugs for the treatment of XDR-TB, offering second-line DST for all MDR-TB cases and 
improving infection control in health care facilities (22).  Despite the introduction of these measures, 
amplification of resistance continues to occur (11).  In KZN, the proportion of XDR-TB cases resistant 
to six drugs increased from 45% in 2005 to 100% in 2009.  Sixty-eight percent of these were resistant 
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to eight anti-TB drugs (11).  This was the first indication that drug-resistance “beyond XDR” was 
present in South Africa.  In 2011, new MDR-treatment guidelines were implemented, whereby 
ofloxacin was replaced with moxifloxacin (MOX), and EMB with terizidone (TZD) (23).  However, 
these measures continue to ignore the high prevalence of PZA resistance and cross-resistance 
between INH and ethionamide (ETH) in some patients (24). 
In 2011, the Department of Health introduced molecular based M. tuberculosis diagnosis and RIF DST 
in the form of GeneXpert to improve case detection.  2014 diagnostic guidelines focus only on 
identifying RIF resistant cases implying that INH mono-resistance will be missed.  The consequence of 
this strategy has not been fully realised as a recent study revealed that the relative risk of acquired RIF 
resistance was significantly increased in patients with undetected INH mono-resistance resulting in 
the emergence of MDR-TB (25).  These guidelines stipulate that patients with RIF resistant TB should 
be placed on standardized MDR-TB treatment (see below).  This implies treating blindly for one to two 
months (26) until the treatment regimen can be adjusted according to the DST profile.  However, 
culture-based DST is restricted to the detection of resistance towards FQ and aminoglycosides.  DST 
for EMB, PZA and ETH is not routinely done.  This potentiates the risk for the amplification of drug 
resistance in cases that have resistance beyond MDR-TB, potentially negatively impacting on 
treatment outcome.   
 
6.4  Current treatment guidelines 
The latest management guidelines recommend that any RIF resistant TB should be treated with a 
standardized MDR regimen (Kanamycin (KAN), MOX, ETH, TZD, PZA), regardless of INH susceptibility 
(23,27).  INH mono-resistant TB will be treated as drug susceptible TB unless subsequent DST is done 
should the patient fail to respond after two months of treatment.  Therefore, INH mono-resistant 
cases are treated with only three effective drugs and one drug during the continuation phase if 
undiagnosed.  This is in contrast to the WHO recommendation of treatment with at least 4 effective 
drugs (28), as well as the South African 2004 guidelines, which states that one of the most common 
errors leading to the selection of resistant bacilli is prescription of inadequate chemotherapy (e.g. 
three drugs during the initial phase of treatment) (17).  However, if INH mono-resistant TB is 
diagnosed, the patient should be treated with the standard first line combination (INH, RIF, EMB, 
PZA) for 6 months, according to the 2014 guidelines (27).  In the case of RIF mono-resistance, the 
current guidelines stipulate that the patient should be treated with a standardized MDR-TB regimen.  
No provision is made for the inclusion of INH in that regimen.  Both of these recommendations 
subject the patient to suboptimal therapy.  The impact of these guidelines on the amplification of 
Stellenbosch University  https://scholar.sun.ac.za
 156 
resistance remains to be determined.   
Proven XDR-TB cases are treated individually, taking into account known resistance and treatment 
history (27).  When the treatment options of the standard regimens are depleted, clinicians turn to 
so-called salvage drugs.  These drugs are not included in standard regimens due to inferior efficacy, 
decreased tolerability, insufficient evidence of their safety, or they may be unavailable or too 
expensive.  Under these conditions, individualized treatment is implemented, often without 
evidence of its efficacy, because funding to conduct extensive testing is not available (29).  However, 
treating a patient with ineffective drugs is a waste of resources and may further compromise the 
efficacy of other drugs.  No drug should be administered without good evidence that the bacilli are 
susceptible to it, and mono therapy is to be avoided.  In treating patients with limited treatment 
options, clinicians are faced with many challenges.  Most importantly, several drugs have no 
standardized test available, preventing accurate diagnosis.  Furthermore, some drugs are frequently 
used for indications other than TB (e.g. FQ, SM, amoxicillin-clavulanic acid), increasing the risk of 
resistance.  Additional considerations include interactions between TB drugs and ARVs where HIV 
co-infection is treated (30), as well as between certain TB drugs with cross-resistance (31–33) or 
which may act synergistically to exacerbate adverse reactions (34,35).  The latest additions to the 
arsenal of anti-TB drugs in South Africa are bedaquiline, which has recently been approved for use in 
the treatment of MDR-TB, and linezolid, a repurposed drug which shows promise to improve 
treatment outcomes (36).  Several clinical trials of further novel drugs are underway.  It is paramount 
that these drugs should be used only as part of a robust regimen, in order to prevent development 
of resistance to these drugs.  Among newer generation drugs, there is concern over the 
simultaneous administration of bedaquiline, clarithromycin, delaminid (not available in South Africa 
yet) and/or MOX, as all of these may cause heart QT prolongation (37–40).  Surgery, as an adjunctive 
therapy, is only used in cases that meet strict criteria and should be evaluated on a patient-by-
patient basis (41).   
 
This situation of exhausted treatment options is common in South Africa.  For example, in the 
Eastern Cape Province of South Africa, an inadequate treatment strategy, along with under-
resourced and poorly managed health systems, has led to practically the worst possible form of TB 
emerging.  The Eastern Cape is one of the most adversely affected South African Provinces in terms 
of TB prevalence, MDR-TB (6.8% among new culture positive patients) and XDR-TB (11.9% of new 
MDR-TB cases) (16).  This is emphasized by a report which showed that almost all XDR-TB patients 
(91.6%) in Jose Pearson TB Hospital (Nelson Mandela Metropole) failed to achieve culture 
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conversion within one year (42).  Furthermore, on average, patients in that study received only 1.7 
drugs that were deemed effective (42), assuming that capreomycin (CAP) was effective for 
treatment of XDR-TB patients.  However, a recent study demonstrated the contrary (31), highlighting 
cross-resistance between amikacin (AMK) and CAP.  Clearly, treatment options for these patients 
was inadequate according to WHO recommendations (28).  Not surprisingly, mortality was high:  
58% of XDR-TB patients died within one year of diagnosis or treatment initiation (42).   
High rates of mortality are not limited to the Eastern Cape and have been reported for the Western 
and Northern Cape Provinces, as well as Gauteng and Kwa-Zulu Natal (2,43).  This situation will 
continue to occur – as supported by other studies (6,42,44) - if treatment regimens fail to be built on 
a comprehensive analysis of the resistance profile of the pathogen and in the absence of novel 
treatment regimens.  
Under these conditions, cases that do not achieve culture conversion within a period of 12 to 18 
months, and have high-level drug-resistance with no options of adding further drugs or surgery are 
considered treatment failures.  These cases are sent home after investigation by a review board, 
with no further anti-TB treatment (23).  This is controversial, as it puts community contacts at risk, 
especially given that such patients may survive in the community for several years.  A recent study 
demonstrated the transmission of XDR-TB from discharged patients to their close contacts, resulting 
in the death of several members within these families (44).  This has created an ethical dilemma: the 
right of the individual vs. the right of the community.  Some argue that transmission occurs before 
hospitalization and therefore the discharged patients are not an additional threat to the community.  
However, these patients are often still smear positive at discharge, indicating a high transmission 
potential (44).  Therefore, the rights of the community dictate that infectious patients should have 
no or very limited contact with the community.  In our opinion, there is a need to develop TB 
palliative care facilities in all high TB prevalence communities. 
 
6.5  Considerations for optimized control 
It is clear that highly resistant forms of TB are developing spontaneously in response to inadequate 
treatment and are subsequently spreading.  These problems can be addressed by two possible 
strategies.  The first is to treat all patients initially with a “super regimen”, containing as many drugs 
as possible.  This regimen would then be tailored down according to DST as it becomes available.  
However, adverse side effects is likely to prevent this strategy from being adopted widely.  
Furthermore, careful investigation would be needed to determine the effect of this strategy on the 
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acquisition of drug-resistance.  The second strategy is to expand the use of rapid, molecular DST as 
well as expanding the set of routinely done tests to include all drugs that are prescribed.  The major 
problem with this strategy, apart from cost and lab capacity, is the unavailability of rapid, reliable 
tests for certain drugs.  The WHO has endorsed the MTBDRplus line probe assay (Hain Lifescience, 
Nehren, Germany) and Xpert MTB/RIF assay (GeneXpert) for detecting M. tuberculosis complex.  The 
efficiency of MTBDRplus is comparable to that of GeneXpert (45), with the additional benefit of 
rapidly determining INH resistance, thereby identifying INH mono-resistant cases who are at risk of 
developing MDR-TB (26).  We advocate that further resistance testing should be undertaken 
immediately with GenoType MTBDRsl (Hain Lifescience, Nehren, Germany) upon identification of RIF 
resistance using GenoType MTBDRplus.  It has been shown by several studies (46) (meta-analysis), 
(47), (48) that this assay can be used as a rule-in test to detect resistance to second-line drugs (FQ, 
AMK, KAN and Cap).  However, due to concern over sensitivities and specificities for the various 
drugs, it has been suggested that this assay be used in conjunction with culture-based DST (48).  A 
further concern is that this test does not detect resistance to PZA and sensitivity and specificity is 
very low for EMB.  This implies that resistance to any of several drugs may still be missed, leading to 
inappropriate treatment and the consequent amplification of resistance.  Although not standardized, 
it is possible to detect PZA resistance with targeted gene sequencing, offering a faster alternative to 
culture-based DST (49).  Several new diagnostic technologies are currently in development that may 
offer improved methods in future (50).  MDR-TB treatment regimens should subsequently be 
strengthened to ensure that at least 4 effective drugs are always present.   
In addition to these knowledge-based strategies, heightened infection control in health care facilities 
as well as specialized TB hospitals is emphasised by nosocomial transmission of drug-resistant TB (2).  
Infection control also need to be extended to community based care, especially for therapeutically 
destitute cases (51,52).  In the face of constrained resources, this goes hand-in-hand with improved 
education of household contacts which is vital to curb the epidemic.   
Precise classification of highly resistant TB is needed in order to improve targeted treatment, and to 
protect the few drugs that may still be effective.  Currently, lack of reliable testing for some drugs 
precludes precise definitions, indicating an urgent need to focus research on improved diagnostics. 
 
It is imperative that we look on the lessons learned from the past: a weak regimen will be easily 
overcome by TB bacilli.  For this reason, it is crucial to not treat a patient without knowing with 
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reasonable certainty that the regimen given contains sufficient effective drugs.  Failing to learn this 
lesson will result in losing new drugs as fast as they become available. 
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Oh, the depth of the riches of the wisdom and knowledge of God! 
    How unsearchable his judgments, 
    and his paths beyond tracing out! 
“Who has known the mind of the Lord? 
    Or who has been his counselor?” 
 “Who has ever given to God, 
    that God should repay them?” 
For from him and through him and for him are all things. 
    To him be the glory forever! Amen. 
- Romans 11:33-36 
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Conclusions 
This work was the first in-depth molecular epidemiological study of the drug-resistant TB epidemic in 
the Eastern Cape (EC) of South Africa.   
We have shown that the population structure of TB in the EC differs dramatically among drug-
susceptible, MDR- and pre-XDR- and XDR-TB strains.  The Atypical Beijing genotype is significantly 
overrepresented among MDR-TB strains, and even more so among Pre-XDR- and XDR-TB strains, 
suggesting a selective advantage among strains with higher resistance.  Our phylogenetic analysis 
concludes that these strains have evolved from a common progenitor, and may be resistant to up to 
11 drugs.  According to the definition of Udwadia et al (1), we demonstrate the evolution and spread 
of “totally” drug-resistant TB in a Province with a failing health care system. 
This work was framed in the South African context, investigating the population structure of MDR-TB 
strains in three additional Provinces.  This analysis showed that the MDR-TB population structure 
was distinct for each Province.  Furthermore, in keeping with EC data, a negative correlation 
between strain diversity and the number of resistance markers was observed.  It was demonstrated 
that the population structure of XDR-TB in the Western Cape was strongly influenced by strains 
originating from the EC, probably through migration of patients seeking better employment 
opportunities and better health care.  This shows how sub-optimal health care management and 
poor socioeconomic conditions in one setting can contribute to the burden of disease in another. 
This emphasises the need for access to appropriate health-care in all provinces as well as a 
functioning National electronic database. 
Our findings highlight a high degree of clustering of drug resistance-causing mutation patterns, 
indicating transmission of highly drug-resistant strains.  This indicates the failure of standardised 
regimens to prevent the acquisition of higher resistance, as well as the failure to provide adequate 
treatment that would result in culture conversion, and therefore limit transmission.  This calls for a 
change in the policy to allow the initiation of individualised treatment based on knowledge of the 
exact resistance profile for each patient. 
We have shown that inhA promoter mutations in MDR-TB strains appear to be instrumental in the 
acquision of further mutations leading to the development of XDR-TB.  Importantly, these mutations 
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are not detected by the primary screening tool, GeneXpert MTB/RIF assay.  However, these 
mutations are detectable by the GenoType® MTBDRplus line probe assay which is currently used to 
confirm rifampicin resistance detected by Xpert MTB/RIF.  Using this diagnostic data will allow for 
the rapid identification of patients at risk of XDR-TB and thereby will facilitate further triaging for 
second-line DST, followed by adjustment of the regimen.  We suggest that further studies are 
needed to investigate the usefulness of this test to detect inhA promoter mutations as a risk screen 
for XDR-TB. 
In the face of extremely limited treatment options for XDR-TB, we investigated cross-resistance 
between capreomycin (CAP) and amikacin (AMK), to determine its potential value in the treatment 
of XDR-TB.  High levels of cross-resistance was observed between CAP and AMK in strains harbouring 
the rrs A1401G mutation.  Furthermore, this study showed that CAP resistance is missed by routine 
DST which led to a change in the methods of CAP testing at the National Health Laboratory Services 
in Port Elizabeth.  Recent evidence presented at the 2014 MDR/XDR TB Conference in Cape Town 
confirmed that treatment with CAP had no therapeutic value in patients with isolates harbouring the 
A1401G mutation.   
We noted that incomplete cross-resistance exist between RIF and rifabutin (RFB) (2,3) in isolates 
from our cohort which were characterised by the rpoB 516 mutation which was present in the 
majority of Atypical Beijing genotype isolates from the EC.  Accordingly, RFB may be an available 
option for the treatment of a large proportion of drug-resistant TB cases in this setting and other 
settings (e.g. Brazil (4)) where MDR-TB is characterised by rpoB 516 mutations.  However, it is 
important that knowledge about the exact mutation is available before inclusion of this drug in a 
treatment regimen.  Clinical studies on the effectiveness of both CAP and RFB are needed in this 
setting. 
Whole genome sequencing (WGS) analysis of a selection of Atypical Beijing genotype isolates 
supported the notion of an endemic presence of these strains.  It was shown that two important 
sub-groups evolved independently from a common progenitor, and subsequently spread throughout 
the region.  Each of these groups harboured group-specific mutations, including a distinct set of drug 
resistance-causing mutations.  Our study also revealed that all Atypical Beijing F31-genotype 
isolates, including those diagnosed as pan-susceptible, harbour an ethA mutation conferring 
ethionamide (ETH) resistance.  Our phylogenetic analysis suggested that the katG, rrs513 and ethA 
mutations were acquired historically before the development of standardised 4-drug regimens.  
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With modern standardised regimens, the ethA mutation is hypothesised to not confer a selective 
advantage to otherwise drug-susceptible strains, as ETH forms part of the second-line regimen.  
However, once a patient is diagnosed with MDR-TB, or RIF resistant TB according to current 
guidelines (5), he or she will receive treatment with a regimen containing ETH.  The hidden 
resistance to ETH weakens the regimen, leading to acquisition of additional resistance.  This 
strengthens our recommendation that comprehensive DST should be available for all suspected 
MDR-TB cases, before the commencement of treatment.  Further research is needed to determine 
the difference in MICs between strains with different permutations of inhA promoter and ethA 
mutations, and whether such a difference will have any clinical relevance. 
The distinct nature of the two groups of the Atypical Beijing genotype was also supported by RNAseq 
analysis.  A large number of genes were significantly differentially regulated, compared to drug-
susceptible isolates in each group:  in Group A, 423 genes were up-regulated and one down-
regulated, while 721 genes were up-regulated and two down-regulated in Group B.  Significant up-
regulation of the inhA operon was shown in all isolates that harboured inhA promoter mutations.  
This confirms that the mechanism of resistance is through over-production of the target of INH and 
ETH, resulting in low-level INH resistance, as well as high-level ETH resistance.   
Cases of TB with resistance beyond XDR are arising around the world and we have shown that these 
highly resistant strains can spread.  The problem is exacerbated when infectious patients without 
any further treatment options are sent home.  We propose that nomenclature be developed that 
adequately describe cases with resistance beyond XDR-TB in order to provide the correct treatment 
and to protect drugs that may still be useful.  Such nomenclature will also aid in epidemiological 
studies to understand the severity of the problem.  We further strongly propose that individualised 
treatment regimens based on known drug susceptibility be designed for all MDR-TB cases.   
This study was conducted before the roll-out of GeneXpert and the associated guidelines for 
treatment management.  We hypothesise that this roll-out will have had a major impact on the 
epidemiology of drug-resistant TB.  According to the 2014 TB treatment guidelines (5), all patients 
with a RIF resistant GeneXpert result are immediately started on MDR-treatment, regardless of the 
spectrum of drug resistance.  This implies that patients infected with strains that are resistant 
beyond MDR (e.g. Atypical Beijing genotype strains) are at increased risk of developing resistance to 
additional first- as well as second-line drugs.  This strategy has the potential to increase mortality as 
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well as to exacerbate transmission.  Further studies are needed to determine the effect these 
guidelines will have in various settings.   
It is currently unknown whether Atypical Beijing genotype strains with different levels of drug 
resistance also differ in terms of virulence.  Studies in in vivo infection models may help to elucidate 
this. This knowledge will improve our understanding of what genetic changes contribute to 
virulence.   
The findings of this thesis pertaining to Atypical Beijing genotype strains, their drug-resistance 
patterns and prevalence in the Eastern Cape Province may not be generalizable to the rest of the 
country.  However, its increasing prevalence in the Western Cape Province is reason for concern, and 
these findings may in future prove valuable in the management of cases infected with Atypical 
Beijing genotype strains.  It also serves as a warning that regular epidemiological studies are needed, 
as the epidemic is dynamic, implying that strategies for diagnosis and treatment need to be adapted 
over time.  Furthermore, the Atypical Beijing genotype and its devastating effect in the Eastern Cape 
may serve as an example and the knowledge gained may be applied to study the dominant strains in 
other regions.  This work also shows that considerable diversity exist within the country, and 
therefore a different diagnostic and treatment approach may be needed for each region according 
to the most dominant strain type and prevailing drug-resistance patterns. 
Together these findings have challenged the use of standardised MDR-TB treatment without 
comprehensive DST.  This widely recognised view has not influenced the South African TB guidelines 
(2014) which promote treatment of rifampicin resistance without relevant knowledge of additional 
drug resistance.  Drug-resistance beyond XDR-TB is present in the EC, and is spreading.  This 
situation will continue to occur unless the way patients are diagnosed and treated is adapted.  We 
propose that the effective treatment of highly resistant TB can only be achieved with the 
development of new drugs, new drug combinations and comprehensive rapid DST.   
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Chapter 8 Appendix 
 
The appendices include further work that was published using data generated during this project. 
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van Pittius NC, van Helden PD, Victor TC, Warren RM. 
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Drug resistant tuberculosis (TB) has reached alarming proportions in South Africa, draining valuable 
resources that are needed to fight drug susceptible TB.  It is currently estimated that 9.6% of all TB 
cases have multi-drug resistant (MDR)-TB, thereby ranking South Africa as one of the highest MDR-
TB burden countries in the world.  Molecular epidemiological studies have demonstrated the 
complexity of the epidemic and have clearly shown that the epidemic is driven by transmission as a 
consequence of low case detection and diagnostic delay.  The latter has in turn fuelled the 
amplification of drug resistance, ultimately leading to the emergence of extensively drug resistant 
(XDR)-TB.  Despite the introduction of new drugs to combat this scourge, culture conversion rates 
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for XDR-TB remain below 20%.  Failure to achieve cure may be explained from DNA sequencing 
results which have demonstrated mutations in 7 genes encoding resistance to at least 8 anti-TB 
drugs.  This review shows how molecular epidemiology has provided novel insights into the MDR-TB 
epidemic in South Africa and thereby has highlighted the challenges that need to be addressed 
regarding the diagnosis and treatment of MDR-TB.  An important step towards for curbing this 
epidemic will be collaboration between clinicians, laboratories and researchers to establish scientific 
knowledge and medical expertise to more efficiently guide public health policy.  
 
Global MDR-TB epidemic  
Recent statistics released by the World Health Organization (WHO) have raised concern about the 
ever-increasing global drug resistant tuberculosis (TB) epidemic.  It is now estimated that 440 000 
cases of multidrug-resistant (MDR)-TB (resistant to at least isoniazid and rifampicin) were diagnosed 
in 2008.  Of these, approximately 40 000 had extensively drug resistant (XDR)-TB (MDR-TB with 
additional resistance to a fluoroquinolone and one of the injectables, i.e. kanamycin, amikacin or 
capreomycin) (WHO media report, 2006; WHO-IUATLD Global Project on anti-tuberculosis drug 
resistance surveillance, 2008). By January 2010 XDR-TB cases had been reported in 58 countries 
around the world (WHO, 2010a).  
 
MDR-TB epidemic in South Africa  
South Africa is ranked as a high burden MDR-TB country with an estimated 13 000 cases being 
diagnosed in 2008 (WHO, 2010a).  In a nationwide survey in South Africa in 2008, 20.2% of all 
notified TB cases showed resistance to isoniazid and nearly half of these (9.6% of all cases) were 
MDR-TB (WHO, 2010a).  This represents a dramatic increase (3-fold) since 2002, when it was shown 
that 3.1% of all TB cases (new and retreatment) had MDR-TB (WHO-IUATLD Global Project on anti-
tuberculosis drug resistance surveillance, 2008).  These findings are supported by a report from the 
National Health Laboratory Service (NHLS) which showed a steady increase in the number of MDR-
TB cases since 2004 (Table 1), (National Health Laboratory Services, 2010) and a study in Khayelitsha 
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which showed that MDR-TB was diagnosed in 4.4% of all TB cases in 2008 (Cox et al., 2010).  NHLS 
data suggest that 6.3% of the diagnosed MDR-TB cases are XDR-TB (after second-line drug 
susceptibility testing, DST) (Table 2), while WHO estimates for South Africa are even more 
pessimistic with an estimate of 10.5% of XDR-TB among MDR-TB cases (National Health Laboratory 
Services, 2010; WHO, 2010a).   
These statistics appear significantly worse if we consider that only 8 200 of the projected 13 000 
patients were diagnosed with MDR-TB or XDR-TB by the NHLS in 2008 – suggesting a case detection 
rate of 63%.  More worrying is the fact that no more than 50% of diagnosed cases were placed on 
MDR treatment in 2009 (Dr. Norbert Ndjeka, Director Drug‐Resistant TB, TB and HIV, National 
Department of Health).  In South Africa the cure rates for MDR-TB cases receiving treatment are in 
the order of 49% (Department of Health Government South Africa, 2007; Shean et al., 2008).  The 
culture conversion rate for XDR-TB is even more dismal, with an almost 100% mortality reported for 
the Tugela Ferry outbreak among human immunodeficiency virus (HIV) co-infected individuals in 
KwaZulu-Natal (Gandhi et al., 2006).  Similarly, culture conversion rates for XDR-TB cases from the 
Western Cape, Eastern Cape and Gauteng provinces were less than 19% among HIV infected and 
uninfected patients (Dheda et al., 2010).  A recent study from the Eastern Cape suggested that 
culture conversion at month 12 was only in the order of 8%, while mortality was 43% (Kvasnovsky et 
al., 2011).   
The ever increasing MDR-TB epidemic in South Africa places significant constraints on the National 
TB Control Program budget (World Health Oganization, 2009).  It has been estimated that treatment 
of MDR-TB cases consumes nearly 70% of the budget allocated to fight the entire TB epidemic in 
South Africa (World Health Oganization, 2009).  Thus, valuable resources are directed away from 
combating the drug susceptible TB epidemic which has now reached alarming proportions with an 
estimated 500 000 cases being diagnosed each year in South Africa (WHO-IUATLD Global Project on 
anti-tuberculosis drug resistance surveillance, 2008).  The above statistics suggest that the current 
TB control strategy is unable to curb the emergence and spread of MDR-TB, despite the 
implementation of the DOTS program in 1996.  This may in part be explained by the poor 
implementation of the DOTS program in certain regions of South Africa.  A recent study in KwaZulu-
Natal showed that only 18% of patients diagnosed with smear-positive pulmonary disease 
completed treatment thereby potentially fuelling the emergence of drug resistance in that province 
(Loveday et al., 2008). 
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Table 1. Number of MDR-TB patients diagnosed by the National Health Laboratory Service by province per year 
(National Health Laboratory Services, 2010). 
Province 2004 2005 2006 2007 2008 2009 Total 
Eastern Cape 379 545 836 1092 1501 1858 6211 
Free State 116 151 198 179 381 253 1278 
Gauteng 537 676 732 986 1028 1307 5266 
Kwazulu-Natal 583 1024 2200 2208 1573 1773 9361 
Limpopo 59 40 77 91 185 204 656 
Mpumalanga 162 134 139 506 657 446 2044 
North West 130 203 225 397 363 520 1838 
Northern Cape 168 155 188 199 290 631 1631 
Western Cape 1085 1192 1179 1771 2220 2078 9525 
Total 3219 4120 5774 7429 8198 9070 37810 
 
 
Table 2. Number of XDR-TB patients diagnosed by the National Health Laboratory Service by province per year 
(National Health Laboratory Services, 2010). 
Province 2004 2005 2006 2007 2008 2009 Total 
Eastern Cape 3 18 61 108 175 123 488 
Free State 1 6 3 4 3 3 20 
Gauteng 5 14 19 38 30 65 171 
Kwazulu-Natal 59 227 336 241 181 254 1298 
Limpopo  2 5 2 2 6 17 
Mpumalanga    12 14 18 44 
North West 1 5 9 4 4 13 36 
Northern Cape 4 10 3 7 19 40 83 
Western Cape 12 16 28 42 60 72 230 
Total 85 298 464 458 488 594 2387 
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Drug resistance surveillance studies in South Africa have in the past quantified the relative 
contribution of resistance in new patients (transmitted) and resistance in previously treated patients 
(acquired) with the view to direct policy to most effectively tackle the drug resistance TB epidemic 
(Weyer K, 2001; Weyer et al., 1995; Weyer and Kleeberg, 1992).  These surveys have highlighted a 
significant association between retreatment and drug resistance, thereby suggesting that such 
patients acquired resistance.  As an example, in a nationwide survey in South Africa in 2002, the 
proportion of MDR-TB in all new cases was estimated at 1.8%, while among previously treated cases 
this estimate rose to 6.7% (WHO-IUATLD Global Project on anti-tuberculosis drug resistance 
surveillance, 2008).  The association between retreatment and drug resistance informed the 
diagnostic policy to be targeted towards high risk patients (retreatment cases, treatment failure 
cases and contacts of drug resistant cases).  In our opinion this was largely a cost saving strategy 
which has had a significant impact on the amplification of drug resistance.   
 
Table 3. Spoligotype patterns of MDR-TB isolates culture from patients resident in the Western Cape Province of South 












BEIJING 1842 1 BEIJING  1833 
  541 BEIJING  4 
  255 BEIJING  2 
     1 
  190 BEIJING  1 
  1674 BEIJING  1 
X-family 366 119 X1  154 
  92 X3  71 
  1329 X1  32 
     31 
  137 X2  20 
  18 X2  9 
  336 X1  9 
     8 
  347 X2  7 
     4 
  348 X1  4 
     4 
     3 
     3 
     2 
     1 
     1 
     1 
     1 
     1 
LAM 359 33 LAM3  146 
  60 LAM4  84 
  719 T1  28 
  1241 U  14 
  42 LAM9  14 
  811 LAM4  8 
  20 LAM1  7 
  130 LAM3  7 
  4 LAM3  5 
     4 
     4 
  1293 LAM3  3 
     3 
     3 
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1873 LAM11_ZWE  3 
   2 
     2 
  125 T2  1 
  177 LAM9  1 
  1354 LAM3  1 
     1 
     1 
  1321 LAM1-LAM4  1 
     1 
  30 LAM9  1 
     1 
  1528 LAM9  1 
     1 
  1830 LAM3  1 
     1 
     1 
  1841 U  1 
     1 
     1 
  1324 T1  1 
     1 
     1 
  815 LAM11_ZWE  1 
  95 LAM6  1 
S family 83 34 S  40 
  790 U  21 
  71 S  7 
  789 S  4 
  1334 S  2 
     1 
  1253 S  1 
     1 
     1 
     1 
     1 
  1783 LAM10_CAM-S  1 
     1 
  721 U  1 
Haarlem 34 50 H3  12 
     9 
  47 H1  6 
  62 H1  4 
  36 H3-T3  3 
CAS 9 21 CAS1_KILI  3 
  26 CAS1_DELHI  3 
  1092 CAS1_DELHI  2 
     1 
EAI 7 48 EAI1_SOM  4 
  8 EAI5 or EAI3  2 
  806 EAI1_SOM  1 
T-Family 245 53 T1  110 
  244 T1  9 
  462 T1  8 
  926 T1  7 
  501 T1  6 
  521 T1  6 
  803 T1  4 
  766 T1  3 
  373 T1  3 
  136 T1  2 
  498 T1  2 
  1202 T1  1 
  649 T1  1 
  1574 T1  1 
  1067 T1  1 
  156 T1  1 
  913 T1  1 
  732 T1  1 
  880 T1  1 
  1688 T1  1 
  1147 T1  1 
  888 T1  1 
  245 T1  1 
  628 T1  1 
  52 T2  5 
  73 T2-T3  2 
  37 T3  14 
  565 T3  4 
  158 T3  1 
  39 T4_CEU1  12 
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44 T5  32 
254 T5_RUS1  2 
OTHER 63 100 MANU1  1 
  54 MANU2  7 
  226 MANU2  3 
  1247 MANU2  2 
  1634 MANU2  1 
  519 U  1 
  237 U (likely H3)  1 
     6 
     4 
     4 
     3 
     2 
     2 
     2 
     2 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
     1 
 
Treatment guidelines between 2002 and 2010 
In order to curb the MDR-TB epidemic in South Africa, the National TB Control Program 
implemented standardized treatment guidelines for MDR-TB in 2002 (Department of Health, 2000).  
At the same time, routine DST was limited to testing for susceptibility to isoniazid, rifampicin and 
ethambutol.  This strategy was based on drug surveillance data which demonstrated that MDR-TB 
associated with ethambutol resistance was rare.  DST for pyrazinamide was not done in that survey.  
Additional DST was only done on request.   
 
The standardized treatment regimen consisted of a four-month intensive phase with five anti-TB 
drugs (kanamycin, ethionamide, pyrazinamide, ofloxacin, and cycloserine or ethambutol), followed 
by a 12-18 month continuation phase with three drugs (ethionamide, ofloxacin and cycloserine or 
ethambutol).  It was recommended that these anti-TB drugs should be administered five times per 
week in out-patient clinics and seven times per week in hospitals.  The continuation period could be 
shortened provided that 12 months of treatment had been given after sputum culture conversion as 
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demonstrated by three consecutive monthly negative cultures.  These treatment guidelines were 
revised in 2007 following the outbreak of XDR-TB in KwaZulu-Natal (Department of Health 
Government South Africa, 2006; Department of Health Government South Africa, 2007).  These 
revisions included DST of second-line anti-TB drugs (ofloxacin and amikacin) for all MDR-TB cases 
(Department of Health Government South Africa, 2007).  In addition, capreomycin and p-
aminosalicylic acid were made available for treatment of XDR-TB (Department of Health 
Government South Africa, 2006).  
 
Molecular Epidemiology   
Re-examination of the surveillance data clearly showed that although the percentage of MDR-TB 
was lower in new cases, the vast majority of MDR-TB cases had primary MDR-TB in South Africa 
(estimated 8 238 new cases vs 5 795 retreatment cases based on the 2002 drug resistance survey) 
confirming that MDR-TB is also efficiently transmitted (WHO-IUATLD Global Project on anti-
tuberculosis drug resistance surveillance, 2008).  Analysis of this data using a very simple model 
suggests that approximately 80% of MDR-TB results from ongoing transmission in South Africa (P. 
Uys et al.  submitted).  This results as a consequence of the reclassification of new primary MDR-TB 
patients as retreatment cases when failing first-line anti-TB therapy.  Similar conclusions were drawn 
from a drug surveillance study in Khayelitsha, Cape Town, which estimated that 81% of MDR-TB was 
transmitted (Cox et al., 2010). 
The importance of transmission as a major driver of the MDR epidemic in South Africa is supported 
by molecular genotypic analysis of MDR-TB and XDR-TB strains.  DNA fingerprinting and DNA 
sequencing of target genes conferring resistance clearly demonstrated that MDR-TB strains are 
clustered, implying ongoing transmission (Johnson et al., 2010; Pillay and Sturm, 2007; Strauss et al., 
2008; Streicher et al., 2004; van Rie et al., 1999; Victor et al., 2006).   The mechanism fuelling these 
outbreaks may be numerous; however, two recent studies have clearly demonstrated that poor 
infection control leads to nosocomial spread of MDR-TB and XDR-TB (Calver et al., 2010; Gandhi et 
al., 2006).  However, the extent to which noscomial spread contributes to the MDR and XDR-TB 
epidemic has not been quantified.  Furthermore, it is not known whether the current infection 
control strategies are sufficient to curb transmission – especially to highly vulnerable individuals.    
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Figure 1. IS6110 DNA fingerprint patterns of outbreak MDR-TB strains identified in South Africa. A – 
Atypical cluster 86 strain (Strauss et al., 2008), B – Beijing R220 strain (Johnson et al., 2010), C – 
Bejing cluster 213 strain (van Rie et al., 1999), D - F15/LAM4/KZN  strain (Pillay and Sturm, 2007), E – 
Low Copy Clade cluster DRF150 strain (Victor et al., 2007), and F – Low Copy Clade 140 strain (Calver 
et al., 2010).  
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Figure 2. Distribution of major MDR genotypes in four South African provinces. The frequency 
distribution of MDR-TB isolates with spoligotype patterns corresponding to Beijing, LAM4, S, T1, X1 
or other genotypes are indicated for the Western Cape, Eastern Cape, KwaZulu-Natal and Gauteng 
Provinces (manuscript in preparation). Isolates from the Western Cape, Eastern Cape and Gauteng 
belonging to the Beijing genotype, were further differentiated into typical and atypical Beijing strains 
(Beijing isolates from KwaZulu-Natal were not available for further characterization) 
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Table 3 shows the spoligotypes of MDR-TB isolates cultured from patients resident in the Western 
Cape.  Multiple recent studies reported MDR-TB outbreaks caused by clones of drug resistant strains 
(Calver et al., 2010; Johnson et al., 2006b; Johnson et al., 2010; Pillay and Sturm, 2007; Strauss et al., 
2008; van Rie et al., 1999; Victor et al., 2007) (See Figure 1 for IS6110 DNA fingerprint patterns of 
major outbreak MDR-TB strains).  For example, the Beijing cluster R220 strain is widely spread in the 
Western Cape province of South Africa and responsible for 42% of the increase in the incidence of 
MDR-TB in the Western Cape Province between 2001 and 2006.  This translates to a doubling time of 
2.38 years (Johnson et al., 2010).  In contrast, the MDR-TB epidemic in the Eastern Cape was 
characterized by the over-abundance of an atypical Beijing strain (Cluster 86), which accounts for 
most of the transmission of MDR-TB in that province (Figure 2) (Strauss et al., 2008).  This differs 
from the KwaZulu-Natal Province of South Africa where it has been shown that the F15/LAM4/ KZN  
strain is the principle MDR-TB strain (Figure 2) (Pillay and Sturm, 2007).  In line with this, a 
comprehensive analysis suggests that the population structure of MDR-TB in South Africa is largely 
distinct in all provinces surveyed with certain lineages being significantly overrepresented in 
different regions (Chihota et al.  submitted).  Interestingly, genotyping of MDR-TB isolates from 
Gauteng show a spectrum of different genotypes representing the strains found in the other 
provinces, thereby probably reflecting human migration (Figure 2)  (Kok et al., 2003).  
 
Diagnostic Delay   
The targeted diagnostic approach adopted by the National TB Control Program implies that the vast 
majority of MDR-TB cases would receive regimen 1 treatment (2 month intensive phase: isoniazid, 
rifampicin, ethambutol and pyrazinamide, and a 4 month continuation phase: isoniazid and 
rifampicin) until treatment failure is noted.  Similarly, retreatment cases with undiagnosed MDR-TB 
would receive regimen 2 (2 month intensive phase: isoniazid, rifampicin, ethambutol, pyrazinamide 
and streptomycin, and 4 month continuation phase: isoniazid and rifampicin) until the diagnosis of 
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MDR-TB is made.  In both instances, this deficient treatment regimen was given thereby increasing 
the risk of amplification of resistance.  Furthermore, the prolonged infectious period will perpetuate 
the drug resistant TB epidemic through transmission to close contacts.  The amplification of 
resistance during inadequate treatment has been illustrated by two recent publications (Calver et 
al., 2010; Pillay and Sturm, 2007).  The study by Calver et al. demonstrated the emergence of 
ethambutol, pyrazinamide and ofloxacin resistance in a well-functioning TB control program as a 
consequence of delayed diagnostics and an inadequate treatment regimen.  This occurred in a 
setting where treatment was hospital-based and adherence was excellent, a disturbing picture when 
compared to the rest of the country where adherence is much less likely.  The extent to which 
amplification of resistance has occurred in South Africa has been illustrated by another study which 
documented that approximately 20% of MDR-TB cases also displayed resistance to ethambutol in 
2006 (Johnson et al., 2006a).  Subsequently, a follow up study showed that more than 50% of MDR-
TB cases had isolates which harbored mutations in the embB gene (which are known to confer 
ethambutol resistance) (Hoek et al., 2009).  These findings are in stark contrast with routine DST 
data as well as surveillance data which suggested that ethambutol resistance was rare (Weyer K, 
2001).  This may be explained by the technical difficulties associated with culture-based ethambutol 
resistance testing.  Similarly, DST for pyrazinamide is technically challenging and is not routinely 
done in South Africa.  For this reason the extent of pyrazinamide resistance is largely unknown and 
was assumed to be rare.  Two recent molecular epidemiological studies confirm that pyrazinamide 
resistance is strongly associated with MDR-TB (Louw et al., 2006; Mphahlele et al., 2008).  In both 
studies, more than 50% of MDR-TB isolates harbored mutations in the pncA gene known to confer 
pyrazinamide resistance.  Together, this suggests that at least 50% of MDR-TB cases have resistance 
to ethambutol and/or pyrazinamide.  This will undoubtedly have impacted significantly on the 
effectiveness of MDR-TB treatment in South Africa over the past few years.  
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XDR-TB in South Africa    
The identification in 2006 of XDR-TB in Tugela Ferry, KwaZulu-Natal, South Africa, highlighted the 
inadequacies of the National TB Control program and emphasized the importance of infection 
control (VanRie and Enarson, 2006).  In that study, 53 cases of XDR-TB were diagnosed between 
January 2005 and March 2006.  The median time to death was 16 days from collection of initial 
sputum specimen (Gandhi et al., 2006).  Genotyping suggested an outbreak, raising fears of the 
spread of a “super bug” which primarily infected HIV infected individuals.  However, a subsequent 
study demonstrated that country-wide, 6% of MDR-TB cases had XDR-TB (Mlambo et al., 2008), that 
strains outside KwaZulu-Natal differed from the Tugela Ferry outbreak and that they were largely 
associated with acquisition given that unique spoligotype patterns were found in XDR-TB isolates 
from different geographical regions (Mlambo et al., 2008).  Genotyping of XDR-TB isolates cultured 
from patients resident in the Western Cape showed a strong association with the Beijing R220 
cluster and the atypical Beijing cluster 86 suggesting ongoing transmission (Streicher et al.  
unpublished data).  DNA sequencing of the inhA promoter, katG, rpoB, embB and pncA genes 
(conferring resistance to isoniazid, rifampicin, ethambutol and pyrazinamide) confirmed clonality.  
However, sequencing of the rrs- and gyrA genes demonstrated that resistance to amikacin and 
ofloxacin, respectively, had been acquired on a number of different occasions.  This suggests that 
poor management of circulating MDR-TB strains was one of the main reasons for the emergence of 
XDR-TB in the Western Cape (Dheda et al., 2010).  The identification of the atypical Beijing cluster 86 
strain (originally identified in the Eastern Cape (Strauss et al., 2008)) suggests migration of patients 
to the Western Cape as this strain was only rarely found in MDR-TB cases in that province (Hanekom 
et al., 2007).  Unpublished genotypic data shows that the Beijing R220 cluster and atypical Beijing 
cluster 86 accounts for 35% and 55% of XDR-TB cases in the Western Cape, while the atypical Beijing 
cluster 86 accounts for >90% of all XDR-TB cases in the Eastern Cape (Tait et al. unpublished data).  
DNA sequencing of the inhA promoter, katG, rpoB, embB, pncA, rrs and gyrA genes identified 
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mutations causing resistance to isoniazid, ethionamide, rifampicin, ethambutol, pyrazinamide, 
streptomycin, amikacin, capreomycin and ofloxacin, suggesting the emergence of totally drug 
resistant (TDR)-TB.  DST for terizidone/cycloserine and p-aminosalicylic acid has not been done.  This 
in part may explain the high mortality and low culture conversion rates reported for XDR-TB in the 
Eastern Cape (Kvasnovsky et al., 2011). 
 
Table 4. 2010 treatment guidelines of MDR-TB and XDR-TB (adapted from 
http://dev.tbsouthafrica.org/Documents/ACSM/TB_job_aids_10_08.pdf).  









Kanamycin (IM)   Capreomycin (IM)  
Ethionamide Ethionamide  Ethionamide Ethionamide 
Pyrazinamide Pyrazinamide    
   p-aminosalicylic acid p-aminosalicylic acid 











Treatment guidelines for MDR-TB and XDR-TB  
In 2010 the Department of Health released new guidelines for the treatment of MDR-TB and XDR-TB 
(Table 4).  Accordingly, ethambutol was replaced by terizidone for the treatment of MDR-TB, while 
capreomycin replaced amikacin/kanamycin, p-aminosalicylic acid replaced pyrazinamde, and 
moxifloxacin replaced ofloxacin for the treatment of XDR-TB.  These changes were implemented 
based on the assumption that both capreomycin and p-aminosalicylic acid have not been used 
extensively in South Africa and therefore resistance to these drugs should be rare.  However, it is 
unclear whether recent molecular epidemiological data was considered when this decision was 
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made, as a recent study in Korea has conclusively demonstrated cross-resistance between the 
aminoglycosides (amikacin and kanamycin) and capreomycin (Via et al., 2010).  In an attempt to 
replicate this finding we have sequenced the rrs gene from clinical isolates which demonstrated both 
susceptibility and resistance to amikacin.  Susceptibility testing in MGIT 960 medium showed that 
the A1401G rrs mutation was associated with high level amikacin resistance (>20µg/ml) and 
resistance to capreomycin (5 µg/ml) (Sirgel et al.  submitted).  This is double the critical 
concentration recommended by the WHO for DST in MGIT 960 media implying a laboratory 
diagnosis of capreomycin resistance (World Health Organization, 2008).  This raises concern as to 
whether patient isolates which show resistance to amikacin will benefit from a regimen which 
includes capreomycin.  Clinical trials are desperately needed to determine the therapeutic value of 
capreomycin, especially since capreomycin may lead to adverse events (Dheda et al., 2010).  
The inclusion of moxifloxacin in the treatment regimen for XDR-TB was informed by improved 
treatment outcomes in XDR-TB cases (Jacobson et al., 2010).  However, it is well known that cross-
resistance occurs between different fluoroquinolones (Devasia et al., 2009).  A study by (Kam et al., 
2006) showed a correlation between specific gyrA mutations and the level of ofloxacin and 
moxifloxacin resistance.  In that study the author suggested that patient isolates with mutations 
conferring a moxifloxacin minimum inhibitory concentration of ≤2µg/ml may benefit from the 
inclusion of moxifloxacin.  However, this is significantly higher than the critical concentration 
(0.25µg/ml) recommended by the WHO to differentiate between resistant and susceptible isolates 
(World Health Organization, 2008).  Provisional data from a study being conducted in South Africa 
confirmed the above findings – all isolates which harbor a mutation in the quinolone resistance 
determining region (QRDR) were resistant to 0.5µg/ml moxifloxacin (Sirgel et al.  unpublished data).  
Again, it will be important to quantify the benefit of including moxifloxacin in the treatment regimen 
for XDR-TB given that these isolates are resistant to fluoroquinolones according to WHO definitions.  
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A further concern about the efficacy of these treatment guidelines has been highlighted (Hoek et al., 
2009; Müller et al., 2011).  This regimen may be weakened by previously unsuspected cross-
resistance.  A number of studies have demonstrated a positive correlation between inhA promoter 
mutations and high level ethionamide resistance (50 to 100 µg/ml) (Abe et al., 2008; Baulard et al., 
2000; Morlock et al., 2003).  The implementation of genetic-based DST in the Western Cape Province 
of South Africa demonstrated that 58.5% of MDR-TB isolates harbored mutations in the inhA 
promoter using the MTBDRplus line probe assay (Barnard et al., 2008).  More recently, DNA 
sequencing showed that in the Western and Eastern Cape Provinces, respectively, 59% and 71% of 
all MDR-TB isolates and 86% and 92% of all XDR-TB isolates harbored an inhA promoter mutation 
(Müller et al., 2011).  This implies that in the Western and Eastern Cape Provinces, treatment of 
MDR-TB with a regimen containing ethionamide against a background of Mycobacterium 
tuberculosis strains with resistance to isoniazid, rifampicin, ethambutol, pyrazinamide and 
ethionamide may enhance the risk of the emergence of XDR-TB.  In fact, the strong association 
observed between inhA promoter mutations and XDR-TB noted in both provinces raises the 
possibility that in these settings, strains with an inhA promoter mutation have been selected to 
become XDR-TB due to the cross-resistance conferred by this mutation.  Thus, the presence of an 
inhA promoter mutation may represent a gateway to the evolution of XDR-TB (Müller et al., 2011).  
Moreover, the predominance of certain transmitted strain groups causing the majority of the MDR-
TB cases in these settings and characteristically harboring inhA promoter mutations will not be 
reduced by the newly implemented standardized treatment regimen for MDR-TB.  
A central step in the emergence of XDR-TB is the acquisition of fluoroquinolone resistance.  The 
reasons for the emergence of resistance to these anti-TB drugs is as yet unknown but is of 
considerable concern, as fluoroquinolones are the backbone of the current MDR-TB treatment 
regimen in South Africa.  A study from Uzbekistan showed the development of ofloxacin resistance 
under well-controlled conditions and suggested that an association between pre-existing second-line 
drug resistance and a severe clinical condition (at baseline) was a risk factor for the development of 
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ofloxacin resistance (Cox et al., 2008).  Similar findings were recently reported in a mine setting in 
South Africa (Calver et al., 2010).  As mentioned above, treatment of MDR-TB in South Africa 
included (until recently) a fluoroquinolone (mostly ofloxacin), an aminoglycoside, pyrazinamide, 
ethambutol or cycloserine, and ethionamide.  Considering the frequently observed resistance to 
pyrazinamide, ethambutol and cross-resistance conferred to ethionamide by the inhA promoter 
mutation, one explanation for the emergence of ofloxacin resistance could be the inadvertent use of 
ofloxacin mono-therapy during the continuation phase of second-line treatment when 
aminoglycosides are removed from the treatment regimen (Hoek et al., 2009).  This implies that 
highly resistant and transmissible forms of M. tuberculosis may develop even under wel- controlled 
conditions with stringent adherence.  This may have significant implications for MDR-TB treatment 




The majority of MDR-TB cases in South Africa are probably a result of the poor programmatic 
treatment of specific and efficiently transmitting MDR strains.  The high incidence of TB and MDR-
TB, low treatment and cure rates and the use of empiric regimens in the context of delayed DST are 
fuelling the continual dissemination and amplification of resistance, thus, perpetuating the 
emergence of XDR-TB.  If the molecular epidemiology results are correct then treatment regimen 
options for XDR-TB are seriously curtailed.  In certain patients only two of the five drugs will be 
active which may reflect currently observed treatment outcomes.  This means that if we continue to 
treat XDR-TB patients with inadequate regimens we will probably generate pan-resistant-TB.  
Anecdotal evidence from clinicians treating these patients seems to suggest that we are already 
entering a stage of non-treatable tuberculosis disease or “TDR-TB” (“totally drug resistant TB”).  At 
this rate, the discovery, evaluation and registration of new classes of anti-TB drugs will not be able to 
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keep up with the organism’s ability to subvert our uncoordinated attacks.  Thus, it is imperative that 
strategies are developed to prevent the amplification of drug resistance.   Ideally, this can be 
achieved by only initiating MDR-TB treatment once the spectrum of drug resistance makers has been 
identified.  However, practically this may not be achievable as patients with HIV co-infection will 
often require an immediate intervention to lower the risk of mortality.  This emphasizes the need for 
the development of rapid diagnostics which can immediately guide treatment.  The WHO 
recommended genetic based tests represent an important step forward in reducing the time to 
diagnosis and concomitantly enhancing the sensitivity of diagnosis (WHO, 2010b; WHO media report 
et al., 2008). However, these tests currently only target first-line anti-TB drugs and thus cannot guide 
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Abstract 
South Africa is ranked 4th among the high burden MDR-TB countries in the world.  Recent statistics 
suggest that the current National TB Control Program is unable to curb the emergence and spread of 
this difficult to treat epidemic.  Numerous factors have contributed to the perpetuation of the MDR-
TB epidemic in South Africa.  Many of which are errors, which in hindsight and with more modern 
technology could have been avoided.  It is therefore essential that we learn from these mistakes and 
use current knowledge to design diagnostic algorithms and treatment guidelines that prevent 
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Introduction 
Recent statistics released by the World Health Organization (WHO) have raised concern about the 
ever increasing global drug resistant tuberculosis (TB) epidemic.  It is now estimated that 440 000 
cases of multi drug resistant (MDR)-TB (resistant to at least isoniazid and rifampicin) were diagnosed 
in 2008.1  Of these approximately 40 000 had extensively drug resistant (XDR)-TB (MDR-TB with 
additional resistance to a fluoroquinolone and one of the injectables kanamycin, amikacin or 
capreomycin2).3  By January 2010 XDR-TB cases had been reported in 58 countries.1  South Africa is 
ranked as a high burden MDR-TB country with an estimated 13000 cases being diagnosed annually.1  
It is calculated that approximately six percent of these cases will be subsequently diagnosed with 
XDR-TB.  Cure rates for MDR-TB are of the order of 49%4 in South Africa, while treatment outcome 
for XDR-TB is exceptionally poor as demonstrated by the high mortality rate among human 
immunodeficiency virus (HIV) co-infected individuals in KZN.5  Similarly, culture conversion rates for 
XDR-TB cases from the Western Cape, Eastern Cape and Gauteng provinces were less than 19% 
among HIV infected and uninfected patients.6  These statistics are significantly worsened if we 
consider that only 8200 of the projected 13000 patients were diagnosed with MDR-TB or XDR-TB by 
the National Health Laboratory Service in 2008 – suggesting a case detection rate of 63% (National 
Health Laboratory Service (NHLS) annual report 2010).  More worrying is the fact that only 50% of 
diagnosed cases were placed on treatment.  Furthermore, analysis of the NHLS annual report 
suggests that the drug resistant TB epidemic has increased from 3200 detected cases in 2003 to 
8200 detected cases in 2008.  This trend is supported by a recent molecular epidemiological study 
conducted in the Western Cape which estimated that the doubling time for MDR-TB was 4 years.7  
Even more alarming is the fact that 42% of the increase was due to a single Beijing genotype with a 
doubling time of 2.38 years.7  This implies extensive transmission of MDR-TB probably due to 
diagnostic delay, thereby emphasizing the need for rapid diagnostics and comprehensive contact 
tracing.  It has been estimated that treatment of MDR-TB cases consumes nearly 70% of the National 
Tuberculosis Program budget allocated to fight the entire TB epidemic in South Africa.8  Thus, 
valuable resources are directed away from combating the drug susceptible TB epidemic which has 
now reached alarming proportions with an estimated 500,000 cases being diagnosed each year in 
South Africa.3    
The above statistics suggest that the current TB control strategy is unable to curb the emergence 
and spread of MDR-TB, despite implementation of the DOTS program in 1996.  Drug resistance 
surveillance studies in South Africa have in the past quantified the relative contribution of resistance 
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in new patients (transmitted) and resistance in previously treated patients (acquired) with the view 
to direct policy to most effectively tackle the drug resistance TB epidemic.9-11  These surveys have 
highlighted a significant association between retreatment and drug resistance, thereby suggesting 
that such patients acquired resistance.  As an example, in South Africa, the proportion of MDR-TB in 
all new cases is estimated at 1.8%, while among previously treated cases it goes up to 6.7%.3  The 
observation is explained by the premise that drug resistance develops spontaneously and that prior 
treatment may select for the resistant population such that a subsequent diagnosis will lead to a 
classification of resistant disease.  This conclusion may also be based on the prior understanding that 
drug resistant strains are attenuated and thus less likely to transmit.12  However, a re-examination of 
the surveillance data clearly showed that although the percentage was lower in new cases, the vast 
majority of MDR-TB cases had primary MDR-TB in South Africa (8238 new cases vs 5795 retreatment 
cases) confirming that MDR-TB is also efficiently transmitted.3  This together with molecular 
epidemiological data from other settings demonstrates that the long standing dogma that drug 
resistant strains are less virulent was largely incorrect.13;14  These findings have important 
implications for the way that health-care providers perceive their patients. In most instances in 
South Africa, patients with MDR-TB were infected with an MDR-TB strain through transmission and 
therefore the patients should not be blamed for having drug resistant TB (legacy of the dogma that 
drug resistant TB is primarily acquired).  In fact greater support is needed to ensure compliance 
during the prolonged treatment period.  Concerns about the lack of patient support from health-
care workers in South Africa have been stated and it has been suggested that this may in part 
account for treatment failure in MDR-TB patients.15 
The strong association between retreatment and drug resistance has informed the diagnostic policy 
to be targeted towards high risk patients (retreatment cases, treatment failure cases and contacts of 
drug resistant cases).  This was largely a cost saving strategy which has had a significant impact on 
amplification of drug resistance.  Given our knowledge that drug resistance is efficiently transmitted 
in South Africa, new cases with undiagnosed/unsuspected MDR-TB will receive regimen 1 treatment 
(2 month intensive phase: isoniazid, rifampicin, ethambutol and pyrazinamide, and  4 month 
continuation phase: isoniazid and rifampicin) until treatment failure is noted. Similarly, retreatment 
cases with undiagnosed MDR-TB will receive regimen 2 (2 month intensive phase: isoniazid, 
rifampicin, ethambutol, pyrazinamide and streptomycin, and 4 month continuation phase: isoniazid 
and rifampicin) until the diagnosis of MDR-TB is made.  In both instances, a weak treatment regimen 
was given thereby increasing the risk of amplification of resistance.  Furthermore, the prolonged 
infectious period will perpetuate the drug resistant TB epidemic through transmission to close 
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contacts.  The amplification of resistance during treatment has been illustrated by two recent 
publications.16;17  The study by Calver et al. illustrated the emergence of ethambutol, pyrazinamide 
and ofloxacin resistance in a well-functioning TB control program as a consequence of delayed 
diagnostics and an inadequate treatment regimen.  This occurred in a setting where treatment was 
hospital-based and adherence was excellent, a disturbing picture when compared to the rest of the 
country where adherence is much less stringent.  The extent to which amplification of resistance has 
occurred in South Africa has been illustrated by another study which documented that 
approximately 20% of MDR-TB cases also displayed resistance to ethambutol in 2006.18  
Subsequently, a follow up study showed that more than 50% of MDR-TB cases had isolates which 
harbored mutations in the embB gene (which are known to confer ethambutol resistance).19  These 
findings are in stark contrast with routine drug susceptibility testing (DST) data as well as 
surveillance data which suggested that ethambutol resistance was rare.11  This may be explained by 
the technical difficulties associated with culture-based ethambutol resistance testing.  Similarly, DST 
for pyrazinamide is technically challenging and is not routinely done in South Africa.  For this reason 
the extent of pyrazinamide resistance is largely unknown and was assumed to be rare.  Two recent 
molecular epidemiological studies confirm that pyrazinamide is strongly associated with MDR-TB.20;21  
In both studies, more than 50% of MDR-TB isolates harbored mutations in the pncA gene known to 
confer pyrazinamide resistance.  Together this suggests that at least 50% of MDR-TB cases have 
resistance to ethambutol and/or pyrazinamide.  This will undoubtedly have significantly impacted on 
the effectiveness of MDR-TB treatment in South Africa over the past few years.  In 2002, 
standardized MDR-TB treatment was implemented in order to combat the emergence and spread of 
drug resistant disease.  The standardized regimen for MDR-TB treatment consisted of five anti-TB 
drugs; three second-line drugs (amikacin/kanamycin, ofloxacin and ethionamide) and two first-line 
drugs (ethambutol and pyrazinamide – included because resistance was thought to be rare).  This 
regimen has been in use in South Africa from 2002 to 2010.  In view of the above molecular 
epidemiological data it must be concluded that this was a very weak regimen as a significant 
proportion of these patients would have only received three effective drugs during the intensive 
phase (kanamycin/amikacin, ofloxacin and ethionamide) and only 2 drugs (ofloxacin and 
ethionamide) during the continuation phase of therapy.  Knowledge about the resistance to these 
three drugs remained sparse as routine DST was curtailed to testing for isoniazid, rifampicin and 
ethambutol during the period 2002 to 2007.  Only after the disclosure of the outbreak of XDR-TB in 
20065 was routine DST expanded to include amikacin/kanamycin, ofloxacin and ethionamide.  
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In response to the technical difficulties associated with phenotypic testing for ethambutol, the WHO 
recommended a revised MDR-TB treatment regimen.22  They advocated the use of at least 4 active 
drugs.  Pyrazinamide was only included in the regimen if the culture was susceptible to this drug, but 
was not counted as one of the 4 effective anti-TB drugs.  Subsequently, the National TB Control 
Program issued a draft policy guideline for the treatment of MDR-TB.  This was criticized as again 
being a weak regimen with the risk of amplification of drug resistance.19  The draft guidelines 
proposed a treatment regimen based on the outcome of ethambutol DST.  If an isolate was 
susceptible to ethambutol, it was included as the 5th drug in the regimen (disregarding the 
inaccuracy of DST for ethambutol), whereas if the results of DST for ethambutol showed resistance, 
it was replaced with terizidone/cycloserine.  Pyrazinamide was included as one of the 4 effective 
drugs. 
In 2010 new guidelines for the standardized treatment of MDR-TB and XDR-TB were issued by the 
Department of Health in South Africa.  In the guidelines for MDR-TB treatment, ethambutol was 
replaced by terizidone/cycloserine (irrespective of the DST results, however, pyrazinamide was 
retained as one of the five drugs thereby fulfilling the criteria as stipulated by the WHO - at least 4 
effective drugs – usually kanamycin/amikacin, ofloxacin, terizidone/cycloserine and ethionamide).  
However, this regimen may be weakened by previously unsuspected cross-resistance.  Recent 
studies have demonstrated a positive correlation between inhA promoter mutations and high level 
ethionamide resistance (50 to 100 μg/ml).23-25  The implementation of genetic-based DST in the 
Western Cape Province of South Africa demonstrated that 58.5% of MDR-TB isolates harbored 
mutations in the inhA gene using the MTBDRplus line probe assay.26  More recently, DNA sequencing 
showed that in the Western and Eastern Cape Provinces, respectively, 59% and 71% of all MDR-TB 
isolates and 86 and 92% of all XDR-TB isolates harbored an inhA promoter mutation.27  This implies 
that in the Western and Eastern Cape Provinces treatment of MDR-TB with a regimen containing 
ethionamide in a background of Mycobacterium tuberculosis strains with resistance to isoniazid, 
rifampicin, ethambutol, pyrazinamide and ethionamide may enhance the risk of the emergence of 
XDR-TB.  In fact, the strong association observed between inhA promoter mutations and XDR-TB 
noted in both provinces raises the possibility that in these settings, strains with an inhA promoter 
mutation have been selected to become XDR-TB due to cross-resistance conferred by this mutation.  
Thus, the presence of an inhA promoter mutation is a gateway to the evolution of XDR-TB.27  This 
hypothesis implies that in these two provinces XDR-TB is emerging.  Moreover, the predominance of 
certain transmitted strain groups causing the majority of the MDR-TB cases in these settings and 
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characteristically harboring inhA promoter mutations will not be reduced by the newly implemented 
standardized treatment regimen for MDR-TB.  
Genotypic analysis of MDR-TB and XDR-TB strains by DNA fingerprinting and DNA sequencing of 
target genes conferring resistance clearly demonstrates that MDR-TB is transmitted16;28-31 and that in 
this early stage of the XDR-TB epidemic, XDR-TB emerges from the transmitted MDR-TB strains 
through acquisition, probably as a result of inadequate treatment as described above (unpublished 
results).  In the Western Cape Province, strains from the Beijing cluster R220,7 the atypical Beijing 
family31 and the LCC family32 mostly contribute to the transmission of MDR-TB while the atypical 
Beijing family accounts for most of the transmission of MDR-TB in the Eastern Cape Province.  This 
differs from the KwaZulu-Natal Province of South Africa where it has been shown that the 
KZN/LAM4/F15 strain is primarily transmitted.5;33  In support of the notion of emergence of 
resistance, we have documented the evolution of ofloxacin resistance during treatment 
(unpublished results).  The reasons for the emergence of resistance to this anti-TB drug is as yet 
unknown but is of considerable concern as ofloxacin is the backbone of the current MDR-TB 
treatment regimen in South Africa.  A study from Uzbekistan showed the development of ofloxacin 
resistance under well controlled conditions and suggested that an association between pre-existing 
second-line drug resistance and a severe clinical condition (at baseline) was a risk factor for the 
development of ofloxacin resistance.34  Similar findings were recently reported in a mine setting in 
South Africa.17  As mentioned above, treatment of MDR-TB in South Africa included (until recently) a 
fluoroquinolone (mostly ofloxacin), an aminoglycoside, pyrazinamide, ethambutol or cycloserine, 
and ethionamide.  Considering the frequently observed resistance to pyrazinamide, ethambutol and 
cross-resistance conferred to ethionamide by the inhA promoter mutation, one explanation for the 
emergence of ofloxacin resistance could be the inadvertent use of ofloxacin mono-therapy during 
the continuation phase of second-line treatment.19  This implies that highly resistant and 
transmissible forms of M. tuberculosis may develop even under well controlled conditions with 
stringent adherence.  This may have significant implications for MDR-TB treatment on a global scale, 
especially in settings where patient management may be suboptimal.34  
The 2010 Department of Health guidelines attempted to improve the treatment outcome of XDR-TB.  
Accordingly, capreomycin replaced amikacin/kanamycin, p-aminosalicylic acid (PAS) replaced 
pyrazinamde, and moxifloxacin replaced ofloxacin.  These changes have been implemented based on 
the assumption that both capreomycin and PAS have not been used extensively in South Africa and 
therefore resistance to these drugs should be rare.  However, it is unclear whether recent molecular 
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epidemiological data has been adequately considered when this decision was made, as a recent 
study in Korea has conclusively demonstrated cross-resistance between the aminoglycosides 
(amikacin and kanamycin) and capreomycin.35  In an attempt to replicate this finding we have 
sequenced the rrs gene from clinical isolates which demonstrated both susceptibility and resistance 
to amikacin.  Susceptibility testing in MGIT 960 media showed that in all instances the A1401G rrs 
mutation correlated with high level amikacin resistance (>20μg/ml) (unpublished results).  Similarly 
all amikacin resistant isolates displayed phenotypic resistance to capreomycin at a concentration of 
5μg/ml (unpublished results), which is twice the critical concentration recommended by the WHO 
for DST in MGIT 960 media.36  According to this criterion a laboratory diagnosis of resistant to 
capreomycin would be given.  This raises concern as to whether patient isolates which show 
resistance to amikacin will benefit from a regimen which includes capreomycin.  Clinical trials are 
desperately needed to determine the therapeutic value of capreomycin, especially since 
capreomycin may lead to adverse events.6  
The inclusion of moxifloxacin in the treatment regimen for XDR-TB was informed by improved 
treatment outcomes in XDR-TB cases.37  However, it is well known that cross-resistance occurs 
between different fluoroquinolones.38  A study by Kam in 2006 showed a correlation between 
specific gyrA mutations and the level of ofloxacin and moxifloxacin resistance.39  The author 
suggested that patient isolates with mutations conferring a moxifloxacin minimum inhibitory 
concentration of ≤2μg/ml may benefit from the inclusion of moxifloxacin.  However, this is 
significantly higher than the current critical concentration recommended by the WHO to 
differentiate between resistant and susceptible isolates.36  Provisional data from a study being 
conducted in South Africa confirmed the above findings – all isolates which harbor a mutation in the 
quinolone resistance determining region (QRDR) were resistant to 0.5μg/ml moxifloxacin.  Again, it 
will be important to quantify the benefit of including moxifloxacin in the treatment regimen for XDR-
TB given that these isolates are resistant to fluoroquinolones according to WHO definitions.  
If the molecular epidemiology results are correct then treatment regimen options for XDR-TB are 
seriously curtailed.  In certain patients only two of the five drugs will be active which may reflect 
currently observed treatment outcomes.  This means that if we continue to treat XDR-TB patients 
with weak regimens we will probably generate pandrug-resistant-TB - or have we already reached 
this point?  Anecdotal evidence from clinicians treating these patients seem to suggest that we are 
already entering a stage of non-treatable tuberculosis disease or “TDR-TB” (“totally drug resistant 
TB”), only 12 years after observing the first documented XDR-TB case in South Africa.  At this rate, 
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the discovery, evaluation and registration of new classes of anti-TB drugs will not be able to keep up 
with the organism’s ability to subvert our uncoordinated attacks.  It is therefore important to acquire 
knowledge that can be translated into practical applications to formulate, implement and review 
policies and programs.  To achieve this goal, collaboration between clinicians, laboratories and 
researchers needs to be improved to establish specialised scientific knowledge and medical 
expertise.  A comedy of errors typically culminates in a happy resolution of the thematic conflict 
caused by the foolish mistakes of the characters in the play.  Whether this will hold true for drug 
resistant tuberculosis remains to be seen.  
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ABSTRACT 
Background and objectives: Multi-drug resistant (MDR) bacteria are a growing threat to global health. 
Studies focusing on single antibiotics have shown that drug resistance is often associated with a fitness 
cost in the absence of drug. However, little is known about the fitness cost associated with resistance 
to multiple antibiotics. 
Methodology: We used Mycobacterium smegmatis as a model for human tuberculosis (TB) and an in 
vitro competitive fitness assay to explore the combined fitness effects and interaction between 
mutations conferring resistance to rifampicin and ofloxacin; two of the most important first- and 
second-line anti-TB drugs, respectively. 
Results: We found that four out of 17 M. smegmatis mutants (24%) resistant to rifampicin and 
ofloxacin showed a statistically significantly higher or lower competitive fitness than expected when 
assuming a multiplicative model of fitness effects of each individual mutation. Moreover, six of the 17 
double drug-resistant mutants (35%) had a significantly higher fitness than at least one of the 
corresponding single drug-resistant mutants. The particular combinations of resistance mutations 
associated with no fitness deficit in M. smegmatis were the most frequent among 151 clinical isolates 
of MDR and extensively drug-resistant (XDR) M. tuberculosis from South Africa.  
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Conclusions and implications: Our results suggest that epistasis between drug resistance mutations 
in mycobacteria can lead to MDR strains with no fitness deficit, and that these strains are positively 
selected in settings with a high burden of drug-resistant TB. Taken together, our findings support a 
role for epistasis in the evolution and epidemiology of MDR- and XDR-TB.  
 
INTRODUCTION  
Epistasis refers to the phenomenon where the phenotypic effect of one mutation differs depending 
on the presence of another mutation (1). The importance of epistasis for our understanding of biology 
is increasingly recognized; it has been implicated in many processes, ranging from pathway 
organization, the evolution of sexual reproduction, mutational load, genomic complexity, to 
speciation and the origin of life (2). Moreover, recent studies have reported a role for epistasis in the 
evolution of antibiotic resistance (3–6). Multidrug-resistant (MDR) bacteria are emerging worldwide, 
in some cases leading to incurable disease. While new antibiotics are urgently needed, a better 
understanding of the forces that lead to the emergence of drug resistance would help prolong the 
lifespan of existing drugs. 
Studies in various bacterial species have shown that the acquisition of antibiotic resistance often 
imposes a physiological cost on the bacteria in absence of the drug (7–9). However, some drug-
resistance conferring mutations have been associated with low- or no fitness cost, and compensatory 
evolution can mitigate some of the initial fitness defects associated with particular drug resistance 
conferring mutations (10). Most of these studies have focused on resistance to a single drug. Given 
the public health threat posed by MDR bacteria, there is a need to understand the factors that 
influence the emergence of resistance to multiple drugs.  
Recent studies in model organisms have shown that mutations conferring resistance to different drugs 
can interact epistatically. A study in Pseudomonas aeruginosa found that the relative fitness of certain 
strains resistant to streptomycin and rifampicin (RIF) (4,6) was lower than expected based on the 
fitness of the corresponding single-resistant mutants. Similarly, a study in Escherichia coli (3) showed 
that strains resistant to two drugs can have a higher fitness than strains resistant to only one drug; a 
phenomenon referred to as ‘sign epistasis‘ (11). However, whether such epistatic interactions play 
any role in the emergence and spread of MDR bacteria in clinical settings has not been determined. 
Multi-drug resistance is a particular problem in human tuberculosis (TB) (12). Recent surveillance data 
showed the highest rates of resistance ever documented with some Eastern European countries 
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reporting up to 50% of TB cases as MDR (13). In M. tuberculosis, the main causative agent of human 
TB, drug resistance is chromosomally encoded and results from de novo acquisition of mutations in 
particular genes (14). These mutations are acquired sequentially, giving rise to MDR and extensively 
drug-resistant (XDR) strains (15,16). MDR-TB is defined as strains resistant to at least RIF and isoniazid, 
the two most important first-line anti-TB drugs. XDR-TB is caused by strains that, in addition to being 
MDR, are also resistant to ofloxacin (OFX), or any other fluoroquinolone, and to at least one of the 
injectable second-line drugs (17).  
In this study, we used Mycobacterium smegmatis as a model for M. tuberculosis to investigate putative 
epistatic interactions between mutations conferring resistance to RIF and OFX, two of the most widely 
used first- and second-line anti-TB drugs, respectively. M. smegmatis is used widely in the TB research 
community because it is non-pathogenic, in contrast to M. tuberculosis, which requires biosafety-level 
3 containment. Moreover, M. smegmatis forms visible colonies in 2-3 days, compared to 3-4 weeks 
for M. tuberculosis. We then compared our experimental data generated with M. smegmatis to the 
clinical frequency of particular combinations of RIF- and OFX- resistance-conferring mutations in a 
panel of MDR and XDR M. tuberculosis clinical strains from South Africa. 
 
MATERIAL AND METHODS 
Bacterial strains and growing conditions   
All strains used for the competitive fitness experiments were derived from the wild-type 
Mycobacterium smegmatis strain mc2155. Bacteria were grown in Middlebrook 7H9 broth 
supplemented with ADC or on Middlebrook 7H11 agar plates supplemented with OADC. The culture 
tubes were incubated in standard conditions and the optical density (OD600) was recorded daily to 
measure the growth. 
 
Selection of single and double-resistant M. smegmatis mutants  
Independent RIF- and OFX- resistant M. smegmatis single mutants were isolated using an approach 
similar to the classic fluctuation tests of Luria and Delbrück (1943) to ensure that the mutants selected 
arise from independent mutational events.  A starting culture of M. smegmatis mc2155 was prepared 
from wild-type M. smegmatis and adjusted to approximately 300 bacilli per ml (OD600 ~ 0.01). 10ml of 
culture was transferred into 14 individual 50ml falcon tubes. When the bacteria reached end of log-
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phase (OD600 ~ 3.00), the cultures were concentrated by centrifugation at 1500rpm for 5 minutes, the 
supernatant discarded, and the bacteria resuspended in 500μl 7H9 media. This concentrated bacterial 
culture was plated onto Middlebrook 7H11 media containing 200μg RIF per ml for the isolation of RIF-
resistant colonies, and 2 μg OFX per ml for the isolation of OFX-resistant colonies. The plates were 
incubated for 3-5 days at 37˚C until colonies became visible. One colony from each plate was picked 
and sub-cultured in antibiotic free Middelbrook 7H9 broth. For the isolation of double-resistant 
mutants, different rpoB- and gyrA-mutants were used to generate different combinations of 
mutations conferring resistance to both antibiotics. Some double-resistant mutants were selected by 
plating on Middlebrook 7H11-OADC media containing both 200µg/ml of RIF and 2µg/ml of OFX. 
 
Mutation identification  
The main target genes for resistance to RIF and OFX are rpoB and gyrA, respectively. To detect the 
relevant drug resistance-conferring mutations, the rpoB and gyrA genes were amplified by PCR using 
DNA extracted from the single- and the double-resistant mutants. The primers used to amplify the 
portion of the rpoB gene encoding the main set of mutations conferring resistance to RIF were: 5’ GGA 
CGT GGA GGC GAT CAC ACC 3’. For amplification of the gyrA gene, the primers 5’ CAT GAG CGT GAT 
CGT GGG CCG and 5’ CAG AAC CGT GGG CTC CTG CAC 3’ were used. The same primers were used for 
direct DNA sequencing from the PCR product.   
 
Fitness assay and calculation of fitness ratio  
The rpoB-, gyrA- and rpoB-gyrA-mutants were competed against the wild-type antibiotic-susceptible 
strain in antibiotic-free Middlebrook 7H9 media. A total of 100 CFU of bacteria per ml were inoculated 
in 10ml of Middlebrook 7H9 media in a 1:1 ratio. For each wild type-mutant pair, between four and 
eight replicate competition assays were performed. At the start of the experiment (t=0 hours), 50μl 
from each competition culture was plated on both antibiotic-free- and antibiotic-containing– 
Middlebrook 7H11 plates in triplicates to estimate the baseline CFU counts. The competition cultures 
were incubated at standard conditions on a shaking incubator at 100rpm, and the optical densities 
(OD600) were recorded daily. After 72 hours, the same competition cultures were diluted 105 to 106-
fold and plated on both selective and non-selective Middlebrook 7H11 media to obtain the endpoint 
CFU counts. For both competing strains, the Malthusian parameters were calculated by taking the 
natural log of the endpoint CFU over the baseline CFU (7). The mean CFU count of the three replicates 
was used for the calculation of the relative competitive fitness. This gave the Malthusian parameters 
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(ms and mr) for both strains, which correspond to the number of doublings (generations) that each 
strain went through during the observed time period. Finally, the relative fitness of the drug-resistant 
strain relative to the wild-type was determined using: Wrs = mr/ ms (7). Shapiro-Wilk test evidenced the 
normality of the fitness data (p=0.3). Student’s t-test was used to detect differences in the mean 
fitness and the limit for statistical significance was set at p=0.05. Test statistics and estimates  
were based on 1000 bootstrap replicates. Statistical analysis was performed with STATA SE/10. 
Measuring Epistasis  
To explore putative genetic interactions between drug resistance mutations, pairwise epistasis (ε) was 
measured assuming a multiplicative model in which ε=WABWab-WAbWaB, where Wab is the fitness of the 
clone carrying alleles a and b, and capital letters represent the wild-type sensitive alleles (3). Following 
this model, values of ε > 0.0 indicate that the fitness of the double-mutant is higher than expected 
based on the fitness values of the individual single mutants. Similarly, values of ε < 0.0 indicate that 
the fitness of the double-mutant is lower than expected based on the fitness values of the individual 
single-mutants. We tested the normality of the epistasis data with a Shapiro-Wilk test. To test if 
epistasis values were significantly different from zero, we used the error-propagation method 
described by Trindade et al. (3). We considered that alleles a and b showed significant epistasis 
whenever the calculated error was smaller than the average value of ε (Figure 3). 
An important type of epistasis is sign epistasis. Sign epistasis exists when a mutation is deleterious on 
some genetic backgrounds but beneficial on others (11). To detect the presence of sign epistasis from 
our experimental data, we performed pairwise comparisons between the fitness of each double-
resistant mutant and the corresponding single-resistant mutants using a one-sided bootstrap 
Student’s t-test with 1000 replicates (Figure 5). The combined p-values were obtained using Fisher’s 
method. 
 
Clinical frequency of rpoB- and gyrA mutation combination in M. tuberculosis 
A total of 151 clinical MDR- and XDR-TB M. tuberculosis isolates were included in this study. These 
were collected in the Eastern (N=99) and Western Cape (N=52) Provinces of South Africa between 
2008-2009 and 2001-2008, respectively. RIF and OFX resistance determining regions in the rpoB and 
gyrA genes were analysed using standardized PCR and sequencing (18,19). Amplification products 
were sequenced using an ABI 3130XL genetic analyzer, and the resulting chromatograms were 
Stellenbosch University  https://scholar.sun.ac.za
 213 
analysed using Chromas software. Only isolates harbouring a combination of resistance mutations in 
the rpoB and gyrA genes analyzed within our M. smegmatis study were included. 
 
RESULTS 
Fitness cost of single drug-resistant mutants 
We first determined the relative fitness of M. smegmatis mutants resistant to a single drug. To this 
end, we selected a series of spontaneous M. smegmatis mutants resistant to RIF or OFX. From the RIF-
selected mutants, we used five clones with rpoB mutations for further analysis (H526R; H526P; H526Y; 
S531W; S531L) (Table S1). These mutants were competed in vitro against their RIF-susceptible 
ancestor as described previously (7). We found that S531L, S531W and H526Y showed no difference 
in relative fitness compared to the ancestor (Figure 1A), while H526R and H526P showed a significantly 
lower relative fitness (Bootstrap p=0.02 and p < 0.01, respectively). Similar to previous work in M. 
tuberculosis (7), we found a strong correlation between fitness cost of rpoB mutations in M. 
smegmatis and the frequency of these mutations in clinical isolates of M. tuberculosis (Spearman Rank 
coefficient 0.9, p=0.04; Table S1). Individually, S531L and H526Y which showed no fitness cost in our 
M. smegmatis model are the most frequent RIF resistance-conferring mutations in clinical settings, 
whereas S526P, which had the lowest relative fitness of all mutants occurs only in 0.1% of clinical 
strains (Table S1). We found no correlation between the spontaneous mutation frequency of rpoB 
mutations and the clinical frequency of these mutations (Table S1). 
From the OFX-selected mutants, we selected four that carried distinct gyrA mutations for further 
analysis (D94G; G88C; D94N; D94Y). In vitro competition against the OFX-susceptible ancestor 
revealed that mutants carrying D94G and D94Y had no fitness defect, while D94N and G88C had a 
significantly lower relative fitness (Bootstrap p = 0.02 and p < 0.01, respectively) (Figure 1B). We 
compared our fitness measures with the frequency of gyrA mutations found in M. tuberculosis clinical 
isolates using data from a recently published review based on 1,220 OFX-resistant M. tuberculosis 
isolates (20) (Table S2). Similar to our findings with RIF-resistant mutants, we found that mutations at 
codon position 94 of gyrA, which showed overall the highest in vitro fitness in M. smegmatis, were 
the most common mutations in M. tuberculosis clinical strains. By contrast, gyrA G88C which had the 
lowest fitness is only rarely (1.6%) found in clinical settings (Table S2). In contrast to the rpoB 
mutations, mutations at codon position 94 of gyrA were also the most frequent during the in vitro 
selection (Table S2).  
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Evidence for epistasis between rpoB and gyrA mutations 
To test for possible epistatic interactions between mutations conferring RIF- and OFX- resistance, we 
selected for spontaneous mutants resistant to both drugs. These double-mutants harbouring a 
mutation in rpoB and gyrA were selected starting from the available single drug-resistant mutants. A 
total of 17 rpoB-gyrA double-mutants were generated out of the 20 possible combinations (Table S3). 
The relative fitness of the double-mutants was determined by standard competition assays against 
the pan-susceptible ancestor strain and compared to the fitness of the corresponding single-resistant 
mutants. We compared the observed fitness of each double-mutant to the expected fitness assuming 
no epistasis based on a multiplicative model (Figure 2, see Material and Methods for details). We 
found that in 11/17 (65%) of the double-mutants, the observed fitness was different from the 
expected, suggesting either negative or positive epistasis between particular RIF- and OFX resistance-
conferring mutations (Figure 2A). 
 
 
Figure 1. Relative fitness of M. smegmatis mutants resistant to a single drug compared to their pan-susceptible ancestor. 
Bars represent 95% confidence intervals. A. Relative fitness of rpoB single mutants resistant to RIF. B. Relative fitness of 
gyrA single mutants resistant to OFX 
 
To measure epistasis quantitatively, we measured pairwise epistasis (ε) between all the different 
single-mutant pairs we had fitness data for, assuming a multiplicative model (Table S4); positive and 
negative values of ε indicate positive or negative epistasis, respectively (3). Overall, the ε values across 
all mutant pairs followed a normal distribution (Shapiro-Wilk, p-value=0.062) with an average positive 
value of 0.027 (95% confidence interval -0.02, 0.08) (Table S4). Four out of 17 (24%) double-mutants  
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Figure 2. Evidence of epistasis between mutations conferring resistance to RIF and OFX. A. Relationship between observed 
and expected multiplicative fitness for the 17 double-resistant mutants (data point over/below the bar). The solid line 
represents the null hypothesis of multiplicative fitness effects. Deviations from this line arise as a consequence of epistatic 
fitness effects. B. Allelic combination analysed and the corresponding sign of epistasis. The grey squares correspond to 
the pairs of mutation showing statistically significant epistasis. 
 
 
Figure 3. Correlation between the average expected fitness and the strength of epistasis. Average epistasis was measured 
as deviation from a multiplicative model of double-resistant mutant fitness scores estimated by head-to-head competition 
in Middlebrook 7H9 broth. MFε: Minimum Fitness for ε. 
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showed statistically significant positive or negative epistasis between RIF- and OFX resistance-
conferring mutations. Moreover as shown in Figure 2B, these epistatic interactions were allele-
specific, showing differences in the sign (i.e. positive vs. negative) of the ε value depending on the 
specific amino acid change at a particular codon position. 
Theoretical and experimental evidence predicts a correlation between the average deleterious effect 
of a single mutation and the strength of epistasis (21–23). Hence, we tested whether this relationship 
holds for drug-resistant mycobacteria. In agreement with these predictions, we found a strong 
correlation between the expected fitness of our double-mutants and the strength of epistasis between 
the respective RIF- and OFX resistance-conferring mutations (R2=0.78; T-test, p<0.001) (Figure 3). 
However, this correlation was only observed above a particular threshold of expected fitness, which 
we refer to as “Minimal Fitness for epistasis” (MFε). Above MFε, epistasis tended to be positive when 
individual mutations were costly and negative when individual mutations were beneficial (21,23). 
Below MFε, the correlation was lost, likely because these data points were all derived from mutants 
carrying the G88C mutation in gyrA, which was associated with a high fitness defect. The correlation 
when all datapoints were included show no significance (R2=0.07; T-test, NS) 
 
 
Figure 4. Evidence for sign epistasis between mutations conferring resistance to RIF and OFX. Sign epistasis occurs when 
the fitness of the double-resistant mutant (pink bar) is greater than the fitness of at least one corresponding single-
resistant mutant [purple- (RIF) and blue- (OFX) bars]. The bars represent the standard deviation of the values. Double-
resistant mutants with a bootstrapped p-value<0.05 are highlighted with a star. 
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Evidence for sign epistasis in rpoB/gyrA double mutants 
Sign epistasis refers to the case where a particular mutation that is deleterious on its own is beneficial 
in the presence of another mutation (3). In the context of drug resistance, sign epistasis occurs when 
the fitness of the double-resistance mutant is higher than at least one of the corresponding single-
resistance mutants. We found that 6 out of 17 double-mutants (35%) showed statistically significant 
evidence of sign epistasis (Figure 4). In addition, the observed sign epistatis was allele specific, i.e. the 
epistasis effects varied according to the specific alleles of the same gene. For example, D94N in gyrA 
led to the conversion of the fitness sign in the S526P RIF-resistant background but not in the S531L 
RIF-resistant background (Figure 4). 
 
Role of epistasis in clinical XDR-TB 
Given the evidence for epistasis between RIF- and OFX resistance mutations in M. smegmatis, we 
investigated how fitness changes along the mutational pathway leading from MDR-TB to XDR-TB might 
be influenced by corresponding epistatic interactions in M. tuberculosis (Figure 5A). In the standard 
treatment protocols for TB (17), RIF is an essential part of the first-line regimen for drug-susceptible 
disease, and OFX is part of the second-line regimen when resistance against first-line drugs has 
developed. Thus, rpoB mutations are generally acquired first and gyrA mutations second. Following 
this trajectory, selection by RIF will occur first, and the RIF-resistant mutants that survive will exhibit 
heterogeneous fitness in the absence of the drug depending on their rpoB mutations (Figure 1) (7,24). 
At this point, MDR-TB has developed and second-line treatment is initiated. Selection for OFX 
resistance begins, but the fitness levels of the emerging double-mutants can still be positively or 
negatively affected depending on which gyrA mutation is acquired. Our M. smegmatis data showed 
that the gyrA D94G mutation was associated with improved fitness in all of the double-mutants, 
irrespective of the rpoB mutation (pink bars compared to purple bars in Figure 4). This was statistically 
significant in two of the five corresponding double-mutants tested. Hence, based on the most likely 
clinical scenario of moving from MDR- to XDR-TB (Figure 5A), we would expect the gyrA D94G 
mutation to be the most commonly found mutation in XDR-TB strains, and also to be found in 
combination with many different rpoB mutations. By contrast, we would expect gyrA G88C, which was 
consistently associated with negative epistasis in our M. smegmatis model (Figure 3, 4 and 5A) to show 
the opposite trend. To test these predictions, we analyzed 151 MDR-and XDR-TB clinical isolates from 
South Africa. Sequencing of the relevant genes revealed that 71/151 (47%) harbored gyrA D94G while 
G88C occurred only once (0.7%). Moreover gyrA D94G was the only mutation that occurred in 
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combination with all three rpoB mutations detected among these clinical dataset (Figure 5B). Taken 
together, our results show that experimental fitness data generated with M. smegmatis can be 
predictive of clinical TB. Moreover, these findings support a role for epistasis in the progression of M. 
tuberculosis from MDR to XDR. 
 
Figure 5. A. Mutational pathway leading to rpoB-gyrA double mutants when a patient undergoes standard TB treatment. 
RpoB mutations are generally acquired first, followed by gyrA mutations. The relative fitness of the various double-
resistant mutants is indicated as determined by in vitro competition using the M. smegmatis model.  wt - drug-susceptible 
wild-type strain; rpoB - point mutations in rpoB conferring RIF resistance; gyrA - point mutations in gyrA conferring OFX 
resistance B. Frequency of rpoB-gyrA mutation pairs found in 151 MDR- and XDR-TB clinical isolates from the Eastern Cape 
and Western Cape Provinces of South Africa.  
 
DISCUSSION 
In the present study, we used M. smegmatis as a model to show that epistasis can occur between 
mutations conferring resistance to RIF and OFX, which are two of the most important anti-TB drugs. 
Specifically, in several of the mutants resistant to both of these drugs, some of the mutations 
conferring resistance to one drug mitigated the negative fitness effects of some the mutations 
conferring resistance to the other drug (or vice-versa). Moreover, we found clear evidence of sign 
epistasis, showing that in some cases, the double-resistant mutants had a higher relative fitness than 
at least one of the corresponding single-resistant mutants. In the context of MDR, sign epistasis 
between different drug resistance-conferring mutations represent the worst case scenario; instead of 
accumulating fitness defects with each additional drug resistance, MDR strains manage to increase 
their relative fitness by acquiring additional drug resistance determinants. One limitation of our study 
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is that we cannot exclude the possibility that additional mutation(s) could have arisen during the 
selection of our mutants, which may compensate for the initial fitness defects associated with the 
individual resistance mutations. 
More work is needed to elucidate the mechanisms involved in the interaction between mutations in 
rpoB and gyrA. Yet, several features make such interactions biologically plausible. GyrA encodes one 
of the subunits of DNA gyrase which is involved in the introduction of negative supercoiling to double 
stranded DNA, thereby relaxing the positive supercoils that form during DNA replication (25). RpoB 
encodes part of the RNA polymerase and therefore important for the transcription of DNA to RNA 
(26).  Although these two pathways are separate (27,28), GyrA and RpoB are both involved in the 
fundamental flow from DNA to RNA. Intriguingly, Gupta et al. isolated an ‘RNA-polymerase-DNA 
gyrase complex’ in M. smegmatis that exhibited both DNA super-coiling and transcriptional activities. 
The authors also found that DNA gyrase inhibitors not only reduced DNA gyrase activity, but also 
reduced transcriptional activity indicating a role of DNA gyrase in transcription (29). Finally, it has been 
shown that during transcription, RNA polymerase introduces positive supercoiling ahead as it slides 
along its template DNA. This leads to a reduced accessibility as supercoiling increases, further 
supporting a potential role for DNA gyrase in transcription (25). 
Our study also showed that experimental data obtained from M. smegmatis is relevant for our 
understanding of clinical TB. Not only did we observe the same drug resistance-conferring mutations 
in M. smegmatis as routinely encountered in clinical strains of M. tuberculosis, but similar to previous 
studies, we found a good correlation for both RIF and OFX between the fitness cost observed in vitro 
in M. smegmatis mutants and the relative clinical frequency of the corresponding mutations in M. 
tuberculosis (20,24). Our M. smegmatis data showed particular relevance when focusing on MDR- and 
XDR-TB. Based on the most probable mutational pathway leading from MDR to XDR, our M. smegmatis 
fitness data predicted particular combinations of rpoB and gyrA mutations to be more frequent than 
others in clinical settings. This prediction was confirmed when screening a large panel of MDR and 
XDR M. tuberculosis clinical strains from South Africa, which is one of the regions with the highest 
burden of XDR-TB in the world (17). 
Our mutational pathway analysis also showed that in some cases, if certain mutations are acquired 
first, the fitness of these drug-resistant strains are permanently set at a high baseline that cannot be 
drastically affected regardless of the individual fitness cost associated with the second mutation. 
Moreover, some gyrA mutations can act as ‘fitness safety nets’ offering the bacteria the possibility to 
recover from loss of fitness caused by any of the initial rpoB mutations. Taken together, our results 
suggest that although evolution towards MDR- and XDR-TB can follow multiple trajectories, these are 
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likely to be influenced by epistatic interactions between the particular drug resistance-conferring 
mutations. This will constrain the particular mutational combinations to those that either increase or 
at least maintain fitness at a minimum level (Figure 4). Above this minimum level of fitness, our study 
indicates that the strength of epistasis between gyrA and rpoB will be stronger when the individual 
mutations are associated with large fitness defects. Whilst the fitness measures reported here were 
generated during in vitro growth, M. tuberculosis is facing harsher environments during human 
infection. The fitness effects of drug resistance mutations have been shown to vary in different 
environments (6,30).  Hence, it would be interesting to explore how host immune pressure, oxidative 
and other stresses might influence epitasis between drug resistance mutations. 
Our finding that a specific gyrA mutation (i.e. D94G; Figure 4 and Figure 5A) can restore the fitness of 
strains carrying different rpoB mutations has implications for the development of new TB treatment 
regimens. So far, OFX and other fluoroquinolones have primarily been used as second-line drugs to 
treat MDR-TB (31). However, because of their potential to shorten TB chemotherapy, they are 
currently being evaluated in the context of new first-line treatment regimens for drug-susceptible TB 
(32). Our results highlight that using fluoroquinolones as first-line treatment is likely to result in the 
early selection of fluoroquinolone resistance-conferring mutations like D94G gyrA that not only confer 
resistance, but might promote the acquisition of additional drug resistance while maintaining bacterial 
fitness at an advantageous level, either through positive epistasis with mutations conferring resistance 
to RIF or other drugs, or by establishing a higher baseline fitness (33). Moreover, exposure to 
fluoroquinolones induces the bacterial SOS response which leads to the induction of error-prone DNA 
polymerases, thereby increasing the bacterial mutation rate and the propensity of acquiring additional 
drug resistance-conferring mutations (34). Interestingly, we found that resistance mutations at codon 
position 94 of gyrA were also most frequent during in vitro selection, suggesting that in addition to 
epistatic interactions between rpoB and gyrA mutations, other mechanisms might influence the 
frequency of particular combinations of drug resistance mutations in clinical settings. 
 
In conclusion, our study together with previous findings demonstrates that epistasis between different 
drug resistance-conferring mutations occurs across several bacterial species. While our study focused 
on the interaction between mutations in rpoB and gyrA, further work should explore possible similar 
effects in resistance to other anti-TB drugs, both existing as well as those currently under development 
(35) (http://www.newtbdrugs.org/pipeline.php). Three new drug candidates have shown promising 
results in recent clinical trials of MDR-TB treatment (32). However, how these new compounds should 
best be deployed, and in what combinations, remains unclear. Our study suggests that considering 
Stellenbosch University  https://scholar.sun.ac.za
 221 
putative epistasis between the relevant drug resistance-conferring mutations could help optimize 
treatment regimens. For example, combining drugs in which the resistance-conferring mutations 
interact negatively would reduce the probability of resistance emerging.  
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